Claims/authorizations for dates of service on or after October 1, 2015 must use the applicable ICD-10 diagnosis code that reflects the policy intent. References in this manual to ICD-9 diagnosis codes only apply to claims/authorizations with dates of service prior to October 1, 2015.
# PHARMACY BENEFITS MANAGEMENT SERVICES

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>SUBJECT</th>
<th>SECTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OVERVIEW</strong></td>
<td>37.0</td>
</tr>
<tr>
<td>Providers should refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information.</td>
<td></td>
</tr>
<tr>
<td><strong>COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS</strong></td>
<td>37.1</td>
</tr>
<tr>
<td>Terms and Conditions</td>
<td></td>
</tr>
<tr>
<td>Tamper-Resistant Prescription Policy</td>
<td></td>
</tr>
<tr>
<td>Authorized Benefits</td>
<td></td>
</tr>
<tr>
<td>Non-Covered Services</td>
<td></td>
</tr>
<tr>
<td>Prior Authorization and Single Preferred Drug List (PDL)</td>
<td></td>
</tr>
<tr>
<td>Clinical Authorization</td>
<td></td>
</tr>
<tr>
<td>Monthly Service Limit</td>
<td></td>
</tr>
<tr>
<td>Limit</td>
<td></td>
</tr>
<tr>
<td>Exceptions to Limit</td>
<td></td>
</tr>
<tr>
<td>Limit Override Procedures</td>
<td></td>
</tr>
<tr>
<td>Drugs with Special Payment Criteria/Limitations</td>
<td></td>
</tr>
<tr>
<td>Age and Gender Restricted Drugs</td>
<td></td>
</tr>
<tr>
<td>Acne Agents</td>
<td></td>
</tr>
<tr>
<td>Agalsidase Beta (Fabrazume®)</td>
<td></td>
</tr>
<tr>
<td>Alglucosidase (Lumizyme®)</td>
<td></td>
</tr>
<tr>
<td>Allergen Extracts</td>
<td></td>
</tr>
<tr>
<td>Anti-Anxiety Drugs</td>
<td></td>
</tr>
<tr>
<td>Analeptics: Armodafinil (Nuvigil®) and Modafinil (Provigil®)</td>
<td></td>
</tr>
<tr>
<td>Anticoagulants</td>
<td></td>
</tr>
<tr>
<td>Antihistamine/Decongestant Products</td>
<td></td>
</tr>
<tr>
<td>Antisense Oligonucleotides: Nusinersen sodium (Spinraza) and Telirsen (Exondys 51®)</td>
<td></td>
</tr>
<tr>
<td>Androgenic Agents (Testosterone and Methyltestosterone containing products)</td>
<td></td>
</tr>
<tr>
<td>Antipsychotic Agents</td>
<td></td>
</tr>
<tr>
<td>Diagnosis Code Requirement on All Antipsychotic Medications</td>
<td></td>
</tr>
<tr>
<td>Age and Dosage Limits</td>
<td></td>
</tr>
<tr>
<td>Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)</td>
<td></td>
</tr>
</tbody>
</table>
Agents

Therapeutic Duplication
Behavioral Health Medications for Recipients Less than 6 Years of Age
Clinical Pre-Authorization for ADHD Medications for Recipients Less Than 48 Months

Buprenorphine and Buprenorphine/Naloxone Agents (Bunavail, Suboxone®, and Zubsolv®)

   Diagnosis Code Requirement
   Quantity Limits on Buprenorphine-Naloxone Products

Concurrent Opioid Analgesic and/or Benzodiazepine Therapies
Buprenorphine Buccal Film (Belbuca®)
Buprenorphine Extended-Release Injection (Sublocade®)
Buprenorphine Implant Kit (Probuphine®)
Buprenorphine Transdermal Patches (Butrans®)
Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack
Carisoprodol
Codiene

Contraceptive Agents

   Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®)
   Etonogestrel (Nexplanon®)
   Etonogestrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®)

Oral Contraceptive Agents
Medroxyprogesterone/Acetate Injectable
Norelgestromin/Ethinyl Estradiol/Transdermal Patches (Ortho-Evra®)

Cytokine and Cell-Adhesion Molecule (CAM) Antagonists
Deferasirox (Exjade®)
   Recipients 2 years of age and less
   Recipients 2-9 years of age
   Recipients 10 years of age and older

Diabetic Testing Supplies
Eculizumab (Soliris®)
Epinephrine Injection (Generic, EpiPen®, and EpiPen Jr.®)

Fertility Agents
Granulocyte Colony Stimulating Factor Agents (GCSF)
Growth Hormone
Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents
Hydroxyprogesterone Caproate (Makena®)
Isotretinoin
Ivacaftor (Kalydeco®)
Ketorolac
Linezolid (Zyvox®)
Lipotropics: Lonitapide (Juxtapid®, Mipomersen (Kynamro®, Alirocumab (Praluent®, and Evolocumab (Repatha®)
Lumacaftor/Ivacaftor (Okambi®)
Monoclonal Antibodies (Respiratory): Benralizumab Injection (Fasenra®, Mepolizumab Injection (Nucala®, Omalizumab (Xolair), and Reslizumab
Pimavanserin (Nuplazid®)
Mosquito Repellents
   Quantity Limits
   Age Restriction
Multiple Sclerosis (MS) Treatment Agents
Naloxone
Nicotine Transdermal Patches, Gum and Spray
Orlistat
Palivizumab (Synagis®)
   Respiratory Syncytial Virus Season
   Age Restriction
   Early Refill
   Maximum Number of Doses Allowed
   Medical Reconsideration for Palivizumab (Synagis®)
   Palivizumab Criteria ICD-10_CM Code and Medication List
   Neuromuscular Disorders
   Congenital Abnormalities of the Airways
   Chronic Lung Disease
   Congenital Heart Diseases (CHD)
Schedule II Narcotic Agents
Fentanyl Buccal, Nasal, and Sublingual Agents
   Diagnosis Code Requirement
   Age Restriction
Methadone
Morphine ER (Avinza®)
Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®)
Paroxetine Mesylate (Brisdelle®)
Perampanel (Fycompa®)
Roflumilast (Daliresp®)
Short Acting Beta2 Agonist Inhalers
   Diagnosis Code Requirement
   Quantity Limit
<table>
<thead>
<tr>
<th>Therapeutic Duplication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sildenafil (Revatio®) and Tadalafil (Adcirca®)</td>
</tr>
<tr>
<td>Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products</td>
</tr>
<tr>
<td>Sodium Oxybate (Xyrem®)</td>
</tr>
<tr>
<td>Clinical Pre-authorization</td>
</tr>
<tr>
<td>Therapeutic Duplication</td>
</tr>
<tr>
<td>Somatropin</td>
</tr>
<tr>
<td>Suvorexant (Belsomra®)</td>
</tr>
<tr>
<td>Tasimelteon (Heltioz®)</td>
</tr>
<tr>
<td>Tazarotene (Tazorac®)</td>
</tr>
<tr>
<td>Tedizolid Phosphate (Sivextro®)</td>
</tr>
<tr>
<td>Tezacaftor/Ivacaftor (Symdeko ®)</td>
</tr>
<tr>
<td>Tramadol</td>
</tr>
<tr>
<td>Triptans</td>
</tr>
</tbody>
</table>

Diagnosis Code Requirement for Selected Medications

Prospective Drug Utilization Policies/Limits/Edits

Duration of Therapy Limits

- H₂ Antagonists and Sucralfate
- Proton Pump Inhibitors (PPIs)
- Early Refill
- Duplicate Drug Therapy

Pregnancy and FDA Category X Drugs

Pregnancy and FDA Category D Drugs

Therapeutic Duplication

First Generation Antihistamine

Second Generation Antihistamine

First Generation Antihistamine-Decongestant

Second Generation Antihistamine-Decongestant

Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations

ACE Inhibitors/Calcium Channel Blocker Combinations

Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations

ARB/Calcium Channel Blocker Combinations

Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations

Calcium Channel Blockers

Calcium Channel Blocker/Antihyperlipemia Agent Combination

Potassium Replacement

Tricyclic Antidepressants
Selective Serotonin Reuptake Inhibitors
Antipsychotic Agents (Typical and Atypical)
Antipsychotic/Selective Serotonin Reuptake Inhibitor Combinations
Anti-Anxiety Agents
Sedative Hypnotic Agents
Attention Deficit Disorder (ADD) Agents
Non-Steroidal Anti-Inflammatory Agents
Short Acting Beta2 Agonist Inhalers
Short Acting Opiate Agents
Long Acting Opiate Agents
Proton Pump Inhibitors

Drug/Drug Interaction
Unnecessary Drug Therapy
   Selective Cox-2 Inhibitor

Maximum Dosage
   Atypical Antipsychotic Agents
   Agents Containing Acetaminophen or Aspirin
   Sedative Hypnotic Agents
   Tapentadol (Nucynta®)
   Agents containing Tramadol
   Botulinum Toxins OnabotulinumtoxinA (Botox®) and IncobotulinumtoxinA
      (Xeomin®)
   Hydrocodone Containing Agents
   Lidocaine Patches (Lidoderm®)
   Naltrexone Injection (Vivitrol®)
   Opioids
   Serotonin Agents (Triptans)

Quantity Limitations
   Maximum Allowable Quantities
   Maintenance Medication Quantities

Coverage and Limitations for Long Term Care Facility Recipients
   Quantities for Long Term Care Facility Recipients
   Co-payment Exemption
   Over-the-Counter Drugs
   Over-the-Counter Drugs for Preventive Care
   Diabetic Supplies
   Nebulizer Medications
   Medicare Skilled Nursing Facilities
   Emergency Kits
Outpatient Drugs Covered by Medicare Part B
Drug Services for Hospice Recipients

PROVIDER REQUIREMENTS AND PARTICIPATION GUIDELINES

Providers should refer to Chapter 1 - General Information and Administration of the Medicaid Services Manual for additional information on provider enrollment and requirements, including general standards of participation.

- Provider Qualifications
- Provider Rights and Responsibilities
- Record Keeping Requirements
- Prohibition of Reassignment of Provider Claims
- Out-of-State Providers
- Provider Enrollment
  - Medicaid Durable Medicaid Equipment/Supplies
  - Medicare Enrollment
- Enrollment Process
- Point of Sale (POS) Enrollment
- Provider Record
- Reporting Changes
- Reporting the IRS
- Louisiana Medicaid Website
- Single Preferred Drug List
- Clinical Drug Inquiries
- Prescriber Numbers
- Prior Approval Program
- Recipient Eligibility
  - Medicaid Eligibility Verification System (MEVS)
  - Recipient Eligibility Verification System (REVS)
- Point of Sale (POS) User Guide
- Vendor Specifications Document for the POS System
- Drug Appendices
- Third Party Liability Carrier Code List
- Medicaid Fraud and Abuse
  - Recipient Prescription Verification Letters
  - Surveillance Utilization Review Subsystem (SURS)
  - Appeals
- Provider Audits
  - Audit Purpose
Audit Authority
Audit Overview and Process
Provider Responsibilities

### REIMBURSEMENT FOR PHARMACY SERVICES 37.3

- Reimbursement Methodology
  - National Drug Code (NDC) System
  - Maximum Allowable Overhead Cost (Dispensing Fee)
  - Provider Fee
- Usual and Customary Charges
- Drug Estimated Acquisition Cost
- Multiple Source Drugs
  - Federal Upper Limit (FUL) Regulations
  - Louisiana State Maximum Allowable Cost (LMAC) Regulations
  - Override of FUL and MAC
- Co-payments for Prescription Services
  - Co-payment Schedule
  - Co-payment Exemptions
  - Other Co-payment Policies
- Medicare Crossover Claims
- Third Party Liability Claims

### MANAGED CARE APPLICABILITY 37.4

### APPENDIXES 37.5

- 37.5.1 – Forms and Links
- 37.5.2 – Claims Related Information
- 37.5.3 – Glossary
- 37.5.4 – Contact Information
- 37.5.5 – Drug List (PDL) and Non-Preferred Drug List (NPDL)
- 37.5.6 – Prescribers
  - Qualified Prescribers
  - Prescriber Numbers
Prescribers Who Are Not Medicaid Program Providers
Sanctioned Providers
Accessing Prescriber Numbers

37.5.7 – Medicare Prescription Drug Coverage
Medicare
Medicare Part B Crossover Claims
General Medicare Part B Crossover Reimbursement Policies
Medicare Part B Outpatient Drug Coverage
  Immunosuppressive Drugs
  Oral Cancer Chemotherapy Drugs
  Antiemetic Drugs
  Nebulizer Drugs
  Diabetic Supplies
  Dispensing/Supply Fees
  Antihemophilia Drugs
Medicare Part D Outpatient Drug Coverage

37.5.8 – Claims Submission and Processing Payments
National Drug Code (NDC)
Drug Quantities and Units of Measurement
Prescriber Numbers
Diagnosis Codes
Overrides
  Federal Upper Limits/Louisiana Maximum Allowable Cost Limitations
  Prescriptions Limit
  Early Refills
  Ingredient Duplication
  Duration of Therapy
  Therapeutic Duplication
  Unnecessary Drug Therapy
  Drug/Drug Interaction
  Coordination of Benefits
  Pregnancy Co-payment
  Age and Gender Overrides
  Maximum Dosage
  Quantity Exceeds Program Maximum
  Prior Authorization (PA) Emergency
  Hospital Discharge Prescriptions for Atypical Antipsychotic Agents
Lock-In Emergency
Types of Pharmacy Claims
Point of Sale (POS) Claim Submission (*Reference Point of Sale User Guide, Appendix A in this Chapter*)
Electronic Claim Submission (BATCH)
Hard Copy Claim Submission
Claim Adjustments
Time Limit for Submission of Medicaid Claims
Billing for Spend-Down Medically Needy Recipients

37.5.9 – Public Health Services 340B Drug Pricing Program
Reimbursement Methodology
Covered Entity
Contract Pharmacies

37.5.10 – Total Parenteral Nutrition
Provider Enrollment
Program Coverage
TPN Medical Necessity Criteria
Documentation Requirements
Exclusionary Criteria
Intradialytic Parenteral Nutrition Therapy
Equipment and Supplies
Prior Authorization
Prior Authorization Requirements
Prior Authorization Requests
Emergency Request
Medicare Crossover Claims
Third Party Liability
Reimbursement Methodology
Claim Submission
Medicaid Claims
Medicare Crossover Claims
Third Party Liability Claims
Adjustments/Voids

37.5.11 – Medication Administration
Louisiana Board of Pharmacy
Pharmacist Provider Number
Influenza Vaccine Administration by Pharmacist

37.5.12 – Patient Counseling and Drug Utilization Review (DUR)
   Patient Counseling
   Prospective Drug Utilization Review (UniDUR)
   Retrospective Drug Utilization Review
   Drug Utilization Review Board

37.5.13 – Lock-In Program
   Choosing a Lock-In Provider
   Lock-In Emergencies
   Referrals

37.5.14 – Medicaid Drug Rebate Program
   Rebate Programs
   Federally Mandated Drug Rebate Program
   State Supplemental Drug Rebate Program
OVERVIEW

The Pharmacy Program within the Louisiana Department of Health (LDH), Bureau of Health Services Financing (BHSF) is responsible for the development, implementation and administration of the Medicaid Pharmacy Program, and is charged with the responsibility of assuring quality pharmacy services while developing efficiencies in operation, service and cost.

Other responsibilities include the daily operations for outpatient pharmacy prescription services. Although total parenteral nutrition (TPN) is reimbursed through the Pharmacy Program, it is managed in collaboration with the Durable Medical Equipment (DME) Program through the prior authorization process.

This provider manual chapter specifies the Medicaid benefits in the Pharmacy Program and the policies related to those benefits. This chapter is intended to explain covered pharmacy services and limits, how to file claims, Medicaid reimbursement, and other relative Medicaid pharmacy program policies and procedures. For various reference contacts and tools, refer to Appendices 37.5.1 through 37.5.14.

All Food and Drug Administration (FDA) approved legend drugs that meet the Omnibus Budget Reconciliation Act (OBRA) ‘90 and OBRA ‘93 criteria are covered with a few exceptions. The Pharmacy Program determines the reimbursement methodology for both the drug ingredient cost and the professional dispensing fee for covered drugs.

The Pharmacy Program is responsible for the following components:

- Policy;
- Program development and implementation;
- Network development;
- Program coverage;
- Preferred drug list development and implementation and prior authorization for certain therapeutic classes;
- Federal upper limit (FUL) for multiple source drugs;
- Claims management;
• Annual provider recertification;
• Clinical interventions;
• Prospective and retrospective drug utilization review (DUR);
• Federal and state supplemental pharmaceutical manufacturer rebates;
• Pharmacy provider desk audits;
• Recipient Lock-In program;
• Provider help desk;
• Recipient help desk;
• Provider relations; and
• Provider education for prescribers and pharmacists.

The Pharmacy Program:

• Initiates policy development;
• Implements new policies and clarifies existing pharmacy policies, which include the services associated with outpatient drugs and Medicare/Medicaid pharmacy claims crossovers;
• Approves all new drugs added to program coverage; and
• Establishes any limitations on reimbursement or coverage in accordance with the federally approved reimbursement methodology.

The Pharmacy Program directs an extensive network of pharmacy providers and is also responsible for the integrity of several subsystems, including the drug file component of reference subsystem, the DUR subsystem and the drug portion of the Surveillance Utilization Review Subsystem (SURS).
Medicaid Management Information System

The Medicaid Management Information System (MMIS) is a computerized claims processing and information system designed to manage the Medicaid Program’s expenditures through effective claims processing and utilization control.

LDH contracts with a fiscal intermediary who operates the federally approved MMIS which is consistent with the Centers for Medicare and Medicaid Services (CMS) and LDH requirements. The fiscal intermediary (FI) is contracted to provide the following pharmacy-related services:

- Pharmacy claim processing through an on-line, real-time point of sale (POS) system;
- Coordination of the federally mandated Omnibus Budget Reconciliation Act of 1990 Drug Utilization Review (DUR) Board activities;
- Retrospective Drug Utilization Review (LaDUR);
- Prospective Drug Utilization Review (UniDUR);
- Educational articles - Provider Update newsletter article;
- Lock-In Program;
- DUR Board coordination;
- Preferred Drug List and prior authorization system;
- Monthly prescription limit system; and
- Electronic Data Inquiry/Clinical Drug Inquiry System (e-CDI).
CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS

COVERED SERVICES, LIMITATIONS AND EXCLUSIONS

This section provides the terms and conditions under which prescription services will be paid by the Medicaid Program and a description of the authorized benefits for eligible beneficiaries.

Terms and Conditions

Licensed Prescribers

Payment will be made for prescription services only when issued by a licensed prescribing practitioner who has an active Medicaid prescriber number. (Refer to Section 37.5.6 - Prescribers for detailed information about prescribers).

Eligible Beneficiaries

The Medicaid Program will only reimburse pharmacy claims when the beneficiary is eligible on the date of service. Pharmacy claims submitted with a date of service after a beneficiary’s date of death are not allowed. (Refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information on Medicaid eligibility).

Rebate Agreements

In accordance with Section 4401 of the Omnibus Budget Reconciliation Act of 1990 (OBRA ‘90), the Medicaid Program will pay only for those drug products for which the pharmaceutical company has entered into a federal rebate agreement with the U.S. Department of Health and Human Services (DHHS).

NOTE: The listing of Medicaid drug federal rebate participating pharmaceutical companies can be accessed by the below link. This listing is updated periodically and is posted on the Louisiana Medicaid website. Providers should take note of the effective dates of the labeler codes. www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDI3.pdf

Coverage will be provided for those drug products labeled by the pharmaceutical companies that have entered into a rebate agreement. As new pharmaceutical companies enter into rebate agreements, labeler codes will be added.
The therapeutic categories, e.g., cough and cold preparations, anorexics and cosmetic drugs, will remain non-payable. The Medicaid Drug Federal Rebate Participation Pharmaceutical Companies listing and additional information can be accessed by the below link or by visiting Section 37.5.1 of this manual chapter.

www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf

Medically Accepted Indications

A drug must be medically necessary and prescribed for medically accepted indications to be eligible for reimbursement.

As defined by Section 1927(k)(6) of the Social Security, the term “medically accepted indication” means any use for a covered outpatient drug which is approved by the Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act or the use of which is supported by one or more citations included or approved for inclusion in any of the following compendia: American Hospital Formulary Service Drug Information, United States Pharmacopeia – Drug Information (or its successor publications), and DRUGDEX Information System.

Drug Utilization Review

OBRA ‘90 also requires that states have a Drug Utilization Review (DUR) program in place and that this program assures that prescriptions are appropriate, are medically necessary and not likely to result in adverse medical results. The DUR program must include prospective drug review, retrospective drug review, and an educational program. (Refer to Section 37.5.12 - Patient Counseling, Drug Utilization Review (DUR) for detailed information regarding DUR).

Patient Counseling Requirement

The Louisiana Board of Pharmacy’s regulations require patient counseling, patient profiles, and prospective drug review, in accordance with OBRA ‘90.

Patient Counseling Documentation

Section 1927(g)(2)(ii)(I) of OBRA ‘90 requires that the pharmacist offer to discuss with each Medicaid beneficiary or a caregiver, in person whenever practicable, or by toll-free telephone for long distance calls, matters which, in his/her professional judgment, the pharmacist deems significant. Such counseling is subject to standards for counseling in accordance with the Louisiana Board of Pharmacy Regulations at LAC, 46:LIII, §517. Such counseling is to be
The Pharmacy Program will require counseling documentation for all prescriptions reimbursed by Louisiana Medicaid. According to the patient counseling standards in the OBRA’90, patient counseling begins with, and focuses on providing information related to the immediately prescribed drug. The only documentation required is a “yes” or “no” checked on the form next to the patient’s signature to indicate whether he or she accepted the offer to provide this information. Counseling records must be retained in the pharmacy for five years from the date of payment and must be readily retrievable upon audit.

NOTE: Refer to Section 37.5.12 of this manual chapter for detailed information.

Pharmacy Signature and Delivery Logs

Pharmacy providers must obtain a signature from the patient or caregiver confirming the receipt of the prescription(s). This applies to all prescription pick-ups, home and facility deliveries. Claim submission is not proof that the prescription(s) or prescription order was actually furnished.

Pharmacy Pick-up

- The signature log documentation should include the prescription number(s) and the date the prescription was picked up. If multiple prescriptions are being picked up at one time, a single signature will be sufficient for all of the patient’s prescriptions.

- Electronic signatures for receipt are permitted only if retrievable upon audit and kept on file by the pharmacy.

- Obtaining a signature to confirm receipt of prescription(s) can be part of a counseling log.

- The signature confirmation must be maintained by the dispensing pharmacy for five years from the date of payment and must be retrievable upon audit.

Facility Delivery

- A signature is required at the time of delivery.
The signature documentation must also include the list of prescription number(s) and date the medication(s) was/were delivered. A single signature will be sufficient for all the medication in the delivery.

Electronic signatures for receipt or electronic tracking slips for delivery are permitted only if retrievable on audit.

A waiver signature form is not an acceptable practice and such forms will not serve as confirmation of delivery.

Confirmation of the delivery must be maintained by the pharmacy for five years from the date of payment and must be retrievable on audit. Delivery industry tracking receipts that contain a signature (e.g., FedEx, UPS, and USPS) qualify as a signature for receipt of delivery.

Home Delivery

If a pharmacy provider chooses to have a pharmacy representative deliver prescription(s) to a beneficiary’s home, the pharmacy should inform the beneficiary or designee of the pharmacy’s delivery schedule, verify the date and location for the delivery, and notify the beneficiary or designee that a signature will be required at the time of delivery.

The pharmacy representative will obtain a signature from the beneficiary or their designee confirming the delivery. A waiver signature form is not an acceptable practice, and such forms will not serve as confirmation of delivery. Delivery confirmation must be maintained by the pharmacy for five years from the date of payment and must be retrievable upon audit. Electronic signatures for receipt are permitted only if retrievable and kept on file by the pharmacy.

Prescription Duration

Scheduled narcotic prescriptions must be filled within six months of the date issued excluding Schedule II narcotic prescriptions. Schedule II narcotic prescriptions will expire 90 days after the date of issue in accordance with the Louisiana Board of Pharmacy regulations. Prescriptions for non-controlled substances expire after 11 authorized refills or one year after the date prescribed, whichever comes first.
Prescription Transfers

The transfer of prescriptions, including those for Schedule III-V narcotics, must be in accordance with the Louisiana Board of Pharmacy regulations.

Date of Service

Claims shall be submitted for the date of service the prescription was dispensed.

Prescription Refills

Prescription refills can be provided if they are authorized specifically by the prescribing practitioner. Prescriptions for non-controlled substances have a one-year expiration and an 11-refill maximum from the date prescribed, whichever comes first.

Refills for Scheduled III-V narcotics have a six month expiration and a five refill maximum from the date prescribed, whichever comes first.

No refills are allowed on Schedule II prescriptions.

National Drug Code

In order to be reimbursed for a pharmacy claim, prescribed items must have an assigned National Drug Code (NDC).

Prescriptions Received via Telecommunication

Most prescriptions are acceptable when received by telephone or other telecommunication device in accordance with state and federal regulations. Providers must file and log prescriptions received via telecommunication as they would any other written or electronic prescriptions.

Tamper Resistant Prescription Policy

Written, non-electronic prescriptions for Medicaid beneficiaries are required to be written on tamper-resistant pads.
The “Transitional Medical Assistance (TMA), Abstinence Education and QI Program Extension Act of 2007” (H.R. 3668) and the “U.S. Troop Readiness, Veterans’ Health Care, Katrina Recovery and Iraq Accountability Appropriations Act of 2007” (H.R. 2206) states that all handwritten prescriptions or those printed from an electronic medical record (EMR), or an ePrescribing application must contain all three characteristics listed below. Exceeding these guidelines is permissible.

- One or more industry-recognized features designed to prevent unauthorized copying of a completed or blank prescription form;
- One or more industry-recognized features designed to prevent the erasure or modification of information written on the prescription by the prescriber; and
- One or more industry-recognized features designed to prevent the use of counterfeit prescription forms.

This provision applies to all written (non-electronic) prescriptions for outpatient drugs including over-the-counter drugs reimbursed by Pharmacy Program, regardless of whether Medicaid is the primary or secondary payer.

It is the responsibility of the prescriber to obtain and purchase tamper-resistant prescription pads.

NOTE: The Table of Tamper Resistant Prescription Criteria and Examples can be accessed in Section 37.5.12 by the below link.


Excluded Prescriptions

The tamper-resistant requirement does not apply to prescriptions which are communicated by the prescriber to the pharmacy electronically, verbally or by facsimile.

Confirming Non-Compliant Prescriptions

If a prescription does not meet the requirements for tamper-resistance, pharmacies may obtain verbal confirmation and document appropriately. The pharmacy does not need to speak with the
prescriber directly. They may receive confirmation from a nurse or administrative staff person who has authority to act on behalf of the prescriber.

Emergency Fills

Emergency fills with non-compliant written prescriptions are permissible as long as the prescriber provides a verbal, faxed, electronic or compliant written prescription within 72 hours after the date on which the prescription was filled. If an emergency fill is confirmed with a verbal order, the pharmacist must document the call on the face of the written prescription.

Authorized Benefits

Provided below are the authorized medications and/or supplies which are payable under Louisiana Medicaid.

NOTE: Refer to “Quantity Limitations” in this section and Section 37.3 - Reimbursement Services for detailed information regarding authorized benefits.

Legend Drugs

Legend drugs are drugs that require a prescription or that have the following statement on the label, “Caution: Federal law prohibits dispensing without a prescription.” Medicaid reimbursement is available for most legend drugs that are dispensed in outpatient settings.

NOTE: Refer to “Non-Covered Services” in this section for detailed information regarding legend drugs.

Legend Vitamin and Mineral Products

Only the following legend vitamin and mineral products will be reimbursed by the Pharmacy Program:

<table>
<thead>
<tr>
<th>Product</th>
<th>Warranty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B 12 preparations</td>
<td>Vitamin E preparations</td>
</tr>
<tr>
<td>Vitamin A preparations</td>
<td>Vitamin K preparations</td>
</tr>
<tr>
<td>Vitamin B preparations</td>
<td>Calcium replacement</td>
</tr>
<tr>
<td>Vitamin B1 preparations</td>
<td>Folic Acid preparation</td>
</tr>
<tr>
<td>Pediatric vitamin preparations</td>
<td>Legend prenatal vitamins for pregnant</td>
</tr>
<tr>
<td></td>
<td>and lactating beneficiaries</td>
</tr>
<tr>
<td></td>
<td>Magnesium salt replacement</td>
</tr>
<tr>
<td></td>
<td>Prescription strength fluoride as a</td>
</tr>
<tr>
<td></td>
<td>single entity</td>
</tr>
</tbody>
</table>
Vitamin B6 preparations   Geriatric vitamin preparations   Urinary pH modifiers (Phosphorus)
Vitamin C preparations   Multivitamin preparations
Vitamin D preparations   Niacin preparations

Injectable Drugs

Reimbursement is provided for most injectable drugs for outpatient beneficiaries when supplied by community pharmacies, long-term care (LTC) pharmacies, and home infusion pharmacies that are enrolled as Medicaid providers.

Some antibiotic and oncologic injections administered in practitioners offices and clinics are reimbursed through the Professional Services Program.

Non-Legend Drugs

Only a limited number of non-legend or over-the-counter (OTC) drugs can be reimbursed by the Louisiana Medicaid program. For Medicaid reimbursement, these drugs must be prescribed by licensed practitioners. **Providers must bill the NDC from the actual package dispensed. Also, the drug manufacturer must participate in the federal rebate program.**

The following non-legend drugs are covered when an authorized prescriber has written a prescription:

- Insulin;
- Sodium chloride solution for inhalation therapy;
- Contraceptives, topical;
- Urinary pH modifiers; and
- Other non-legend drugs that have Pharmacy Program approval.
Non-Legend Items and Supplies

Only a limited number of non-legend items and supplies can be reimbursed by the Medicaid Program. In order to receive Medicaid reimbursement, these items and supplies must be prescribed by licensed practitioners. **Providers must bill the NDC from the actual package dispensed.**

- OTC Vitamin D preparations;
- OTC Vitamin E preparations;
- OTC Niacin preparations;
- OTC Calcium replacement agents;
- OTC Magnesium replacement agents;
- OTC Phosphate replacement agents;
- OTC Iron replacement agents;
- Normal saline and heparin flushes;
- Disposable needles and syringes used to administer insulin;
- Test strips for determining blood glucose levels;
- Lancets;
- Urine test strips (e.g., Clinitest® and Clinistix®);
- Family planning items; and
- Other non-legend items and supplies that have Pharmacy Program approval.
Total Parenteral Nutrition

Total Parenteral Nutrition (TPN) and associated supplies and equipment are covered services in the Pharmacy Program. (Refer to Section 37.5.10 - Total Parenteral Nutrition for additional information).

Medication Administration

Enrolled pharmacies may be reimbursed for the administration of the influenza vaccine. Pharmacists who have the “Authority to Administer” authorized by the Louisiana Board of Pharmacy may administer the vaccine. (Refer to Section 37.5.11 - Medication Administration for detailed information).

Non-Covered Services

Drugs Excluded From Coverage

The following drugs and/or therapeutic categories are excluded from coverage:

- Anorexics – Medicaid does not reimburse for anorexics with the exception of orlistat;
- Compounded prescriptions (mixtures of two or more ingredients; the individual drugs will continue to be reimbursed);
- Cosmetic drugs;
- Cough and cold preparations;
- Drug Efficacy Study Implementation (DESI) Drugs (refer to those drugs that the FDA has proposed to withdraw from the market because they lack substantial evidence of effectiveness);
- Erectile dysfunction drugs;
- Experimental drugs;
• Fertility drugs when used for fertility treatment;

• Medications which are included in the reimbursement to a facility, i.e. hospitals, skilled nursing facility for beneficiaries receiving benefits under Part A of Title XVIII, mental hospitals, or some other nursing facilities;

• Narcotics prescribed only for narcotic addiction;

• Non-legend or OTC drugs or items with some exceptions; and

• Vaccines covered in other programs.

**Durable Medical Equipment/Supplies Excluded**

Durable medical equipment (DME) and supplies, other than those included in this section, are not covered in the Pharmacy Program. These items are covered in the Home Health Program and must be billed to that program. (Refer to Chapter 18 - Durable Medical Equipment of the Medicaid Services Manual for specific information covered through the DME program).

**Prior Authorization and Single Preferred Drug List**

The Medicaid Program administers a prior authorization process for pharmacy services. This process utilizes a single preferred drug list (PDL) for selected therapeutic classes. Drugs included on the PDL are preferred. Drugs in these classes that are not included on the PDL require prescribers to obtain prior authorization.

**PDL Provider Notification**

Lists of covered drug products, including those that require prior authorization, will be posted on the Louisiana Medicaid website.

**Prior Authorization Process General Information**

The prior authorization process provides for a turn-around response by either telephone or other telecommunications device within 24 hours of a prior authorization (PA) request. In emergency situations, providers may dispense at least a 72 hour or a three day supply of medication.
Prior Authorization and Single PDL Information Site

The Louisiana Medicaid Single Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL) and the Louisiana Uniform Prescription Drug Prior Authorization Form and its instructions can be accessed by the below link or by visiting Section 37.5.5 of this manual chapter.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Who Can Obtain Prior Authorization

The prescribing practitioner is responsible for obtaining prior authorization. Pharmacist or beneficiary calls/requests will not be accepted. The prescribing practitioner must have and provide his/her valid individual Louisiana Medicaid prescribing provider number to obtain prior authorization. Only individual provider numbers will be accepted. The prescribing practitioner may obtain the prior authorization by telephone, facsimile or mail. Refer to the Section 37.5.4 – Contact Information for access to additional information on prior authorization. In addition, refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

The Prior Authorization Unit’s hours of operation are 8:00 am to 6:00 pm Central Time, Monday through Saturday.

NOTE: If a prescribing practitioner does not have an individual prescriber number, refer to Section 37.5.6 - Prescribers for detailed information.

Prior Authorization Request Form

The Louisiana Uniform Prescription Drug Prior Authorization Form must be used by the prescriber to request a prior authorization. The form and its instructions can be accessed by the below link or by visiting Section 37.5.5 of this manual chapter.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Emergency Procedures

Prescriptions indicating emergency situations shall be dispensed in a minimum quantity of a three day supply. **Refills for the dispensing of the non-preferred products in these emergency situations are not permitted.** The beneficiary’s practitioner must contact the Prior Authorization Unit (RxPA) to request authorization to continue the medication past the emergency supply, and a new prescription must be issued.
This process may be used when the RxPA Unit is closed (Sundays; Monday – Saturday before 8:00 am and after 6:00 pm) or when the PA system is unavailable. The pharmacist may also use professional judgment in situations that would necessitate an emergency supply.

The prescribing practitioner must indicate that the prescription is an emergency Rx on the face of the prescription if hard copy or if the prescription is called in to the pharmacy, the emergency status of the prescription must be communicated to the pharmacist who must indicate “Emergency Rx” on the hard copy prescription. When the pharmacist determines the prescription is an emergency, the pharmacist must indicate “Emergency by Pharmacist” on the hard copy prescription.

NOTE: The Point of Sale (POS) User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed claim submission and processing information.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

RBeneficiaries are exempt from paying co-payments for emergency situations.

Monitoring of emergency prescriptions/beneficiaries is conducted on an ongoing basis through management reports, pharmacy provider audits, and other monitoring programs to review the number of and the reasons for these prescriptions.

Hospital Discharge Prescriptions for Atypical Antipsychotic Agents

When a beneficiary is discharged from a hospital with a prescription for an atypical antipsychotic prescription, the prescribing practitioner must indicate on the face of the prescription, if hard copy, that the prescription is a “Hospital Discharge”. If the prescription is called in to the pharmacy, the “Hospital Discharge” status of the prescription must be communicated to the pharmacist who must indicate “Hospital Discharge” on the hard copy prescription.

In situations where the prescribing practitioner is unavailable and the pharmacist determines the prescription is a “Hospital Discharge” prescription, the pharmacist must indicate “Hospital Discharge on the hard copy prescription.

Claims for “Hospital Discharge” prescriptions needing prior authorization will be submitted using the same process used for an emergency override.

Prescriptions for “Hospital Discharge” products shall be dispensed in a minimum quantity of a three-day supply, and refills for the dispensing of the non-preferred products are not
**permitted.** The beneficiary’s practitioner must contact the RxPA Unit to request authorization to continue the medication past the “Hospital Discharge” supply, and a new prescription must be issued.

**Prescriptions Issued Prior to the Effective Dates of Prior Authorization**

The prior authorization process does not impact original prescriptions (or refills) issued by a prescribing practitioner prior to a drug’s effective date of prior authorization.

**Beneficiaries with Retroactive Eligibility**

Drugs that are not on the PDL are sometimes dispensed to patients who are awaiting Medicaid eligibility determinations. Pharmacy providers will be reimbursed for these claims when the date of service falls within the beneficiaries’ retroactive time period. The retroactive time period is defined as the time period between the first date of eligibility and the date that the beneficiary’s eligibility is placed on the beneficiary file. Pharmacy providers shall submit these claims electronically.

**Important Facts**

When a beneficiary elects to self-pay for an original prescription which requires prior authorization, attempts to have Medicaid pay for the refill of this prescription will result in the pharmacy claim being denied.

If an approved prior authorization exists in the system, the pharmacy claim will bypass the prior authorization edit and continue with existing POS edits. If an approved prior authorization does not exist, the pharmacy claim will be denied through the POS system.

An approved prior authorization does not guarantee payment of the claim by Medicaid. It only indicates that the drug has been approved as a course of treatment within the Medicaid Program. All existing POS claim edits will continue to be applied.

The prior authorization process does not verify a beneficiary’s Medicaid eligibility. It only verifies that the beneficiary is “on file” (i.e., has a valid Medicaid ID number on file – not that the beneficiary is eligible on the date of service). Beneficiary eligibility will continue to be verified by the Pharmacy POS subsystem or through the Medicaid Eligibility Verification System (MEVS) or Recipient Eligibility Verification System (REVS) automated beneficiary eligibility systems.
Only practitioners’ individual prescriber numbers are accepted to request prior authorization of a non-preferred drug. Any provider number other than an individual prescribing provider number WILL NOT be accepted to prior authorize non-preferred drugs.

Clinical Authorization

There are certain medications that require clinical authorization. Clinical authorization is a prescriber initiated request for authorization on a selected number of drugs.

Prescribers must complete the Louisiana Uniform Prescription Drug Prior Authorization Form in full. The clinical authorization criteria can be used as a reference when completing the form. Clinical authorization requests should be faxed or mailed to the RxPA Unit. (Refer to Section 37.5.4 – Contact Information in this manual chapter for contact information).

NOTE: Refer to the Single Preferred Drug List (PDL) to access the clinical authorization drug list, forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Monthly Service Limit

Limit

Medicaid reimburses up to four prescriptions per calendar month per beneficiary. Claims including those for emergency prescriptions and prior-authorization prescriptions that are in excess of four per calendar month per beneficiary will deny.

Exceptions to Limit

The following federally mandated beneficiary groups are exempt from the four prescriptions per calendar month limitations:

- Persons under 21 years of age;
- Persons who are residents of long-term care institutions, such as nursing homes and Individuals with Intellectual Disabilities (ICF/IID) facilities; and
- Beneficiaries who are pregnant.
Limit Override Procedures

The four prescriptions per month limit can be exceeded when the prescriber determines an additional prescription is medically necessary and communicates the following information to the pharmacist on the hard prescription, by telephone or other telecommunications device:

- “Medically necessary override; and
- A valid diagnosis code that directly relates to each drug prescribed that is over the four prescription limit (an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM, or its successor) literal description is not acceptable).

The prescriber should use the Electronic Clinical Drug Inquiry (e-CDI) in his/her clinical assessment of the beneficiary’s disease state or medical condition and the current drug regimen before making a determination that more than four prescriptions per calendar month is required by the beneficiary. (Refer to Section 37.5.4 for details on how to access the e-CDI).

Printed statements without the prescribing practitioner’s signature, check-off boxes or stamped signatures are not acceptable documentation. An acceptable statement and diagnosis code are required for each prescription in excess of four for each calendar month.

Pharmacists and prescribers are required to maintain documentation to support the override of a prescription limitation.

NOTE: Refer to Section 37.1 to access the POS User Guide to obtain detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Drugs with Special Payment Criteria/Limitations

Coverage of some drugs is limited to special criteria being met. These are explained below.

NOTE: Refer to Section 37.5.8 - Claim Submission for detailed override information as well as Section 37.5.1 to access the POS User Guide for detailed billing instructions, where applicable.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf
Age and Gender Restricted Drugs

Certain drugs have age and gender restrictions placed on them. For further assistance, providers should contact the Molina Provider Helpdesk (Refer to Section 37.5.4 for contact information).

Acne Agents

Pharmacy claims for all acne agents will be reimbursed for beneficiaries less than 21 years of age with an approved clinical authorization.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Allergen Extracts

Pharmacy claims for the following allergen extracts are subject to physician prescriber requirements and an auto-injectable epinephrine prescription requirement for reimbursement:

- Timothy Grass Pollen Allergen Extract (Grastek®);
- Short Ragweed Pollen Allergen Extract (Ragwitek®); and
- Grass Mixed Pollens Allergen Extract (Oralair®).

Physician Prescriber Requirements for Allergen Extracts

Prescribers of allergen extracts must have a specialty of 1) Allergy, 2) Otology, Laryngology, Rhinology, or 3) Ophthalmology, Otology, Laryngology, Rhinology for reimbursement.

Auto-Injectable Epinephrine Requirement for Allergen Extracts

Pharmacy claims for allergen extracts require a pharmacy claim for an auto-injectable epinephrine product within the last year for reimbursement.
Anti-Anxiety Drugs

Pharmacy claims for solid oral dosage forms of alprazolam IR (Xanax®), chlordiazepoxide (Librium®), lorazepam (Ativan®), oxazepam (Serax®), clonazepam (Klonopin®), clorazepate (Tranxene®), and diazepam (Valium®) have quantity limits of 90 units per rolling 30 days.

Quantity limits will be bypassed for clonazepam (Klonopin®), clorazepate (Tranxene®), and diazepam (Valium®) when an acceptable diagnosis code is submitted.

Acceptable diagnosis codes that will bypass the edit are:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P90</td>
<td>Convulsions in Newborn</td>
</tr>
<tr>
<td>G40.*</td>
<td>Epilepsy, Seizures</td>
</tr>
<tr>
<td>R56.*</td>
<td>Other Convulsions</td>
</tr>
</tbody>
</table>

Alprazolam ER (Xanax XR®) and Alprazolam ODT (Niravam®)

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) are subject to the following for reimbursement:

- Age Restriction; and
- Diagnosis Code Requirements.

Pharmacy claims for alprazolam ER (Xanax XR®) also have quantity limits.

Age Restriction

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) will deny at POS for beneficiaries 17 years old or younger on the date of service.
Diagnosis Code Requirements

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) require a diagnosis code. The diagnosis code must be documented by the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Acceptable diagnosis codes for alprazolam ER (Xanax XR®) are:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F40.01</td>
<td>Panic Disorder with Agoraphobia</td>
</tr>
<tr>
<td>F41.0</td>
<td>Panic Disorder without Agoraphobia</td>
</tr>
</tbody>
</table>

Acceptable diagnosis codes for alprazolam ODT (Niravam®) are:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F41.1</td>
<td>Generalized Anxiety Disorder</td>
</tr>
<tr>
<td>F40.01</td>
<td>Panic Disorder with Agoraphobia</td>
</tr>
<tr>
<td>F41.0</td>
<td>Panic Disorder without Agoraphobia</td>
</tr>
</tbody>
</table>

Quantity Limits

There is a quantity limit of 30 units per rolling 30 days for alprazolam ER (Xanax XR®).

Analeptics: Armodafinil (Nuvigil®), Modafinil (Provigil®), Pitolisant (Wakix®), and Solriamfetol (Sunosi®)

Age Restriction

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when the beneficiary is 16 years of age or younger.
Pharmacy claims for solriamfetol (Sunosi®) and pitolisant (Wakix®) will deny at POS when the beneficiary is less than 18 years old.

**Diagnosis Code Requirements**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) require an appropriate diagnosis code documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system by the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis is required for claim submission. The appropriate diagnosis codes are listed in the chart:

<table>
<thead>
<tr>
<th>Medication</th>
<th>Description of Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armodafinil (Nuvigil®); Modafinil (Provigil®)</td>
<td>Obstructive Sleep Apnea</td>
<td>G47.33</td>
</tr>
<tr>
<td></td>
<td>Circadian rhythm sleep disorder, shift work type</td>
<td>G47.26</td>
</tr>
<tr>
<td></td>
<td>Narcolepsy</td>
<td>G47.4*</td>
</tr>
<tr>
<td>Solriamfetol (SunosiTM)</td>
<td>Obstructive Sleep Apnea</td>
<td>G47.33</td>
</tr>
<tr>
<td></td>
<td>Narcolepsy</td>
<td>G47.4*</td>
</tr>
<tr>
<td>Pitolisant (Wakix®)</td>
<td>Narcolepsy</td>
<td>G47.4*</td>
</tr>
</tbody>
</table>

* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

**Therapeutic Duplication**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary’s file for either armodafinil (Nuvigil®) or modafinil (Provigil®).
Therapeutic Duplication with Stimulants

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary’s file for other stimulants or atomoxetine (Strattera®).

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny at POS when there is an active claim on the beneficiary's file for either solriamfetol (Sunosi®), pitolisant (Wakix®), modafinil (Provigil®) or armodafinil (Nuvigil®). Also, modafinil (Provigil®) and armodafinil (Nuvigil®) should deny at POS when there is an active claim on the beneficiary’s file for either solriamfetol (Sunosi®) or pitolisant (Wakix®).

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny if there is an active claim on the beneficiary’s file for another stimulant or atomoxetine (Strattera®).

Concurrent Use with Sedative Hypnotics

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary’s file for a sedative hypnotic.

If in the professional judgment of the prescriber a determination is made which necessitates therapy with modafinil (Provigil®) or armodafinil (Nuvigil®) and a sedative hypnotic, the pharmacist may override this edit. After consultation with the prescriber to verify the necessity of both agents, the pharmacist must document on the hardcopy prescription the prescriber’s reason for concurrent therapy. The reason for service code, professional service code and result of service code used in submitting the claim must also be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny if there is an active claim on the beneficiary’s file for a sedative hypnotic. Pharmacy claims for a sedative hypnotic will deny if there is an active claim on the beneficiary’s file for solriamfetol (Sunosi®) or pitolisant (Wakix®).
Agalsidase Beta (Fabrazyme®)
Pharmacy claims for agalsidase beta (Fabrazyme®) require a diagnosis code for reimbursement.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.21</td>
<td>Fabry (-Anderson) Disease</td>
</tr>
</tbody>
</table>

Alglucosidase (Lumizyme®)
Pharmacy claims for alglucosidase (Lumizyme®) require a diagnosis code for reimbursement.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E74.02</td>
<td>Pompe Disease</td>
</tr>
</tbody>
</table>

Amikacin Inhalation Suspension (Arikayce®)
Pharmacy claims for amikacin inhalation suspension (Arikayce®) require a diagnosis code for reimbursement.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A31.0, A31.2</td>
<td>Mycobacterium avium complex</td>
</tr>
</tbody>
</table>

Anticoagulants
Prescriptions for select anticoagulants are subject to the following clinical edits for reimbursement:

- Quantity limits; and
- Duration of therapy.

Quantity Limits
The quantity limits for anticoagulant agents are listed in the chart.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Representative Brand</th>
<th>Dosage Form</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban</td>
<td>Eliquis®</td>
<td>Tablet</td>
<td>60 units/30 days</td>
</tr>
</tbody>
</table>
### Generic

<table>
<thead>
<tr>
<th>Generic</th>
<th>Representative Brand</th>
<th>Dosage Form</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apixaban Starter Pack</td>
<td>Eliquis® Starter Pack</td>
<td>Tablet Dose Pack</td>
<td>1 unit/365 days</td>
</tr>
<tr>
<td>Dabigatran Eteilate Mesylate</td>
<td>Pradaxa®</td>
<td>Capsule</td>
<td>60 units/30 days</td>
</tr>
<tr>
<td>Dalteparin Sodium</td>
<td>Fragmin®</td>
<td>Vial/Syringe</td>
<td>60 units/30 days</td>
</tr>
<tr>
<td>Edoxaban Tosylate</td>
<td>Savaysa®</td>
<td>Tablet</td>
<td>30 units/30 days</td>
</tr>
<tr>
<td>Enoxaparin Sodium</td>
<td>Lovenox®</td>
<td>Vial/Syringe</td>
<td>60 units/30 days</td>
</tr>
<tr>
<td>Fondaparinux Sodium</td>
<td>Arixtra®</td>
<td>Syringe</td>
<td>30 units/30 days</td>
</tr>
<tr>
<td>Rivaroxaban 2.5mg</td>
<td>Xarelto®</td>
<td>Tablet</td>
<td>60 units/30 days</td>
</tr>
<tr>
<td>Rivaroxaban 10mg, 15mg &amp; 20mg</td>
<td>Xarelto®</td>
<td>Tablet</td>
<td>30 units/30 days</td>
</tr>
<tr>
<td>Rivaroxaban Starter Pack</td>
<td>Xarelto® Starter Pack</td>
<td>Tablet Dose Pack</td>
<td>1 unit/365 days</td>
</tr>
</tbody>
</table>

### Duration of Therapy

The duration of therapy for select anticoagulant agents are listed in the chart.

<table>
<thead>
<tr>
<th>Generic</th>
<th>Maximum Duration of Therapy*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dalteparin</td>
<td>35 days</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>35 days</td>
</tr>
<tr>
<td>Fondaparinux Sodium</td>
<td>35 days</td>
</tr>
</tbody>
</table>

*Maximum 35-day course of therapy within a 90-day period

### Antidepressant Medications

Prescriptions for antidepressant medications will require an approved clinical authorization for beneficiaries under 6 years of age. Pharmacy claims for antidepressant medications will be checked for therapeutic duplication.

### Therapeutic Duplication

Pharmacy claims for a tricyclic antidepressant will deny if there is an active claim on the beneficiary’s file for a tricyclic antidepressant.
Pharmacy claims for selective serotonin reuptake inhibitors (SSRIs) will deny if there is an active claim on the beneficiary’s file for a SSRI.

**Antihistamine/ Decongestant Products**

Prescribed single-entity antihistamines are covered for all beneficiaries. Antihistamine-decongestant combinations are covered for all beneficiaries when prescribed for the medically approved indication of allergic rhinitis (seasonal or perennial).

The program, in accordance with the Social Security Act Section 1927 (d) (2), excludes drugs or classes of drugs containing cough and cold agents when those products are prescribed for the treatment of cough and cold.

**Therapeutic Duplication**

Pharmacy claims for first and/or second generation antihistamines and antihistamine-decongestant products will deny if there is an active claim on the beneficiary’s file for another first and/or second generation antihistamine or antihistamine-decongestant product. A change in therapy from an antihistamine to an antihistamine-decongestant or the reverse will have override provisions.

**Exclusions**

Claims for diphenhydramine, hydroxyzine HCL, and hydroxyzine pamoate are excluded from the therapeutic duplication.

After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system the following:

- The reason the prescribing provider chose to override the therapeutic duplication; and
- The National Council for Prescription Drug Program (NCPDP) DUR override codes used in submitting the claim.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits” in this section for policy regarding first and second generation antihistamines and combination agents included in the therapeutic duplication edit.
Antiretroviral Agents
Pharmacy claims for select antiretroviral agents require a diagnosis code for reimbursement. The following chart lists acceptable diagnosis codes.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>B16.1</td>
<td>Acute hepatitis B with delta-agent without hepatic coma</td>
</tr>
<tr>
<td>B16.2</td>
<td>Acute hepatitis B without delta-agent with hepatic coma</td>
</tr>
<tr>
<td>B16.9</td>
<td>Acute hepatitis B w/o delta-agent and without hepatic coma</td>
</tr>
<tr>
<td>B18.0</td>
<td>Chronic viral hepatitis B with delta-agent</td>
</tr>
<tr>
<td>B18.1</td>
<td>Chronic viral hepatitis B without delta-agent</td>
</tr>
<tr>
<td>B19.1</td>
<td>Unspecified viral hepatitis B</td>
</tr>
<tr>
<td>B19.10</td>
<td>Unspecified viral hepatitis B without hepatic coma</td>
</tr>
<tr>
<td>B19.11</td>
<td>Unspecified viral hepatitis B with hepatic coma</td>
</tr>
<tr>
<td>B20</td>
<td>Human immunodeficiency virus [HIV] disease</td>
</tr>
<tr>
<td>B97.35</td>
<td>Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere</td>
</tr>
<tr>
<td>W46.0XXA</td>
<td>Contact with hypodermic needle (initial enc.)</td>
</tr>
<tr>
<td>W46.0XXD</td>
<td>Contact with hypodermic needle (subsequent enc.)</td>
</tr>
<tr>
<td>W46.1XXA</td>
<td>Contact with contaminated hypodermic needle (initial enc.)</td>
</tr>
<tr>
<td>W46.1XXD</td>
<td>Contact with contaminated hypodermic needle (subsequent enc.)</td>
</tr>
<tr>
<td>Z20.2</td>
<td>Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission</td>
</tr>
<tr>
<td>Z20.6</td>
<td>Contact with and (suspected) exposure to HIV</td>
</tr>
<tr>
<td>Z20.828</td>
<td>Contact with and (suspected) exposure to other viral communicable diseases</td>
</tr>
<tr>
<td>Z20.89</td>
<td>Contact with and (suspected) exposure to other communicable diseases</td>
</tr>
<tr>
<td>ICD-10-CM Diagnosis Code</td>
<td>Diagnosis Description</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>Z20.9</td>
<td>Contact with and (suspected) exposure to unspecified communicable disease</td>
</tr>
<tr>
<td>Z22.51</td>
<td>Carrier of viral hepatitis B</td>
</tr>
<tr>
<td>Z72.5</td>
<td>High risk sexual behavior</td>
</tr>
<tr>
<td>Z72.51</td>
<td>High risk heterosexual behavior</td>
</tr>
<tr>
<td>Z72.52</td>
<td>High risk homosexual behavior</td>
</tr>
<tr>
<td>Z72.53</td>
<td>High risk bisexual behavior</td>
</tr>
<tr>
<td>Z77.21</td>
<td>Contact with and (suspected) exposure to potentially hazardous body fluids</td>
</tr>
<tr>
<td>Z77.9</td>
<td>Other contact with and (suspected) exposure hazardous to health</td>
</tr>
</tbody>
</table>

**Antisense Oligonucleotides: Nusinersen sodium (Spinraza®) and Eteplirsen (Exondys 51®)**

Pharmacy claims for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) will be subject to the following for reimbursement:

- Clinical authorization; and
- Diagnosis code requirements.

**Clinical Authorization Requirement**

Pharmacy claims for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) require an approved clinical authorization.

**Diagnosis Code Requirement**

The acceptable diagnosis codes for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) are listed in the chart.
Antipsychotic Agents

Pharmacy claims for antipsychotic medications are subject to the following clinical edits:

- Diagnosis Code Requirement;
- Age and Dosage Limits; and
- Therapeutic Duplication.

**Diagnosis Code Requirement on All Antipsychotic Medications**

Prescriptions for antipsychotic agents require appropriate diagnosis codes documented on all prescriptions.

The numeric diagnosis code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for antipsychotic medications that have a missing or invalid diagnosis code will deny at POS.
NOTE: The ICD-10-CM Diagnosis Codes can be accessed by the below link to the Louisiana Medicaid Single PDL for Fee-for-Service and Managed Care Organizations or by visiting Section 37.5.1 of this manual chapter.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

If the prescriber does not indicate a diagnosis code, and the pharmacist determines the beneficiary cannot wait to receive the medication, the pharmacy provider may override the denial. The pharmacist must document “Emergency” on the hard copy prescription or in the pharmacy’s electronic recordkeeping system and the reason for the emergency.

Antipsychotic agents are also subject to prospective drug utilization reviews when a third antipsychotic agent is submitted for payment.

Age and Dosage Limits

Pharmacy claims for selected antipsychotic medications will be subject to age and dosage limits.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Quantity Limits

Pharmacy claims for selected antipsychotic medications have quantity limits.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Therapeutic Duplication

Pharmacy claims for a beneficiary with an active oral antipsychotic prescription on file will deny when an additional pharmacy claim for a second oral antipsychotic prescription is submitted.

Pharmacy claims for a beneficiary with an active injectable antipsychotic prescription on file will deny when an additional pharmacy claim for a second injectable antipsychotic prescription is submitted.
Asenapine (Secuado®)

Pharmacy claims for asenapine (Secuado®) will be subject to the following:

- Maximum daily dose,
- Quantity limit, and
- Therapeutic duplication.

Maximum Daily Dose

Pharmacy claims for asenapine (Secuado®) for recipients 0-17 years of age will deny at POS when the maximum daily dose exceeds 0 mg.

Quantity Limit

Pharmacy claims for asenapine (Secuado®) will have a quantity limit of 30 patches per 30 days.

Therapeutic Duplication

A pharmacy claim for asenapine (Secuado®) will deny with a therapeutic duplication if the recipient has an active prescription on file for any traditional and/or atypical oral antipsychotic. Conversely, a pharmacy claim submitted for a traditional or atypical oral antipsychotic will deny if the recipient has an active prescription on file for asenapine (Secuado®).

Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) Agents

Prescriptions for Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD agents will require an appropriate diagnosis code for reimbursement. ADD/ADHD will be checked for therapeutic duplication.

The numeric diagnosis code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist...
must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for ADD and ADHD medications that have a missing or invalid diagnosis code will deny at POS.

When beneficiaries are established on ADD/ADHD medications, but the diagnosis codes submitted are not included in the table of covered diagnoses, prescribing providers may call the RxPA Unit (Refer to Section 37.5.4 for contact information.)

NOTE: Refer to the link to access the POS User Guide for detailed billing instructions. www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Therapeutic Duplication

Pharmacy claims for ADD/ADHD medications will be subject to a therapeutic duplication.

An incoming pharmacy claim for a short-acting ADD/ADHD medication will deny when there is an active claim on file for another short-acting ADD/ADHD medication. An incoming claim for a long-acting ADD/ADHD medication will deny when there is an active claim on file for another long-acting ADD/ADHD medication.

An incoming pharmacy claim for an ADD/ADHD medication will deny when there is an active claim on file for another ADD/ADHD medication written by a different prescriber.

Behavioral Health Medications for Beneficiaries Less Than 6 Years of Age

Pharmacy claims for behavioral health medications for beneficiaries less than 6 years of age require an approved clinical authorization for reimbursement.

NOTE: Refer to Section 37.5.1 to access the POS User Guide to obtain detailed billing instructions and override procedures. www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Clinical Authorization for ADD/ADHD Medications for Beneficiaries Less Than 6 years of Age
Pharmacy claims for ADD/ADHD medications for beneficiaries less than 6 years of age require an approved clinical authorization for reimbursement.

**Buprenorphine and Buprenorphine/Naloxone Agents (Bunavail, Suboxone®, and Zubsolv®)**

Prescriptions for buprenorphine and buprenorphine/naloxone agents (i.e. Bunavail®, Suboxone®, and Zubsolv®) are only reimbursed when the following criteria are met:

- The prescriber is a physician;
- The physician has an X Drug Enforcement Administration (DEA) number;
- The prescriber is licensed to prescribe buprenorphine and buprenorphine/naloxone agents (i.e. Bunavail®, Suboxone®, and Zubsolv®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating the X DEA number and a copy of a Provider Enrollment File Update Form to Provider Enrollment;
- Concurrent prescriptions for opioid analgesics and/or benzodiazepines are only reimbursed when written by the same physician who prescribed the buprenorphine or buprenorphine/naloxone;
- Beneficiaries must be sixteen years of age or older;
- Prescriptions for Suboxone® (buprenorphine/naloxone) are allowed a maximum daily dose of 24mg/day (based on buprenorphine);
- Prescriptions for buprenorphine agents are allowed a maximum daily dose of 24mg/day; and
- Prescriptions for Zubsolv® are allowed a maximum of up to 17.1 mg/day (based on buprenorphine) per beneficiary for an initial 90 consecutive day period. After the initial 90 day period, a maximum daily dose of up to 11.4 mg/day (based on buprenorphine) is allowed per beneficiary.

**Diagnosis Code Requirement**
Prescriptions for buprenorphine agents require an appropriate diagnosis code documented on the hard copy prescription after written or verbal consultation with the physician. The diagnosis code is required for the claim submission.

Acceptable diagnosis codes are as follows:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F11.2*</td>
<td>Opioid Type Dependence</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Buprenorphine Agents are also subject to prospective drug utilization reviews when concurrent opioid analgesics (i.e. Suboxone, and Zubsolv®) are written by the same physician.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits; Therapeutic Duplication” in this section for further policy as well as the POS User Guide accessed by visiting Section 37.5.1 for detailed billing information.


**Quantity Limits on Buprenorphine-Naloxone Products**

The quantity limits for buprenorphine/naloxone products are listed in the following chart:

<table>
<thead>
<tr>
<th>Product</th>
<th>Dose Form Route</th>
<th>Buprenorphine/Naloxone Strength</th>
<th>Quantity Limit (units/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bunavail®</td>
<td>Film Buccal</td>
<td>2.1mg 0.3mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.2mg 0.7mg</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6.3mg 1mg</td>
<td>2</td>
</tr>
<tr>
<td>Buprenorphine/Naloxone</td>
<td>Tablet Sublingual</td>
<td>2mg 0.5mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8mg 2mg</td>
<td>2</td>
</tr>
<tr>
<td>Suboxone®</td>
<td>Film Sublingual</td>
<td>2mg 0.5mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4mg 1mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8mg 2mg</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12mg 3mg</td>
<td>2</td>
</tr>
<tr>
<td>Zubsolv®</td>
<td>Tablet Sublingual</td>
<td>1.4mg 0.36mg</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.9mg 0.71mg</td>
<td>1</td>
</tr>
</tbody>
</table>
### Concurrent Opioid Analgesic and/or Benzodiazepine Therapies

- Concurrent opioid analgesic, benzodiazepine, and/or any buprenorphine containing agent prescriptions written by a different prescriber for beneficiaries on a buprenorphine agent will deny. There are no override provisions through the POS system using NCPDP service codes;

- Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for any buprenorphine containing agent on the beneficiary’s file. There are no override provisions through the POS system using NCPDP service codes; and

- When a beneficiary has an active prescription for any opioid analgesic and/or any buprenorphine containing agent by the same prescriber, the incoming prescription will deny as a therapeutic duplication. The pharmacist must contact the physician for his/her authorization to assure the physician wants concurrent therapy before overriding the denial edit and filling the incoming prescription.

### Buprenorphine Buccal Film (Belbuca®)

Prescriptions for buprenorphine buccal film (Belbuca®) will be reimbursed when:

- A valid diagnosis code is entered at claims submission; and

- The maximum daily dose limit of 1800 mcg/day is not exceeded.

All diagnosis codes are acceptable **EXCEPT** for the following:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F11.2*</td>
<td>Opioid Type Dependence</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code
Buprenorphine Extended-Release Injection (Sublocade®)

Buprenorphine extended-release injection (Sublocade®) will be reimbursed when the following criteria is met:

- Prescriber requirements;
- Age requirements;
- Diagnosis code requirements;
- Quantity limits; and
- Therapeutic duplication.

Prescriber Requirements

The prescriber is:

- A physician;
- Has an XDEA number; and
- Is licensed to prescribe buprenorphine extended-release injection (Sublocade®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating XDEA number and a copy of a Provider Enrollment File Update form to Provider Enrollment.

Age Requirements

- The patient must be 18 years of age or older.

Diagnosis Code Requirements

Prescriptions for buprenorphine agents require an appropriate diagnosis code entered at claim submission. The diagnosis code may be documented on the hard copy prescription or by the pharmacist after written or verbal consultation with the physician.
F11.2* Opioid Type Dependence

Quantity Limits

Buprenorphine extended-release injection (Sublocade®) have a quantity limit of one pre-filled syringe per rolling 30 days.

Therapeutic Duplication

When a patient has an active prescription for any opioid analgesic (including buprenorphine) written by the same prescriber, the incoming buprenorphine prescription will deny as a therapeutic duplication. Override provisions are available. The pharmacist will have to contact the physician for his/her authorization to verify the physician wants concurrent therapy.

Concurrent opioid analgesic and/or benzodiazepines prescriptions written by a different prescriber for patients on buprenorphine will deny. There are no provisions for overrides.

Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for buprenorphine agents on the beneficiary’s file. There are no provisions for overrides.

NOTE: The POS User Guide can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf
Buprenorphine Implant Kit (Probuphine®)

Buprenorphine implant kit (Probuphine®) will be reimbursed when the following criteria is met:

- Prescriber requirements;
- Age requirements;
- Diagnosis code requirements;
- Quantity limits; and
- Therapeutic duplication.

Prescriber Requirements

The prescriber is:

- A physician;
- Has an XDEA number; and
- Is licensed to prescribe buprenorphine implant (Probuphine®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating XDEA number and a copy of a Provider Enrollment File Update form to Provider Enrollment.

Age Requirements

- The patient must be 16 years of age or older.

Diagnosis Code Requirements

Prescriptions for buprenorphine agents require an appropriate diagnosis code entered at claim submission. The diagnosis code may be documented on the hard copy prescription or by the pharmacist after written or verbal consultation with the physician.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code (s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>F11.2*</td>
<td>Opioid Type Dependence</td>
</tr>
</tbody>
</table>
Quantity Limits

Buprenorphine implant kits (Probuphine®) have a quantity limit of two implant kits per 720 rolling days.

Therapeutic Duplication

When a patient has an active prescription for any opioid analgesic (including buprenorphine) written by the same prescriber, the incoming buprenorphine prescription will deny as a therapeutic duplication. **Override provisions are available.** The pharmacist will have to contact the physician for his/her authorization to verify the physician wants concurrent therapy.

Concurrent opioid analgesic and/or benzodiazepines prescriptions written by a different prescriber for patients on buprenorphine will deny. **There are no provisions for overrides.**

Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for buprenorphine agents on the beneficiary’s file. **There are no provisions for overrides.**

**NOTE:** The POS User Guide can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures.  
www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Buprenorphine Transdermal Patches (Butrans®)

Pharmacy claims for Buprenorphine Transdermal Patches (Butrans®) require an appropriate diagnosis code for reimbursement. The diagnosis code must be written on the hardcopy prescription by the prescribing practitioner or by the pharmacist after consultation with the prescriber. Claims submitted without a diagnosis code or with a diagnosis code related to the management of addictive disorders or substance abuse will deny.

There is no provision to override the denial when the diagnosis code is related to the management of addictive disorders or substance abuse. When the prescribing provider does not indicate a diagnosis code on the prescription and when the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden if the pharmacist determines that the beneficiary cannot wait to receive the medication.

When the cumulative daily dosage for Buprenorphine Transdermal Patches (Butrans®) exceeds the maximum daily dosage, the claim will deny. The maximum daily dosage for this agent is 480
mcg/24hr (20mcg/hr). Do not exceed a dose of one 20mcg/hr buprenorphine patch. Refer to prescribing information. Each patch is intended to be worn for seven days.

There is no provision for override through the POS system for Buprenorphine Transdermal Patches (Butrans®) when the maximum daily dosage is exceeded.

**Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack**

**Dose Limit for cariprazine (Vraylar®)**

**Beneficiaries 15 Years of Age or Younger**

All pharmacy claims for any strength of cariprazine (Vraylar®) for beneficiaries 15 years of age or younger will deny.

**Beneficiaries 16 – 17 Years of Age**

Pharmacy claims for cariprazine (Vraylar®) for beneficiaries 16 – 17 years of age, with a dose greater than 4.5mg/day, will deny. Overrides will be addressed by faxing a Rx PA16 to the RXPA Unit.

**Beneficiaries 18 Years of Age or Older**

Pharmacy claims for cariprazine (Vraylar®) for beneficiaries 18 years of age or older, with a dose greater than 6 mg/day, will deny.

After consultation with the prescriber to verify the necessity of exceeding 6mg/day for beneficiaries 18 years of age and older, the pharmacist may override the denial. The reason for service code, professional service code and result of service code used in submitting the claim must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**NOTE:** The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

Age Limit for Cariprazine (Vraylar®) Therapy Pack

Beneficiaries 15 Years of Age or Younger

All pharmacy claims for any strength of cariprazine (Vraylar®) therapy pack will deny for beneficiaries 15 years of age or younger. There are no override provisions through the POS system using NCPDP service codes.

Quantity Limit for Cariprazine (Vraylar®) Therapy Pack

Pharmacy claims for cariprazine (Vraylar®) therapy pack will have a quantity limit of one package per beneficiary (not to exceed one package per 18 months). There are no override provisions through the POS system using NCPDP service codes.

Diagnosis Requirement for Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack

Pharmacy claims for cariprazine (Vraylar®) and cariprazine (Vraylar®) therapy pack require a valid diagnosis code submitted at POS. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

Prescribing providers may call Louisiana Medicaid RxPA Unit for guidance when beneficiaries are established on antipsychotic medications but the diagnosis codes submitted are not included in the table of covered diagnoses.

When the diagnosis code written on the prescription is not included in the list of covered diagnoses, and when the pharmacist cannot reach the prescriber or when the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the antipsychotic prescription to be an “emergency”. In these emergency cases, the pharmacist must indicate “Emergency Prescription” on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system and may override the diagnosis code requirement.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Carisoprodol
Pharmacy claims for carisoprodol will deny when the quantity exceeds 90 tablets per rolling 90 days. The quantity limit is cumulative and applies to all strengths and combinations of carisoprodol. The pharmacy claim will deny as exceeding the program’s maximum allowed. **There are no provisions for overrides.**

**Codeine**

Pharmacy claims for products containing codeine have an age limit for reimbursement. The acceptable age limits are listed in the chart.

<table>
<thead>
<tr>
<th>Description</th>
<th>Age (Y=Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine (Single Ingredient)</td>
<td>≥18 Y</td>
</tr>
<tr>
<td>Codeine Combination Product</td>
<td>≥12 Y</td>
</tr>
</tbody>
</table>

**Collagenase Topical (Santyl®)**

Prescriptions for collagenase topical (Santyl®) will have a quantity limit of seven (7) 90 gram tubes per prescription, for a total of 630 grams.

**Contraceptive Agents**

**Drospirenone/Ethinylestradiol/Levomefolate Calcium (Beyaz®)**

Pharmacy claims for Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®) require an appropriate diagnosis code for reimbursement. Claims submitted with diagnosis codes for cosmetic indications will deny.

**Etonogestrel (Nexplanon®)**

Pharmacy claims for Etonogestrel (Nexplanon®) will be limited to one implant every two years.

If the prescriber chooses to exceed the quantity limit for Etonogestrel (Nexplanon®), the pharmacist may override the limit after consultation with the prescribing practitioner. The pharmacist must document the NCPDP override codes and reason for the override on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.
Etonogestrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®)

Prescription claims for Etonogestrel/Ethinyl Estradiol vaginal ring (Nuvaring®) for quantities of four and greater will deny. There is no provision for override as these claims exceed the program maximum of a 100 day supply.

In addition, there will be a valid days’ supply range dependent on the quantity billed:

- If quantity = 1, then Days’ Supply must be 21 to 28;
- If quantity = 2, then Days’ Supply must be 42 to 56; and
- If quantity = 3, then Days’ Supply must be 63 to 84.

Pharmacists are allowed to override the denial on days’ supply after consultation with the prescriber.

**NOTE:** The POS User Guide can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures. [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Oral Contraceptive Agents**

Oral contraceptive agents will have an age limit of 12-55 years of age per program policy for legacy Medicaid.

Pharmacy claims for oral contraceptive agents are subject to an educational alert encouraging the submission of a diagnosis code at POS. The acceptable diagnosis codes for oral contraceptives as a family planning benefit or for menstrual disorders are listed in the chart.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z30*</td>
<td>Encounter for oral contraceptive management</td>
</tr>
<tr>
<td>F32.81</td>
<td>Premenstrual dysphoric disorder</td>
</tr>
</tbody>
</table>
ICD-10-CM Diagnosis Code | Diagnosis Description
--- | ---
N92* | Excessive, frequent and irregular menstruation

*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

**Medroxyprogesterone Acetate Injectable**

Prescription claims for Medroxyprogesterone Acetate injectable for female beneficiaries billed with a quantity of one and a days’ supply less than 84 will deny. Quantities of two and greater will not be payable with no provision for override as they exceed the program maximum of a 100 days’ supply.

Claims for Medroxyprogesterone Acetate sub-q 104 injectable for female beneficiaries, billed with a quantity of 0.65 and a days’ supply less than 84, will deny. Quantities of 1.3 and greater will not be payable, with no provision for override, as they exceed the program maximum of a 100 days’ supply.

Pharmacists are allowed to override the denial on days’ supply after consultation with the prescriber.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures.


**Norelgestromin /Ethinyl Estradiol Transdermal Patches (Ortho-Evra) ®)**

Reimbursement of these contraceptive transdermal patches when dispensed using the package size of three must be billed in multiples of three. If the quantity billed is not a multiple of three, the claim will deny. There are no provisions for override.

**Cytokine and Cell-Adhesion Molecule (CAM) Antagonists**

Prescriptions for cytokine and cell-adhesion molecule (CAM) antagonists will be reimbursed when the prescriber has obtained an approved clinical authorization.
Deferasirox (Exjade®)

Pharmacy claims for deferasirox (Exjade®) are subject to diagnosis code requirements and age limitations.

**Beneficiaries 2 years of age and less**

Pharmacy claims for deferasirox (Exjade®) will deny for beneficiaries 2 years of age or less.

**Beneficiaries 2-9 years of age**

Pharmacy claims for deferasirox (Exjade®) require a diagnosis code of chronic iron overload due to blood transfusions for payment for beneficiaries 2-9 years of age. The diagnosis code must be documented on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Beneficiaries 10 years of age and older**

Pharmacy claims for deferasirox (Exjade®) require a valid numeric diagnosis code for reimbursement.

The appropriate diagnosis codes for deferasirox (Exjade®) are listed in the chart:

<table>
<thead>
<tr>
<th>Covered Indications at POS</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2 years and up</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic iron overload due to blood transfusion</td>
<td>E83.111</td>
</tr>
<tr>
<td><strong>10 years and up</strong></td>
<td></td>
</tr>
<tr>
<td>Chronic iron overload in non-transfusion dependent thalassemia (NTDT) syndromes</td>
<td></td>
</tr>
<tr>
<td>β-thalassemia intermedia</td>
<td>D56.1</td>
</tr>
</tbody>
</table>

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.  

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf
### Covered Indications at POS

<table>
<thead>
<tr>
<th>Indication</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin E/β-thalassemia</td>
<td>D56.5</td>
</tr>
<tr>
<td>Hemoglobin S/β-thalassemia</td>
<td>D57.4*</td>
</tr>
</tbody>
</table>

#### 10 years and up

<table>
<thead>
<tr>
<th>Indication</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic iron overload in non-transfusion dependent thalassemia (NTDT) syndromes</td>
<td>D56.8</td>
</tr>
<tr>
<td>α-thalassemia intermedia [hemoglobin H disease]</td>
<td>D56.0</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

### Diabetic Testing Supplies

The Pharmacy Program reimburses claims for prescribed diabetic testing supplies.

All diabetic supply claims submitted to Medicaid will deny when beneficiaries are Medicare Part B eligible. Medicare Part B covers diabetic supplies for all diabetic beneficiaries regardless of insulin requirements. Pharmacy providers shall submit these claims to the Medicare durable medical equipment regional carrier (DMERC). These claims will then automatically cross over to the Medicaid fiscal intermediary for payment of the coinsurance and deductible amounts, where applicable.

Diabetic supplies and glucometers for long-term care beneficiaries are not covered in the Medicaid Pharmacy Program or through prior authorization because they are covered in the nursing facility per diem rate.

It is allowable for Medicare Part B to be billed if the long-term care beneficiary is eligible for the benefit. Medicaid is not obligated to pay the coinsurance and deductible if the items are included in the Medicaid per diem. The Medicaid fiscal intermediary will automatically deny any crossover claims for diabetic supplies for long-term care beneficiaries.

**NOTE:** Refer to Section 37.5.7 - Medicare Prescription Drug Coverage for detailed information.

### Dextromethorphan/Quinidine (Nuedexta®)
Pharmacy claims for dextromethorphan/quinidine (Nuedexta®) are subject to the quantity limit listed in the chart.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Description of Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextromethorphan/Quinidine</td>
<td>Nuedexta®</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Doxepin Cream (Prudoxin®, Zonalon®)

Pharmacy claims for doxepin cream will be subject to the following edits:
- Diagnosis code requirement,
- Age limit,
- Quantity limit, and
- Therapeutic duplication.

Diagnosis Code Requirement

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) require a diagnosis code. The acceptable diagnosis codes are listed in the chart.

*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Age Limit

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny when the recipient is less than 18 years old.

Quantity Limit
Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will have a quantity limit of 45 grams per rolling 30 days.

**Therapeutic Duplication**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny with a therapeutic duplication if there is an active claim on the recipient’s file for doxepin cream (Prudoxin®, Zonalon®).

**Eculizumab (Soliris®)**

Pharmacy claims for eculizumab (Soliris®) require a diagnosis code for reimbursement.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code*</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D59.3</td>
<td>Hemolytic-uremic syndrome</td>
</tr>
<tr>
<td>D59.5</td>
<td>Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]</td>
</tr>
<tr>
<td>G36.0</td>
<td>Neuromyelitis Optica Spectrum Disorder (NMOSD)</td>
</tr>
<tr>
<td>G70.0</td>
<td>Myasthenia Gravis</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Edaravone (Radicava®)**

Pharmacy claims for edaravone (Radicava®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.
Epinephrine Injection (Generic, EpiPen®, and EpiPen Jr®)

Prescriptions for epinephrine injection have the following quantity limits for reimbursement.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epipen® (Brand and Generic)</td>
<td>4 boxes of 2 syringes (8 syringes total) per rolling 365 days</td>
</tr>
<tr>
<td>Epipen Jr® (Brand and Generic)</td>
<td></td>
</tr>
</tbody>
</table>

Esketamine Intranasal (Spravato®)

Pharmacy claims for esketamine intranasal (Spravato®) require an approved clinical authorization for reimbursement.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Elagolix (Orilissa ®)

Pharmacy claims for elagolix (Orilissa®) require an approved clinical authorization for reimbursement.

Fertility Agents

Fertility preparations, when they are used solely for the treatment of infertility, are not reimbursable. The drugs include Clomiphene citrate tablets 50mg, Urofollitropin ampules 75IU, and Menotropins ampules 150IU and 75IU. If prescriptions for these products are prescribed for any indications other than infertility, the physician shall certify the indication, in his own handwriting, on the prescription. In order for the pharmacist to be reimbursed for the product, a
hard copy claim along with a copy of the original prescription will have to be submitted to the fiscal intermediary for processing indicating a diagnosis other than infertility.

**Galcanezumab Injection (Emgality®)**

Prescriptions for galcanezumab-gnlm (Emgality®) 100 mg single-dose pen/syringe will have a quantity limit of one (1) carton of three (3) single-dose syringes per 30 days.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

**Granulocyte Colony Stimulating Factor Agents (GCSF)**

The GCSF agents are listed in the following chart.

<table>
<thead>
<tr>
<th>Granulocyte Colony Stimulating Factor (GCSF) Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filgrastim (Neupogen®)</td>
</tr>
<tr>
<td>Filgrastim-aafi (Nivestym®)</td>
</tr>
<tr>
<td>Filgrastim-sndz (Zarxio®)</td>
</tr>
<tr>
<td>Pegfilgrastim (Neulasta®)</td>
</tr>
<tr>
<td>Pegfilgrastim-jmdb (Fulphila®)</td>
</tr>
<tr>
<td>Sargramostim (Leukine®)</td>
</tr>
<tr>
<td>Tbo-filgrastim (Granix®)</td>
</tr>
</tbody>
</table>

Prescriptions for Granulocyte Colony Stimulating Factor agents will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

**Growth Hormone**
Prescriptions for Growth Hormone will be reimbursed when:

- The prescriber has obtained an approved clinical authorization; and
- An acceptable diagnosis code has been submitted with the pharmacy claim.

**Diagnosis Code Requirement**

Pharmacy claims for Growth Hormone will require an acceptable diagnosis code for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

**Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents**

Hepatitis C Direct Acting Antiviral Agent(s) may be subject to clinical edits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

**Hereditary Angioedema (HAE) Agents**

Pharmacy claims for Hereditary Angioedema agents require an approved clinical pre-authorization for reimbursement. The select HAE agents are as follows:

- C1 Inhibitor, Human Injection (Berinert®)
- C1 Inhibitor, Human Injection (Cinryze®)
- C1 Inhibitor, Human Injection (Haegarda®)
- C1 Inhibitor (Recombinant) Injection (Ruconest®)
- Ecallantide Injection (Kalbitor®)
- Icatibant Acetate Injection (Firazyr®)
- Lanadelumab Injection (Takhzyro®)

Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf
Hydroxyprogesterone Caproate (Makena®)

Hydroxyprogesterone Caproate (Makena®) is a covered pharmacy and medical benefit.

Prescriptions for hydroxyprogesterone caproate (Makena®) require the following for reimbursement:

- The prescriber has submitted an acceptable diagnosis code of O09.21* Pregnancy with a history of pre-term labor.

- The acceptable diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code may be communicated to the pharmacist from the prescriber (or prescriber’s agent) electronically, via telephone, or facsimile.

- The acceptable diagnosis code must be submitted at POS.

When the prescriber does not indicate a diagnosis code on the prescription and the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden by the pharmacist. The pharmacist must also document “Emergency Prescription” on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**NOTE:** The POS User Guide can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures.


Incretin Mimetic/Enhancers

Prescriptions for incretin mimetic/enhancer will be reimbursed when:

- There is prior use of metformin or another incretin mimetic/enhancer; and

- The maximum daily dose limit is not exceeded.

**Prior Use of Metformin Required**
An incoming pharmacy claim for an incretin mimetic/enhancer will require evidence of previous use of metformin or a paid claim for the requested medication or another medication within the same therapeutic class.

An incoming claim for an incretin mimetic/enhancer will deny if there is no evidence of a paid claim(s) for at least 90 days of metformin therapy OR there is no evidence of at least 60 days of paid claims for the requested medication (or another incretin mimetic/enhancer).

**Maximum Daily Dose Limit**

<table>
<thead>
<tr>
<th>Medication (Brand Name Example)</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alogliptin (Nesina®)</td>
<td>25mg/day</td>
</tr>
<tr>
<td>Alogliptin/Metformin (Kazano®)</td>
<td>25mg/2000mg per day</td>
</tr>
<tr>
<td>Alogliptin/Pioglitazone (Oseni®)</td>
<td>25mg/45mg per day</td>
</tr>
<tr>
<td>Dulaglutide (Trulicity®)</td>
<td>1.5mg/week</td>
</tr>
<tr>
<td>Exenatide (Bydureon®, Bydureon® BCise™)</td>
<td>2mg/week</td>
</tr>
<tr>
<td>Exenatide (Byetta®)</td>
<td>20mcg/day</td>
</tr>
<tr>
<td>Linagliptin (Tradjenta®)</td>
<td>5mg/day</td>
</tr>
<tr>
<td>Linagliptin/Metformin (Jentadueto®, Jentadueto XR®)</td>
<td>5mg/2000mg per day</td>
</tr>
<tr>
<td>Liraglutide (Victoza®)</td>
<td>1.8mg/day</td>
</tr>
<tr>
<td>Lixisenatide (Adlyxin®, Adlyxin® Starter Kit)</td>
<td>20mcg/day</td>
</tr>
<tr>
<td>Pramlintide (Symlin®)</td>
<td>Type 1 diabetes: 60mcg SQ immediately prior to each major meal</td>
</tr>
<tr>
<td></td>
<td>Type 2 diabetes: 120mcg SQ immediately prior to each major meal</td>
</tr>
<tr>
<td>Saxagliptin (Onglyza®)</td>
<td>5mg/day</td>
</tr>
<tr>
<td>Saxagliptin/Metformin ER (Kombiglyze XR®)</td>
<td>5mg/2000mg per day</td>
</tr>
<tr>
<td>Semaglutide (Ozempic®)</td>
<td>1mg/week</td>
</tr>
<tr>
<td>Sitagliptin (Januvia®)</td>
<td>100mg/day</td>
</tr>
<tr>
<td>Sitagliptin/Metformin (Janumet®, Janumet XR®)</td>
<td>100mg/2000mg per day</td>
</tr>
</tbody>
</table>

*Authorization at POS is required to exceed maximum doses.

The maximum dose for select incretin mimetic/enhancers are listed in the chart.

**Inotersen (Tegsedi®)**
Pharmacy claims for inotersen (Tegsedi®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

### Isotretinoin

Isotretinoin capsules will be covered only if a handwritten prescription signed by the prescribing practitioner, with no provisions for refills, is submitted.

### Ivacaftor (Kalydeco®)

Pharmacy claims for Ivacaftor (Kalydeco®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

[http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf](http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf)
Ketorolac

Pharmacy claims for oral forms of ketorolac will deny for a quantity greater than 20 or the day supply is greater than five days as exceeding the program’s maximum allowed. The pharmacist may override the denial after consultation with the prescriber. The prescriber must supply the diagnosis code and the rationale for using greater than a five day supply of ketorolac. The diagnosis code is required for the claim submission.

NOTE: The POS User Guide can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures.

L-glutamine oral powder (Endari®)

Pharmacy claims for l-glutamine oral powder (Endari®) require an approved clinical authorization for reimbursement.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

Linezolid (Zyvox®)

Prescriptions for linezolid (Zyvox®) injections, tablets, and oral suspension will only be reimbursed when the prescriber has obtained an approved clinical authorization.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

Lipotropics: Lomitapide (Juxtapid®), Mipomersen (Kynamro®), Alirocumab (Praluent®), and Evolocumab (Repatha®)

Prescriptions for lomitapide (Juxtapid®), mipomersen (Kynamro®), alirocumab (Praluent®), and evolocumab (Repatha®) will be reimbursed when:

- The prescriber has obtained an approved clinical authorization.
Lumacaftor/Ivacaftor (Orkambi®)

Clinical Authorization

Pharmacy claims for lumacaftor/ivacaftor (Orkambi®) will be reimbursed at POS when the prescriber has obtained an approved clinical authorization.

Override provisions should be addressed through the Clinical Authorization process.

Diagnosis Code Requirements

Pharmacy claims for lumacaftor/ivacaftor (Orkambi®) require a valid ICD-10-CM diagnosis code. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system. The following table lists the acceptable diagnosis code for lumacaftor/ivacaftor (Orkambi®).

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cystic fibrosis</td>
<td>E84.*</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Lumacaftor/ivacaftor (Orkambi®) claims submitted at POS without a valid diagnosis code will deny.

Prescribing providers may call the RxPA Unit for guidance when beneficiaries are established on medications but the ICD-10-CM diagnosis code(s) submitted are not included in the covered diagnoses.

When the diagnosis code written on the prescription is not included in the list of covered diagnoses AND when the pharmacist cannot reach the prescriber OR when the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the prescription to be an “emergency”. In these emergency cases, the pharmacist must indicate “Emergency Prescription”
on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system AND may override the diagnosis code requirement.

Monoclonal Antibodies (Respiratory): Benralizumab Injection (Fasenra®), Mepolizumab Injection (Nucala®), Omalizumab (Xolair®), and Reslizumab Injection (Cinqair®)

Benralizumab Injection (Fasenra®), Mepolizumab Injection (Nucala®), Reslizumab Injection (Cinqair®)

Prescriptions for benralizumab injection (Fasenra®), mepolizumab injection (Nucala®), and reslizumab injection (Cinqair®) will only be reimbursed when the prescriber has obtained an approved clinical authorization.

Omalizumab (Xolair®)

Prescriptions for omalizumab (Xolair®) will be reimbursed when the following criteria are met:

- The prescriber has obtained prior authorization for the beneficiary to receive the omalizumab or the beneficiary has an existing prior authorization for omalizumab; and
- The beneficiary is 12 years of age or older on the date of service.

The following are acceptable diagnoses for omalizumab claims submitted for prior authorization:

<table>
<thead>
<tr>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergic (extrinsic) asthma</td>
</tr>
<tr>
<td>Allergic (extrinsic) asthma unspecified</td>
</tr>
<tr>
<td>Allergic (extrinsic) asthma with status asthmaticus</td>
</tr>
<tr>
<td>Allergic (extrinsic) asthma with acute exacerbation</td>
</tr>
<tr>
<td>Chronic Idiopathic Urticaria</td>
</tr>
</tbody>
</table>
Pimavanserin (Nuplazid®)

Prescriptions for pimavanserin (Nuplazid®) are subject to:

- An approved clinical authorization;
- Diagnosis code requirement; and
- Quantity limit.

**Diagnosis Code Requirement**

Pharmacy claims for pimavanserin (Nuplazid®) will require a diagnosis code of G20 (Parkinson’s disease).

**Quantity Limit**

Pharmacy claims for pimavanserin (Nuplazid®) have a quantity limit of 60 (17mg) tablets or 30 (34mg) capsules per rolling 30 days.

**Mosquito Repellents**

Prescriptions for mosquito repellents are covered to decrease the risk of exposure to the Zika virus. Mosquito repellent coverage will be limited to Medicaid beneficiaries:

- Who are pregnant; or
- Of childbearing years (women and men 14-44 years of age) who are trying to conceive.

A prescription will be required to cover one of the following products:
CHAPTER 37:  PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION 37.1:  COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Ounces</th>
<th>Bill As</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutter Backwoods 25 percent Spray</td>
<td>6 oz.</td>
<td>170 g</td>
</tr>
<tr>
<td>Cutter Skinsations 7 percent Spray</td>
<td>6 oz.</td>
<td>177 mL</td>
</tr>
<tr>
<td>OFF! Family Care 15 percent Spray</td>
<td>2.5 ounces</td>
<td>71 g</td>
</tr>
<tr>
<td>OFF! Deep Woods Dry 25 percent Spray</td>
<td>4 ounces</td>
<td>113 g</td>
</tr>
<tr>
<td>OFF! Deep Woods 25 percent Spray</td>
<td>6 ounces</td>
<td>170 g</td>
</tr>
<tr>
<td>OFF! Active 15 percent Spray</td>
<td>6 ounces</td>
<td>170 g</td>
</tr>
<tr>
<td>Repel Sportsmen 25 percent Spray</td>
<td>6.5 ounces</td>
<td>184 g</td>
</tr>
<tr>
<td>Repel Sportsmen Max 40 percent Spray</td>
<td>6.5 ounces</td>
<td>184 g</td>
</tr>
<tr>
<td>Natrapel 20 percent Picaridin</td>
<td>5 ounces</td>
<td>177 mL</td>
</tr>
<tr>
<td>Sawyer Insect Repellent 20 percent Picaridin</td>
<td>4 ounces</td>
<td>118 mL</td>
</tr>
</tbody>
</table>

**Quantity Limit**

One bottle of mosquito repellent will be covered every rolling 30 days.

**Age Restriction**

Pharmacy claims for mosquito repellents have an age limit of 14 to 44 (of childbearing) years of age.

**Multiple Sclerosis (MS) Treatment Agents**

Prescriptions for Multiple Sclerosis treatment agents will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

**Naloxone**
Pharmacy claims for naloxone have a quantity limit requirement for reimbursement. Refer to the chart below.

<table>
<thead>
<tr>
<th>Description</th>
<th>Dosage Form</th>
<th>Strength</th>
<th>Units per 90 Rolling Days</th>
<th>Representative Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naloxone</td>
<td>Injectable Solution</td>
<td>0.4mg/ml</td>
<td>2</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injectable Solution Cartridge</td>
<td>0.4mg/ml</td>
<td>2</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injectable Solution Prefilled Syringe</td>
<td>1mg/ml</td>
<td>2</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injectable Solution (5ml, 10ml, 20ml)</td>
<td>1mg/ml</td>
<td>1</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injectable Solution (10ml)</td>
<td>0.4mg/ml</td>
<td>1</td>
<td>Naloxone</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Injectable Solution Auto-Injector</td>
<td>0.4mg/0.4ml</td>
<td>2</td>
<td>Evzio®</td>
</tr>
<tr>
<td>Naloxone</td>
<td>Nasal Liquid</td>
<td>4mg/0.1ml</td>
<td>2</td>
<td>Narcan®</td>
</tr>
</tbody>
</table>

**Nicotine Transdermal Patches, Gum and Spray**

Nicotine transdermal patches, nicotine polacrilix gum, and nicotine spray are covered only with a handwritten prescription signed by the prescribing practitioner. There are no provisions for refills. The physician will need to rewrite a prescription each time.

Also, physicians must certify, in their own handwriting, either directly on the prescription or on an attachment to the prescription that the beneficiary is enrolled in a physician-supervised behavioral program in order for Medicaid to provide coverage for nicotine adhesive patches, gum and spray. Pharmacy providers should verify that the above noted documentation is written on, or attached to, the prescription when the prescription is dispensed.

This information must be retained by the pharmacy as evidence of compliance with program policy, and it must be readily retrievable when requested by audit staff.
Orlistat

Medicaid will provide reimbursement to outpatient pharmacies for orlistat prescriptions based on the following criteria:

- An authorized prescriber has hand written the prescription - no facsimiles allowed;
- Patient is 12 years of age or older;
- The prescription is an original—no refills are allowed;
- The prescription is for a maximum of 90 capsules and 30 days’ supply;
- The beneficiary has a documented current body mass index (BMI) of 27 or greater and the prescriber had identified the BMI, in his/her handwriting, on the dated prescription or a dated and signed attachment to the prescription;
- The beneficiary has other risk factors warranting the use of Orlistat and the prescriber has identified an approved diagnosis code in his/her handwriting, on the dated prescription or a dated and signed attachment to the prescription; and
- There are no provisions for override of the prospective drug utilization edits, i.e., early refill (ER) and duplicate drug (ID) editing.

The following risk factors, as identified by ICD-10-CM numeric codes only, are acceptable:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E11.*</td>
<td>Type II Diabetes</td>
</tr>
<tr>
<td>R73.02</td>
<td>Impaired Glucose Tolerance</td>
</tr>
<tr>
<td>E15, E16.1</td>
<td>Hyperinsulinemia</td>
</tr>
<tr>
<td>E78.0-E78.5</td>
<td>Dyslipidemia</td>
</tr>
<tr>
<td>I10, I11.<em>, I12.</em>, I13.<em>, I15.</em></td>
<td>Hypertension</td>
</tr>
<tr>
<td>I21.<em>, I22.</em>, I24.<em>, I25.</em></td>
<td>Ischemic Heart Disease</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Description</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>I70</td>
<td>Atherosclerosis</td>
</tr>
<tr>
<td>I73</td>
<td>Other peripheral vascular diseases</td>
</tr>
<tr>
<td>K21.0, K21.9</td>
<td>Gastric Reflux Disease</td>
</tr>
<tr>
<td>M16.<em>, M17.</em></td>
<td>Osteoarthritis of Hips/Knees</td>
</tr>
<tr>
<td>G47.30</td>
<td>Sleep Apnea</td>
</tr>
<tr>
<td>I60.<em>, I61.</em>, I62.<em>, I63.</em>, I65.<em>, I66.</em>, I68.<em>, I69.</em></td>
<td>Cerebrovascular Disease</td>
</tr>
<tr>
<td>G93.2</td>
<td>Pseudotumor cerebri</td>
</tr>
<tr>
<td>I83.2</td>
<td>Varicose Veins of the lower extremities with ulcer and inflammation</td>
</tr>
<tr>
<td>I80.0</td>
<td>Phlebitis &amp; Thrombophlebitis of the superficial vessels of the lower extremities</td>
</tr>
<tr>
<td>I80.1</td>
<td>Phlebitis &amp; Thrombophlebitis of the femoral vein</td>
</tr>
<tr>
<td>I80.2</td>
<td>Phlebitis &amp; Thrombophlebitis of other deep vessels</td>
</tr>
<tr>
<td>I80.3</td>
<td>Phlebitis &amp; Thrombophlebitis of lower extremities, unspecified</td>
</tr>
<tr>
<td>I83.0</td>
<td>Varicose veins of lower extremities, with ulcer</td>
</tr>
<tr>
<td>I83.1</td>
<td>Varicose veins of lower extremities, with inflammation</td>
</tr>
<tr>
<td>I83.9</td>
<td>Varicose veins of lower extremities, without mention of ulcer &amp; inflammation</td>
</tr>
</tbody>
</table>

The prescriber identified diagnosis code must be included in the claim submission. The required supporting documentation for coverage must be retained by the pharmacy as evidence of compliance with program policy, and it must be readily retrievable when requested by audit staff.

**Onasemnogene Abeparvovec Injection (Zolgensma®)**

Pharmacy claims for onasemnogene abeparvovec injection (Zolgensma®) require a clinical authorization.
Palivizumab (Synagis®)

Prescriptions for palivizumab (Synagis®) will only be reimbursed when prescriptions meet the following criteria:

- The prescriber has obtained an approved clinical authorization.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Respiratory Syncytial Virus Season

Louisiana’s respiratory syncytial virus (RSV) activity may be followed during the RSV season by frequently accessing the Center for Disease Control’s website. (Refer to Section 37.5.4 for web address.) The RSV season in Louisiana begins November 1st and ends March 31st.

Age Restriction

Palivizumab claims for beneficiaries who are 24 months of age or younger on November 1st of the current RSV season meet the POS age requirement.

Early Refill

Palivizumab claims will only process for payment every 28 days. When a pharmacy submits a claim for Synagis® and there is an active paid Synagis® claim on file, the incoming claim will deny. An active prescription is a prescription in which the days’ supply has not expired.

Maximum Number of Doses Allowed

Claims billed for Synagis® outside the allowable number of doses will deny. Based upon the diagnosis code submitted, a maximum of five doses of Synagis® will be reimbursed each RSV
season. If the initial dose is given in October, the fifth and final dose should be given in February. If initial dose is given in November, the fifth and final dose should be given in March.

Medical Reconsideration for Palivizumab (Synagis®)

Medical reconsideration of a denied clinical authorization decision may be requested by the prescribing practitioner. Medical reconsideration requires completion of the Palivizumab Request for Reconsideration Form.

Palivizumab Criteria ICD-10-CM Code and Medication List

NOTE: Any accepted diagnosis code listed on the Palivizumab Clinical Authorization Form must have supporting documentation attached. Supporting documentation is supplemental information submitted to support the patient meeting the criteria and may include copies of progress notes, hospital discharge notes, pediatric cardiologist consult notes, chart notes, pharmacy profiles, etc.

Neuromuscular Disorders

Acceptable ICD-10 codes include:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A80.0-A80.39</td>
<td>Infantile paralysis</td>
</tr>
<tr>
<td>G31.9</td>
<td>Cerebral degenerations</td>
</tr>
<tr>
<td>G25.3</td>
<td>Myoclonus</td>
</tr>
<tr>
<td>G11.1, G11.4</td>
<td>Spinocerebellar disease</td>
</tr>
<tr>
<td>G12.0</td>
<td>Werdnig-Hoffman disease (Infantile spinal muscular atrophy)</td>
</tr>
<tr>
<td>G12.1, G12.8, G12.9</td>
<td>Spinal muscular atrophy</td>
</tr>
<tr>
<td>G12.2*</td>
<td>Motor neuron disease</td>
</tr>
</tbody>
</table>

Exclude (but not limited to) the following (i.e. the following are NOT accepted):
### ICD-10-CM Code | Description
--- | ---
G80* | Cerebral palsy
G40.3* | Generalized convulsive epilepsy
G40.4* | Grand mal seizures
G40* | Epilepsy
Q05* | Spina bifida
P90 | Newborn seizures
R56* | Infantile seizures

**Congenital Abnormalities of the Airways**

Acceptable ICD-10 codes include:

### ICD-10-CM Code | Description
--- | ---
G47.35 | Congenital central alveolar hypoventilation syndrome
Q32.0, Q32.1 | Other diseases of the trachea and bronchus, not elsewhere classified (Must specify Tracheomalacia or tracheal stenosis)
Q31.1, Q31.5, Q32.1, Q32.4 | Other anomalies of larynx, trachea, and bronchus (Must specify congenital tracheal stenosis, subglottic stenosis, atresia of trachea, laryngomalacia, or absence or agenesis of bronchus, trachea)
Q33.0 | Congenital cystic lung
Q33.3, Q33.6 | Agenesis, hypoplasia, and dysplasia of the lung
Q33.4 | Congenital bronchiectasis
Q38.2 | Macroglossia
Q38.5 | Uvula anomaly
Diaphragmatic paralysis
Beckwith-Wiedemann syndrome

Exclude (but not limited to) the following (i.e. the following are NOT accepted):

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J98.6</td>
<td>Diaphragmatic paralysis</td>
</tr>
<tr>
<td>Q87.3</td>
<td>Beckwith-Wiedemann syndrome</td>
</tr>
<tr>
<td>Q33.9</td>
<td>Anomaly of lung, unspecified</td>
</tr>
<tr>
<td>Q33.1, Q33.8</td>
<td>Other anomaly of the lung</td>
</tr>
</tbody>
</table>
Chronic Lung Disease

Acceptable ICD-10 code:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P27*</td>
<td>Chronic respiratory disease arising in the perinatal period (CLD/BPD/Interstitial pulmonary fibrosis of prematurity/Wilson-Mikity syndrome)</td>
</tr>
</tbody>
</table>

Exclude (but not limited to) the following (i.e. the following are NOT accepted):

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J05.0</td>
<td>Croup</td>
</tr>
<tr>
<td>J06*</td>
<td>URI</td>
</tr>
<tr>
<td>J20*</td>
<td>Bronchitis</td>
</tr>
<tr>
<td>J21*</td>
<td>Bronchiolitis</td>
</tr>
<tr>
<td>J45*</td>
<td>Asthma</td>
</tr>
<tr>
<td>R06.2</td>
<td>Wheezing</td>
</tr>
</tbody>
</table>

Congenital Heart Diseases

Per AAP guidelines, prophylaxis with palivizumab in children with chronic heart disease (CHD) should be made on the degree of cardiovascular compromise. CHD that is deemed hemodynamically insignificant will not meet criteria. Documentation must specifically support CHD being hemodynamically significant (e.g. medications, etc.).

Acceptable ICD-10 codes include:

Acyanotic CHD
### Covered Services, Limitations, and Exclusions

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q23.0</td>
<td>Aortic stenosis</td>
</tr>
<tr>
<td>I37.0, I37.1, I37.2, Q22.1, Q22.2</td>
<td>Pulmonary valve disorders (incompetence, insufficiency, regurgitation, and stenosis)</td>
</tr>
<tr>
<td>I42*, I43</td>
<td>Cardiomyopathy (must be moderate to severe)</td>
</tr>
<tr>
<td>Q21.0</td>
<td>Ventricular septal defect</td>
</tr>
<tr>
<td>Q21.1</td>
<td>Atrial septal defect</td>
</tr>
<tr>
<td>Q21.2</td>
<td>Atrioventricular canal (endocardial cushion defect)</td>
</tr>
<tr>
<td>Q22.3</td>
<td>Anomalies of pulmonary valve congenital</td>
</tr>
<tr>
<td>Q22.1</td>
<td>Pulmonic stenosis</td>
</tr>
<tr>
<td>Q23.0</td>
<td>Congenital stenosis of aortic valve (congenital aortic stenosis) [Excludes: congenital subaortic stenosis; supravalvular aortic stenosis]</td>
</tr>
<tr>
<td>Q23.3</td>
<td>Congenital mitral insufficiency</td>
</tr>
<tr>
<td>Q25.0</td>
<td>Patent ductus arteriosus</td>
</tr>
<tr>
<td>Q25.1</td>
<td>Coarctation of the aorta</td>
</tr>
<tr>
<td>Q25.2, Q25.3</td>
<td>Atresia and stenosis of aorta (absence, aplasia, hypoplasia, stricture of the aorta) Supra (valvular)-aortic stenosis [Excludes: congenital aortic (valvular) stenosis or stricture; hypoplasia of aorta in hypoplastic left heart syndrome]</td>
</tr>
</tbody>
</table>

**NOTE:** Must currently be receiving medication to control congestive heart failure.

### Cyanotic CHD

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q20.0</td>
<td>Truncus arteriosus</td>
</tr>
</tbody>
</table>
ICD-10-CM Code | Description
--- | ---
Q20.3 | Transposition of the great vessels
Q21.3 | Tetralogy of Fallot
Q22.0 | Atresia, congenital
Q22.4 | Tricuspid atresia and stenosis, congenital
Q22.5 | Ebstein’s anomaly
Q23.4 | Hypoplastic left heart
Q22.6 | Hypoplastic right heart
Q25.5 | Pulmonary atresia
Q26.2 | Total anomalous pulmonary venous return

**NOTE:** Does not require use of medication/must not have had or completed surgical correction.

**Pulmonary Hypertension**

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I26.0*</td>
<td>Acute cor pulmonale</td>
</tr>
<tr>
<td>I27.0</td>
<td>Primary pulmonary hypertension</td>
</tr>
<tr>
<td>I27.2</td>
<td>Other chronic pulmonary heart disease (pulmonary hypertension, secondary)</td>
</tr>
<tr>
<td>P29.3</td>
<td>Persistent fetal circulation (persistent pulmonary hypertension/primary pulmonary hypertension of newborn)</td>
</tr>
</tbody>
</table>

*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Acceptable Medications Used in CHD**

- Digoxin
- ACE Inhibitors
- Supplemental oxygen
- Beta Blockers
- Nitroglycerin
- Diuretics
Calcium Channel Blockers        Anti-Coagulants

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits”, and as well as the POS User Guide accessed by the below link or by visiting Section 37.5.1 for detailed claims filing information.


**Penicillamine (Cuprimine®, Depen®)**

Pharmacy claims for penicillamine (Cuprimine®, Depen®) have quantity limits. The quantity limits are listed in the chart.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillamine</td>
<td>Cuprimine®</td>
<td>240 capsules/30 days</td>
</tr>
<tr>
<td></td>
<td>Depen®</td>
<td>240 tablets/30 days</td>
</tr>
</tbody>
</table>

**Pyrimethamine (Daraprim®)**

Prescriptions for pyrimethamine (Daraprim®) will be reimbursed when:

- The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

[http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf](http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf)

**Schedule II Narcotic Agents**

All prescriptions for Schedule II narcotic agents require a diagnosis code indicating the reason for use documented on the hardcopy prescription. The diagnosis code must be written on the hardcopy prescription by the prescribing practitioner or by the pharmacist after consultation with the prescriber.
Except for methadone, when the prescribing practitioner does not indicate a diagnosis code on the prescription and when the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden if the pharmacist determines that the beneficiary cannot wait to receive the medication.

Schedule II narcotic agents are also subject to prospective drug utilization reviews which address quantity limits.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits” in this section for further information.

**Fentanyl Buccal and Sublingual Agents**

Claims for fentanyl buccal and sublingual agents (Abstral®, Actiq®, Fentora® and Onsolis®) **must** contain a cancer-related diagnosis code in order for the claim to process for payment through the POS System.

Acceptable diagnosis codes are as follows:

<table>
<thead>
<tr>
<th>ICD-10-CM Code Range</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C00.<em>-C96</em></td>
<td>Cancer</td>
</tr>
</tbody>
</table>

Buccal and sublingual agents are subject to prospective drug utilization reviews which address quantity limits.

**Diagnosis Code Requirement**

Pharmacy claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) require an appropriate diagnosis code documented on the hardcopy prescription by either the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Age Restriction**

Claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) will deny when the beneficiary is 17 years of age or younger.
Methadone

All prescriptions for methadone must have a diagnosis code for payment. There are no provisions for an override of methadone when a diagnosis code is omitted. Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs shall only be dispensed by opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

Prescriptions for methadone will be reimbursed when the prescriber has obtained an approved clinical authorization.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Morphine ER (Avinza®)

When the cumulative daily dosage for Morphine ER (Avinza®) exceeds the maximum daily dosage, the claim will deny. The maximum daily dosage for this agent is 1600mg per day. There is no provision for override through the POS system for Morphine ER (Avinza®) when the maximum daily dosage is exceeded.

Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®)

Prescriptions for oxycodone/acetaminophen (Xartemis XR®) require an appropriate diagnosis code documented on the hard copy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

Pharmacy claims for oxycodone/acetaminophen (Xartemis XR®) have a quantity limit of 30 units every 15 days within a 30-day period.

Paroxetine Mesylate (Brisdelle®)

Pharmacy claims for paroxetine mesylate (Brisdelle®) require submission of a valid diagnosis code at POS for reimbursement. The diagnosis code must be documented on the hardcopy
prescription or in the pharmacy’s electronic recordkeeping system. The following table lists the acceptable diagnosis codes for paroxetine mesylate (Brisdelle®).

<table>
<thead>
<tr>
<th>Medication</th>
<th>Diagnosis Code</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxetine Mesylate (Brisdelle®)</td>
<td>E28.310</td>
<td>Moderate to severe vasomotor symptoms associated with menopause</td>
</tr>
<tr>
<td></td>
<td>E89.41</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N95.1</td>
<td></td>
</tr>
</tbody>
</table>

**Patisiran (Onpattro®)**

Pharmacy claims for patisiran (Onpattro®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patisiran</td>
<td>Onpattro®</td>
<td>Polyneuropathy of hereditary transthyretin-mediated amyloidosis</td>
<td>E85.1</td>
</tr>
</tbody>
</table>

**Perampanel (Fycompa®)**

**Age Limit**

Pharmacy claims for perampanel (Fycompa®) will deny for beneficiaries under four years of age.

After consultation with the prescriber to verify the necessity of prescribing perampanel (Fycompa®) for a beneficiary under four years of age, the pharmacist may override the age restriction. The reason for service code, professional service code and result of service code used in submitting the claim must be documented on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.
NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures. www.lamedicaid.com/Provweb1/Pharmacy/LAPPOS_User_Manual_static.pdf

### Progesterone (Crinone® 4%)
Pharmacy claims for progesterone (Crinone® 4%) will require a diagnosis code for payment.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progesterone micronized</td>
<td>Crinone® 4%</td>
<td>Secondary Amenorrhea</td>
<td>N91.1</td>
</tr>
</tbody>
</table>

*Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

### Riluzole (Rilutek®, Tiglutik®)
Pharmacy claims for riluzole (Rilutek®, Tiglutik®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riluzole</td>
<td>Rilutek®; Tiglutik®</td>
<td>Amyotrophic lateral sclerosis</td>
<td>G12.21</td>
</tr>
</tbody>
</table>

### Risankizumab Injection (Skyrizi®)
Pharmacy claims for risankizumab injection (Skyrizi®) require a clinical authorization.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.
Roflumilast (Daliresp®)

Pharmacy claims for roflumilast (Daliresp®) require an approved clinical authorization for reimbursement.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

Semaglutide (Rybelsus®)

Pharmacy claims for semaglutide (Rybelsus®) will require previous use of metformin or a paid claim for semaglutide (Rybelsus®) or another Incretin Mimetic Enhancers. An incoming claim for semaglutide (Rybelsus®) will deny if there is no evidence of a paid claim(s) for at least 90 days of metformin therapy in the previous 180-day period or if there is no evidence of paid claims of at least 60 days of semaglutide (Rybelsus®) or other Incretin Mimetic/Enhancers within the previous 90 days.

Short-Acting Beta₂ Agonist Inhalers

Prescriptions for short-acting beta₂ agonist inhalers (SABAs) (i.e albuterol, levalbuterol, and pirbuterol):

- Require an appropriate diagnosis code; and
- Are subject to a maximum quantity of six short-acting beta₂ agonist inhalers per calendar year.

Diagnosis Code Requirement

The diagnosis code must be documented on the hardcopy prescription by either the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone or facsimile. Claims submitted with a diagnosis associated with chronic obstructive pulmonary disease, emphysema, or cystic fibrosis will bypass the edit.
Diagnosis codes which bypass the six inhaler limit are noted below:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Diagnosis Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E84*</td>
<td>Cystic fibrosis</td>
</tr>
<tr>
<td>J40</td>
<td>Bronchitis, not specified</td>
</tr>
<tr>
<td>J44*</td>
<td>Obstructive chronic bronchitis</td>
</tr>
<tr>
<td>J43*</td>
<td>Emphysema</td>
</tr>
<tr>
<td>J44*</td>
<td>Chronic obstructive asthma</td>
</tr>
<tr>
<td>J44.9</td>
<td>Chronic airway obstruction</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Pharmacy claims that do not indicate a diagnosis code on the prescription and the prescriber cannot be reached; a denial for a missing diagnosis code may be overridden by the pharmacist entering the emergency override.

**Quantity Limit**

If the prescriber chooses to exceed the quantity limit, the prescriber must provide the reason why the limit needs to be exceeded. The pharmacist may override the limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record-keeping system the following:

- The prescriber’s reason why the limit needs to be exceeded; and
- The NCPDP DUR override codes used in submitting the claim.

If the prescriber cannot be reached, the pharmacist may override the quantity limit by entering the emergency override. The pharmacist must document “Emergency” on the hardcopy prescription and the reason for entering the emergency override.
Therapeutic Duplication

Pharmacy claims billed for concurrent use of different SABAs will deny with a therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. This consultation is necessary to confirm that:

- The prescriber is aware of the current active SABA claim; and
- The addition of a different SABA is necessary (i.e., a change in therapy).

To bill concurrent therapy with different SABAs, the pharmacist must document on the hardcopy prescription or the pharmacy’s electronic recordkeeping system the following:

- The reason why an additional SABA was requested by the prescriber; and
- The NCPDP DUR override codes used in submitting the claim.

NOTE: Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta2 agonist inhalers.

Sildenafil (Revatio®) And Tadalafil (Adcirca®)

Prescriptions for Sildenafil (Revatio®) and Tadalafil (Adcirca®) are payable when prescribed for primary pulmonary hypertension. An appropriate diagnosis code must be documented on all prescriptions by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. The diagnosis code is required for the claim submission.

The following diagnosis codes are acceptable:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I27.0, I27.2, I27.89, P29.3</td>
<td>Pulmonary Arterial Hypertension</td>
</tr>
</tbody>
</table>

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products
Prescriptions for Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and combination products will be reimbursed when:

- The prescriber has obtained an approved clinical authorization.

**Prior Use of Metformin Required (SGLT2 Inhibitors Only)**

An incoming pharmacy claim for a SGLT2 inhibitor will require evidence of previous use of metformin or a paid claim for the requested medication or another medication within the same therapeutic class.

An incoming claim for a SGLT2 inhibitor will deny if there is not a paid claim(s) for at least 90 days of metformin therapy OR there is no evidence of at least 60 days of paid claims for the requested medication (or another SGLT2 inhibitor).

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

[http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf](http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf)

**Sodium Oxybate (Xyrem®)**

**Clinical Pre-Authorization**

Pharmacy claims for sodium oxybate (Xyrem®) will be reimbursed when the prescriber has obtained an approved clinical authorization. A diagnosis of narcolepsy or cataplexy must be submitted in the clinical authorization process.

**Therapeutic Duplication**

Pharmacy claims for sodium oxybate (Xyrem®) will deny when the beneficiary has an active claim on file for a CNS depressant. Claims for CNS depressants will deny when the beneficiary has an active claim on file for sodium oxybate (Xyrem®).

CNS depressant medications include the following agents, whether given as a single entity or as a component of a combination product:

- Alprazolam
- Dantrolene
- Metaxalone
- Quazepam
The therapeutic duplication edit for sodium oxybate (Xyrem®) and CNS depressants can be overridden in emergency circumstances. These claims will require consultation and approval from the prescribing provider to override the therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication with the emergency override. The pharmacist must document “Emergency” on the hardcopy prescription and the reason why the prescribing provider choose to override the therapeutic duplication.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

### Somatropin

Pharmacy claims for Somatropin (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Tev-Tropin®, and Zorbtive®) require an appropriate diagnosis code for reimbursement. The numeric code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile.

There are no overrides for this edit. However, the pharmacist may contact the prescriber for a valid diagnosis code and resubmit the claim.

The following chart addresses acceptable diagnosis code(s) which are in accordance with the reimbursement criteria for somatropin.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Code Type</th>
<th>Code Number</th>
<th>Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baclofen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diazepam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramelteon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dihydrocodeine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methocarbamol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remifentanil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buspirone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxepin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secobarbital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butabarbital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estazolam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sufentanil</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butalbital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eszopiclone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nalbuphine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suvorexant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Butorphanol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fentanyl</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opium</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tapentadol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carisoprodol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flurazepam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orphenadrine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tasmelteon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlor Diazepoxide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tizanidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorzoxazone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydromorphone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxymorphone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonazepam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levorphanol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxymorphone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triazolam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clorazepate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paregoric</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triazolam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meperidine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentazocine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zaleplon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meprobamate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenobarbital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zolpidem</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### ICD-10-CM Diagnosis Code(s)

<table>
<thead>
<tr>
<th>Code(s)</th>
<th>Diagnoses</th>
</tr>
</thead>
</table>
| N25.0   | Growth failure in children associated with:  
|         | • Renal insufficiency or chronic kidney disease |
| Q87.1   | • Noonan Syndrome |
| Q87.1   | • Prader-Willi Syndrome |
| Q96     | • Turner Syndrome |
| P05.1   | • Small for gestational age at birth (fetal growth retardation) who fail to manifest catch-up growth or with no catch-up growth |
| R62.52  | Short Stature in children (idiopathic or SHOX deficiency)  
|         | • Short stature  
|         | • Lack of expected normal physiological development in childhood |
| E23.0   | Pituitary dwarfism |
| E23.0   | Panhypopituitarism |
| E23.1, E89.3 | Iatrogenic pituitary disorders |
| K90.2, K91.2 | (Zorbitive® only) Short Bowel Syndrome in patients receiving specialized nutritional support:  
|         | • Blind Loop Syndrome  
|         | • Other unspecified post-surgical nonabsorption |
| R64     | (Serostim® only) HIV-associated cachexia or wasting |

**Suvorexant (Belsomra®)**

Pharmacy claims for suvorexant (Belsomra®) are subject to a maximum daily dosage limit of 20 mg/day.
Tafamidis (Vyndaqel®, Vyndamax®)

Pharmacy claims for tafamidis (Vyndaqel®, Vyndamax®) have a quantity limit.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tafamidis</td>
<td>Vyndaqel®</td>
<td>120 capsules/30 days</td>
</tr>
<tr>
<td>Tafamidis</td>
<td>Vyndamax®</td>
<td>30 capsules/30 days</td>
</tr>
</tbody>
</table>

Tasimelteon (Hetlioz®)

Prescription claims for tasimelteon (Hetlioz®) will have the following clinical edits:

- Clinical Authorization;
- Maximum Daily Dose; and
- Therapeutic Duplication.

Clinical Authorization for tasimelteon (Hetlioz®)

Pharmacy claims for tasimelteon (Hetlioz®) will be reimbursed at POS when the prescriber has obtained an approved clinical authorization.

Override provisions should be addressed through the Clinical Authorization process.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Maximum Dose for tasimelteon (Hetlioz®)

Pharmacy claims for tasimelteon (Hetlioz®) have a maximum daily dose of 20mg/day. There are no override provisions through the POS system using NCPDP service codes.

Therapeutic Duplication for tasimelteon (Hetlioz®)
Pharmacy claims for tasimelteon (Hetlioz®) will deny at POS if there is an active claim for another sedative-hypnotic agent.

After consultation with the prescriber to verify the necessity of the therapeutic duplication, the pharmacist may override the therapeutic duplication.

The pharmacist must document the override codes on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Tazarotene (Tazorac®)**

Pharmacy claims for Tazarotene (Tazorac®) require an appropriate diagnosis code for reimbursement. The prescribing provider must document the diagnosis code on the hard copy prescription or may communicate the diagnosis code to the pharmacist electronically, via telephone, or facsimile.

The acceptable diagnosis codes are:

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L40*</td>
<td>Psoriatic Arthritis</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Pharmacy providers may direct questions to the Provider Help Desk concerning overrides for this edit. (Refer to Section 37.5.4 for contact information).

**NOTE:** The *POS User Guide* can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.


**Tedizolid Phosphate (Sivextro®)**

Prescriptions for tedizolid phosphate (Sivextro®) will be reimbursed when:

- The prescriber has obtained an approved clinical pre-authorization.

**Tesaromelin (Egrifta®)**
Pharmacy claims for tesamorelin (Egrifta®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Tezacaftor/Ivacaftor (Symdeko®)**

Prescriptions for tezacaftor/ivacaftor (Symdeko®) will only be reimbursed when the prescriber has obtained an approved Clinical Pre-Authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesamorelin</td>
<td>Egrifta®, Egrifta SV®</td>
<td>Human immunodeficiency virus [HIV] disease</td>
<td>B20</td>
</tr>
</tbody>
</table>

**Tobramycin/Nebulizer (Kitabis Pak®)**

Pharmacy claims for tobramycin (Kitabis Pak®) will require a diagnosis code for payment.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tobramycin Nebulizer</td>
<td>Kitabis Pak® 4%</td>
<td>Cystic Fibrosis with Pseudomonas</td>
<td>E84*</td>
</tr>
</tbody>
</table>

*Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10_CM diagnosis code.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.
Tolvaptan (Samsca®)

Pharmacy claims for tolvaptan (Samsca®) have quantity limits. The quantity limits for tolvaptan (Samsca®) are listed in the chart.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolvaptan</td>
<td>Samsca® 15mg</td>
<td>30 tablets/30 days</td>
</tr>
<tr>
<td></td>
<td>Samsca® 30 mg</td>
<td>60 tablets/30 days</td>
</tr>
</tbody>
</table>

Tramadol

Pharmacy claims for tramadol containing products have an age limit for reimbursement. The acceptable age limits are listed in the chart.

<table>
<thead>
<tr>
<th>Description</th>
<th>Age (Y=Year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol</td>
<td>≥17 Y</td>
</tr>
<tr>
<td>Tramadol Combination Product</td>
<td>≥17 Y</td>
</tr>
</tbody>
</table>

Triptans

Pharmacy claims for triptans for beneficiaries under 18 years of age will require a valid diagnosis code for reimbursement. Triptans are identified in the following chart:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Representative Brand(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Almotriptan</td>
<td>Axert®6</td>
</tr>
<tr>
<td>Eletriptan</td>
<td>Relpax®</td>
</tr>
<tr>
<td>Frovatriptan</td>
<td>Frova®</td>
</tr>
<tr>
<td>Naratriptan</td>
<td>Amerge®</td>
</tr>
</tbody>
</table>
Generic Name | Representative Brand(s)  
---|---  
Rizatriptan | Maxalt®, Maxalt MLT®  
Sumatriptan | Alsuma®, Imitrex®, Sumavel®, Zecuity®  
Zolmitriptan | Zomig®, Zomig ZMT®

The acceptable ICD-10-CM diagnosis codes for triptans in beneficiaries less than 18 years of age are as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>ICD-10-CM Diagnosis Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migraine diagnosis</td>
<td>G43.0*, G43.1*, G43.7*</td>
</tr>
</tbody>
</table>

**Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors**

Prescriptions for Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: deutetrabenazine (Austedo®), tetrabenazine (Xenazine®), and valbenazine (Ingrezza®) will be reimbursed when:

- The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

[http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf](http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf)

**Zoledronic Acid (Reclast®)**

Pharmacy claims for zoledronic acid (Reclast®) are subject to the quantity limit listed in the chart.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Quantity Limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoledronic Acid</td>
<td>Reclast®</td>
<td>1 vial/365 days</td>
</tr>
</tbody>
</table>

**Diagnosis Code Requirement for Selected Medications**
Prescriptions for selected medications require a diagnosis code for reimbursement for both FFS Medicaid and the MCOs. The diagnosis code should be documented on the hardcopy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system after electronic or verbal consultation with the prescribing practitioner.

NOTE: Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf

Prospective Drug Utilization Policies/Limits/Edits

Prospective drug utilization review (UniDUR) consists of criteria set forth by the state-established DUR board which monitors for inappropriate use of medications and identifies potential drug conflicts. UniDUR is designed to work alongside the POS claims processing and eligibility systems. Prospective Drug Utilization Review displays alert messages, based on severity level, to alert of any possible harmful effects that a medication may have on a patient. The alerts generated are caused by various combinations of interactions between a beneficiary’s condition, beneficiary’s historical drug prescription records on file and the current medications prescribed for them.

Professional judgment regarding appropriate drug use is the responsibility of the pharmacist. Improper use of DUR override codes by pharmacy staff may result in the disallowance of these override codes and administrative sanctions by Medicaid and the Board of Pharmacy.

UniDUR has predetermined standards to monitor:

- Duration of therapy;
- Early refill;
- Duplicate drug therapy;
- Pregnancy and FDA Category X drugs;
- Therapeutic duplication;
• Drug to drug interaction;
• Unnecessary drug therapy;
• Age and gender restrictions;
• Maximum dosage;
• Quantity Limits; and
• Drugs to diagnosis.

NOTE: Refer to Section 37.5.12 for an overview of Patient Counseling, Drug Utilization Review (DUR).

Duration of Therapy Limits

H₂ Antagonists & Sucralfate

The program utilizes a duration of therapy module for H₂ antagonists, and sucralfate for beneficiaries who are 16 and older. Acute dosage guidelines for these drugs are monitored. H₂ antagonists have a duration of therapy limit of 180 days in a rolling 365 days. Sucralfate has a duration of therapy limit of 90 days per calendar year. Acute dosing of H₂ antagonists and sucralfate requires documentation of an appropriate diagnosis code. When authorized by the prescriber, claims beyond the duration of therapy limit can be processed through the POS system at the pharmacy. The chronic use of these agents at full therapeutic dosage is generally not indicated.
The acute dosage schedules of these drugs are as follows:

<table>
<thead>
<tr>
<th>Generic Description</th>
<th>Acute mg/day dose</th>
<th>Duration of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine HCl</td>
<td>300</td>
<td>180 days</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>1200</td>
<td>180 days</td>
</tr>
<tr>
<td>Nizatidine</td>
<td>300</td>
<td>180 days</td>
</tr>
<tr>
<td>Famotidine</td>
<td>40</td>
<td>180 days</td>
</tr>
<tr>
<td>Sucralfate</td>
<td>4000</td>
<td>90 days</td>
</tr>
</tbody>
</table>

Maintenance dose drug therapy will continue to be payable after the duration of therapy has been exceeded with prescriber authorization.

If, in the professional judgment of the prescriber, a determination is made to continue acute therapy beyond the appropriate duration of therapy, the prescriber must indicate in writing on the prescription or a signed and dated attachment, a diagnosis code necessitating the continuation of acute therapy. Beneficiary specific diagnosis information from the prescriber via facsimile is acceptable.

Only the prescriber who issues a prescription is authorized to sign off on a diagnosis override.

For acute therapy to continue as a reimbursable service beyond the above listed therapy limits, duration of therapy, the pharmacy provider must supply the reason for service code, professional service code and result of service code.

NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures. 
www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Select diagnosis codes which may justify the long-term usage of sucralfate are listed below.
<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>B96.81</td>
<td>\textit{H. pylori}</td>
</tr>
<tr>
<td>C96.2</td>
<td>Malignant Mast Cell Tumors</td>
</tr>
<tr>
<td>D44.0, D44.2, D44.9</td>
<td>Multiple Endocrine Adenomas</td>
</tr>
<tr>
<td>E16.4</td>
<td>Zollinger-Ellison Syndrome</td>
</tr>
<tr>
<td>K20.9</td>
<td>Esophagitis, Unspecified</td>
</tr>
<tr>
<td>K21.0</td>
<td>Reflux Esophagitis</td>
</tr>
<tr>
<td>K20.8</td>
<td>Abscess of Esophagus</td>
</tr>
<tr>
<td>K22.1*</td>
<td>Ulcer of Esophagus with or without bleeding</td>
</tr>
<tr>
<td>K22.7*</td>
<td>Barrett’s Esophagus</td>
</tr>
<tr>
<td>K25.*</td>
<td>Gastric Ulcer</td>
</tr>
<tr>
<td>K26.*</td>
<td>Duodenal Ulcer</td>
</tr>
<tr>
<td>K27.*</td>
<td>Peptic Ulcer</td>
</tr>
<tr>
<td>K29.*</td>
<td>Gastritis/Duodenitis</td>
</tr>
<tr>
<td>K30</td>
<td>Gastric Hyperacidity</td>
</tr>
<tr>
<td>K21.9</td>
<td>Gastroesophageal Reflux Disease (GERD)</td>
</tr>
<tr>
<td>K50.*</td>
<td>Crohn’s Disease</td>
</tr>
<tr>
<td>K86.0, K86.1</td>
<td>Chronic Pancreatitis</td>
</tr>
<tr>
<td>K92.2</td>
<td>Gastrointestinal Hemorrhage</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Select diagnosis codes which may justify the long-term usage of H$_2$ antagonists are listed below.
Proton Pump Inhibitors (PPIs)

Prescriptions for Proton Pump Inhibitors have a duration of therapy of 180 days in a rolling 365 days.

Diagnosis Codes Exempt from the Duration of Therapy Limit for PPIs

Select diagnosis codes are exempt and bypass the duration of therapy edit for PPIs. (See the following chart for the listing.)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abscess of Esophagus</td>
<td>K20.8</td>
</tr>
<tr>
<td>Angiodysplasia of Stomach and Duodenum (with OR without Mention of Hemorrhage)</td>
<td>K31.81*</td>
</tr>
</tbody>
</table>
### Diagnosis and ICD-10-CM Diagnosis Code(s)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>ICD-10-CM Diagnosis Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrophic Gastritis with Hemorrhage</td>
<td>K29.41</td>
</tr>
<tr>
<td>Barrett’s Esophagus</td>
<td>K22.7*</td>
</tr>
<tr>
<td>Cerebral Palsy (<em>new Aug 2019</em>)</td>
<td>G80*</td>
</tr>
<tr>
<td>Chronic Pancreatitis</td>
<td>K86.0, K86.1</td>
</tr>
<tr>
<td>Congenital Tracheoesophageal Fistula</td>
<td>Q39.1, Q39.2</td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td>E84.*</td>
</tr>
<tr>
<td>Eosinophilic Esophagitis</td>
<td>K20.0</td>
</tr>
<tr>
<td>Eosinophilic Gastritis</td>
<td>K52.81</td>
</tr>
<tr>
<td>Gastrointestinal Hemorrhage</td>
<td>K92.2</td>
</tr>
<tr>
<td>Gastrointestinal Mucositis (Ulcerative)</td>
<td>K92.81</td>
</tr>
<tr>
<td>Malignant Mast Cell Tumors</td>
<td>C96.2*</td>
</tr>
<tr>
<td>Multiple Endocrine Adenomas</td>
<td>D44.0, D44.2, D44.9</td>
</tr>
<tr>
<td>Tracheoesophageal Fistula</td>
<td>J86.0</td>
</tr>
<tr>
<td>Ulcer of Esophagus with OR without Bleeding</td>
<td>K22.1*</td>
</tr>
<tr>
<td>Zollinger-Ellison Syndrome</td>
<td>E16.4</td>
</tr>
</tbody>
</table>

* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

Claims for beneficiaries under six years of age are excluded from the PPI duration of therapy module. In addition, claims for beneficiaries receiving pancreatic enzymes are excluded from the PPI duration of therapy module as well.

**Early Refill**

The Medicaid Program denies pharmacy claims for early refills if the patient has requested the same medication at the same pharmacy prior to 85 percent of medication being utilized. This translates into a five day window based on a 30-day supply.
Prescriptions for narcotic analgesics will deny for an early refill edit when less than 90 percent of the medication had been utilized. This translates into a two day window based on a 30-day supply.

Pharmacists must enter the actual days’ supply for each pharmacy claim. If the number of days is not apparent, an estimate must be given based on professional judgment.

In some cases, the pharmacist may have knowledge of dosage changes which would warrant a beneficiary’s request for medication earlier than previously reported in the estimated days’ supply. The pharmacist must document the circumstances on the prescription hard copy.

**NOTE:** The *POS User Guide* can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.


### Duplicate Drug Therapy

A claim denial will occur if the beneficiary attempts to obtain the same drug (form and strength) from a different pharmacy sooner than is anticipated based on the estimated days’ supply.

After consultation with the physician, beneficiary and/or the POS help desk, the provider must determine whether there are extenuating circumstances which substantiate the dispensing of a duplicate claim.

The pharmacy provider shall record documentation of circumstances and specific contacts for the override.

For those isolated instances when one pharmacy has billed a claim, and special circumstances prevented the beneficiary from receiving the prescription from the pharmacy originally billing the claim an override is allowed. An override should only be used if the second pharmacy attempting to bill a claim for the same ingredient for the same beneficiary and cannot have the first claim reversed by the original billing pharmacy. A notation to that effect must be written on the hardcopy prescription. Pharmacy claims submitted with an override code are subject to the pharmacy audit process.

When both duplicate drug therapy and early refill clinical events occur, reimbursement will not be made. These situations indicate multiple pharmacy shopping patterns.
NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Pregnancy and FDA Category X Drugs

The Medicaid Program denies pharmacy claims with FDA Pregnancy Category for pregnant women. Pharmacy claims submitted for a drug in this category for beneficiaries with a co-payment designation of pregnancy will be denied.

The specific drugs that are currently included in FDA Pregnancy Category X are listed below. The Medicaid Program may add drugs to these lists as new drugs appear on the market or as FDA indications change.

There is no override option for these claims.

Pregnancy and FDA Category D Drugs

Pharmacy claims submitted with FDA Pregnancy Category D drugs will receive an educational edit in the response from the Medicaid Program. These claims will not deny.

Prior Drug Use

Pharmacy claims for select drugs will require prior use of other drug(s) before reimbursement.

Olmesartan/amlodipine/hydrochlorothiazide (Tribenzor®) and amlodipine/valsartan/hydrochlorothiazide (Exforge HCT®) will require prior drug use of two drug therapies from these select drug classes: calcium channel blockers, angiotensin receptor blockers, and/or diuretics. If previous claims for drugs in two of these three drug classes (calcium channel blockers, angiotensin receptor blockers, and/or diuretics) are not identified, the pharmacy claim will deny.

NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Therapeutic Duplication
The Medicaid Program denies pharmacy claims for oral formulations of drugs in the following classes and specific drugs if the beneficiary has an active paid claim on file for another drug in the same therapeutic class. An active prescription is a prescription in which the days’ supply has not expired.

If an override is determined appropriate after contacting the prescriber, additional hard-copy documentation of the reason for service code, professional service code and result of service code is required on the new prescription for audit purposes. Additional requirements may be associated with certain drug classes or specific drugs.

**First Generation Antihistamine**

- Brompheniramine Maleate
- Carbinoxamine Maleate
- Clemastine Fumarate
- Cyproheptadine HCL

If a first generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**Second Generation Antihistamine**

- Cetirizine HCL
- Desloratadine
- Fexofenadine HCL
- Levocetirizine Dihydrochloride
- Loratadine

If a second generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**First Generation Antihistamine-Decongestant**

- Pseudoephedrine HCL /Brompheniramine
- Pseudoephedrine HCL /Triprolidine HCL
- Phenylephrine/Diphenhydramine
- Pseudoephedrine HCL/Chlorpheniramine
If a first generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**Second Generation Antihistamine-Decongestant**

- Cetirizine HCL/Pseudoephedrine
- Fexofenadine/Pseudoephedrine
- Loratadine/Pseudoephedrine
- Desloratadine/Pseudoephedrine

If a second generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

Claims for diphenhydramine, hydroxyzine HCl, and hydroxyzine pamoate are not included in the antihistamine edits for therapeutic duplication.

**Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations**

- Benazepril HCl
- Benazepril HCl/Hydrochlorothiazide
- Captopril
- Captopril/Hydrochlorothiazide
- Enalapril Maleate
- Enalapril/Hydrochlorothiazide
- Fosinopril Sodium
- Fosinopril/Hydrochlorothiazide
- Lisinopril
- Lisinopril/Hydrochlorothiazide
- Moexipril HCl
- Moexipril/Hydrochlorothiazide
- Perindopril Erbumine
- Quinapril HCl
- Quinapril/Hydrochlorothiazide
- Ramipril
- Trandolapril

**ACE Inhibitors/Calcium Channel Blocker Combinations**

- Benazepril/Amlodipine
- Trandolapril/Verapamil HCl

**Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations**
Candesartan Cilexetil
Candesartan/Hydrochlorothiazide
Olmesartan Medoxomil
Eprosartan Mesylate
Eprosartan/Hydrochlorothiazide
Irbesartan
Irbesartan/Hydrochlorothiazide
Losartan Potassium
Losartan/Hydrochlorothiazide
Olmesartan Medoxomil
Olmesartan/Hydrochlorothiazide
Telmisartan
Telmisartan/Hydrochlorothiazide
Valsartan
Valsartan/Hydrochlorothiazide

ARB/Calcium Channel Blocker Combinations

Omesartan Medoxomil/Amlodipine
Valsartan/Amlodipine

Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations

Acebutolol HCl
Atenolol
Atenolol/Chlorthalidone
Betaxolol HCl
Bisoprolol Fumarate
Bisoprolol/Hydrochlorothiazide
Carvedilol
Carvedilol CR
Labetalol HCl
Metoprolol ER
Metoprolol Tartrate
Metoprolol/Hydrochlorothiazide
Nadolol
Nadolol/Bendroflumethiazide
Nebivolol HCl
Penbutolol Sulfate
Pindolol
Propranolol HCl
Propranolol/Hydrochlorothiazide
Sotalol AF
Sotalol HCl
Timolol Maleate
Timolol/Hydrochlorothiazide

Calcium Channel Blockers

Amlodipine
Diltiazem
Felodipine
Isradipine
Nicardipine
Nifedipine
Nimodipine
Nisoldipine
Verapamil
Calcium Channel Blocker/Antihyperlipemia Agent Combination

Amlodipine/Atorvastatin Calcium

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor

A pharmacy claim for a Glucagon-Like Peptide-1 (GLP-1) receptor agonist will deny with a therapeutic duplication if there is an active claim on the recipient's file for a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. A pharmacy claim for a DPP-4 inhibitor will deny with a therapeutic duplication if there is an active claim on the recipient’s file for a GLP-1 receptor agonist.

Potassium Replacement

Potassium Acetate
Potassium Chloride
Potassium Bicarbonate / Citric Acid
Potassium Citrate

Tricyclic Antidepressants

Amitriptyline HCl
Amoxapine
Clomipramine HCl
Desipramine HCl
Doxepin HCl
Imipramine HCl
Imipramine Pamoate
Maprotiline HCl
Nortriptyline HCl
Protriptyline HCl
Trimipramine Maleate

Selective Serotonin Reuptake Inhibitors

Citalopram HBr
Escitalopram Oxalate
Fluoxetine HCl
Fluvoxamine Maleate
Paroxetine HCl
Paroxetine Mesylate
Sertraline HCl
Antipsychotic Agents (Typical and Atypical)

Prescriptions for antipsychotic agents will deny for therapeutic duplication when the beneficiary has two active antipsychotic prescriptions on their file. The pharmacist must document on the hard copy prescription the reason the prescriber required the beneficiary to receive a third antipsychotic agent.

Note: Refer to “Drugs with Special Payment Criteria/Limitations” in this section for further policy regarding antipsychotic agents.

Typical Antipsychotic Agents

- Chlorpromazine
- Fluphenazine
- Haloperidol
- Loxapine
- Molindone
- Perphenazine
- Pimozide
- Thioridazine
- Thiothixene
- Trifluoperazine

Atypical Antipsychotic Agents

- Aripiprazole
- Asenapine
- Brexpiprazole
- Cariprazine
- Clozapine
- Iloperidone
- Lurasidone
- Olanzapine
- Paliperidone
- Quetiapine
- Risperidone
- Ziprasidone

Antipsychotic /Selective Serotonin Reuptake Inhibitor Combinations

Pharmacy claims for olanzapine/fluoxetine will deny when there are two active prescriptions for antipsychotic agents on the beneficiary’s file or when there is one active prescription for a selective serotonin reuptake inhibitor (SSRI) on the beneficiary’s history file.

Olanzapine/Fluoxetine

Anti-Anxiety Agents
The pharmacist must document on the hardcopy prescription the reason an additional anti-anxiety agent was requested by the prescriber.

An additional anti-anxiety agent may be submitted without a therapeutic duplication when the beneficiary has a diagnosis of seizures. The diagnosis code must be documented on the hardcopy prescription after written or verbal consultation with the prescriber and submitted electronically for the override.

Acceptable diagnosis codes are:

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>P90</td>
<td>Convulsions in Newborn</td>
</tr>
<tr>
<td>G40.*</td>
<td>Epilepsy, Seizures</td>
</tr>
<tr>
<td>R56.*</td>
<td>Other Convulsions</td>
</tr>
</tbody>
</table>

**Sedative Hypnotic Agents**

- Estazolam
- Eszopiclone
- Flurazepam HCl
- Quazepam
- Temazepam
- Triazolam
- Zaleplon
- Zolpidem Tartrate

**Attention Deficit Disorder (ADD) Agents**

- Armodafinil
- Atomoxetine
- Dexamphetamine
- Modafinil
- Lisdexamfetamine
- Methylphenidate
- Guanfacine
- Dextroamphetamine/amphetamine
- Dextroamphetamine
An incoming pharmacy claim for any of the above ADD agents will deny when there is an active paid claim for any of these agents on the beneficiary’s file written by a different prescriber.

**Non-Steroidal Anti-Inflammatory Agents**

- Celecoxib
- Diclofenac Potassium
- Diclofenac Sodium
- Diclofenac Sodium/Misoprostol
- Diflunisal
- Etodolac
- Fenoprofen Calcium
- Flurbiprofen
- Ibuprofen
- Ibuprofen/Hydrocodone Bitartrate
- Ibuprofen/Oxycodone
- Indomethacin
- Ketorolac Tromethamine
- Meclofenamate Sodium
- Mefenamic Acid
- Meloxicam
- Nabumetone
- Naproxen
- Naproxen Sodium
- Naproxen/Lansoprazole
- Oxaprozin
- Piroxicam
- Sulindac
- Tolmetin Sodium

**Short-Acting Beta2 Agonist Inhalers**

- Albuterol
- Pirbuterol
- Levalbuterol

Pharmacy claims billed for concurrent use of different short-acting beta2 agonist inhalers (SABAs) will deny with a therapeutic duplication.

**Note:** Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta2 agonist inhalers.

**Short-Acting Opiate Agents**

- Buprenorphine*
- Buprenorphine/Naloxone*
- Butorphanol Tartrate
- Codeine Phosphate
- Codeine Phosphate/APAP
- Codeine/ASA
- Codeine Sulfate
- Codeine/APAP/Caffeine/Butalbital
- Codeine/ASA/Caffeine/Butalbital
- Hydrocodone/APAP
- Hydrocodone/Ibuprofen
- Hydromorphone HCl IR
- Levorphanol Tartrate
- Meperidine HCl
- Methadone HCl
- Morphine Sulfate IR
- Oxycodone HCl IR
- Oxycodone/APAP
**Chapter 37: Pharmacy Benefits Management Services**

**Section 37.1: Covered Services, Limitations, and Exclusions**

<table>
<thead>
<tr>
<th>Drug/Antibiotic</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine/Carisoprodol/ASA</td>
<td>Oxycodone ASA</td>
</tr>
<tr>
<td>Dihydrocodeine/APAP/Caffeine</td>
<td>Oxycodone/Ibuprofen</td>
</tr>
<tr>
<td>Fentanyl Citrate Buccal</td>
<td>Oxymorphone</td>
</tr>
<tr>
<td>Pentazocine/APAP</td>
<td>Propoxyphene/APAP</td>
</tr>
<tr>
<td>Pentazocine/Naloxone</td>
<td>Tramadol HCl</td>
</tr>
<tr>
<td>Propoxyphene HCl</td>
<td>Tramadol HCl/APAP</td>
</tr>
<tr>
<td>Propoxyphene/Napsylate</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Concurrent prescriptions for opioid analgesics with buprenorphine agents may only be overridden when issued by the same physician.

**Long-Acting Opiate Agents**

<table>
<thead>
<tr>
<th>Opiate Agent</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl Transdermal</td>
<td>Oxycodone HCl CR</td>
</tr>
<tr>
<td>Morphine Sulfate CR</td>
<td>Oxymorphone ER</td>
</tr>
</tbody>
</table>

**Proton Pump Inhibitors**

<table>
<thead>
<tr>
<th>Proton Pump Inhibitor</th>
<th>Limitation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esomeprazole</td>
<td>Omeprazole/Sodium Bicarbonate</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>Pantoprazole</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>Rabeprazole</td>
</tr>
</tbody>
</table>

**Sulfonylureas**

A pharmacy claim for a sulfonylurea will deny if there is an active claim on the recipient’s file for another sulfonylurea.

The Department may add drugs to these lists as new drugs appear on the market.

**NOTE:** Refer to Section 37.5.8 - Claim Submission and Processing Payments for override information as well as the *POS User Guide* accessed by the below link or by visiting Section 37.5.1 for detailed billing information.


**Drug/Drug Interaction**
There may be some situations where adverse interactions could potentially occur between two drugs. In these instances the UniDUR system denies one or both of these claims.

Prescriptions for nitrates will deny when there is an active prescription for Sildenafil (Revatio®) or Tadalafil (Adcirca®) on the beneficiary’s drug history file. Conversely, prescriptions for Sildenafil (Revatio®) and Tadalafil (Adcirca®) will deny when there is an active prescription for nitrates on the drug history file.

Upon consultation with the prescriber, the pharmacist may override this interaction. The pharmacist must document the reason the prescriber required the beneficiary to receive a nitrate and Sildenafil (Revatio®) or Tadalafil (Adcirca®). In addition, documentation of the reason for service code, professional service code and result of service code is required on the hardcopy prescription. These DUR codes are required for the claim submission.

**Unnecessary Drug Therapy**

**Selective Cox-2 Inhibitor**

Pharmacy claims for the selective COX-2 inhibitor, celecoxib (Celebrex®) will deny for “drug use not warranted” if they are not submitted with an appropriate diagnosis code and reason for treatment documented on the hard prescription.

The FDA issued a public health advisory which stated that use of a COX-2 selective agent may be associated with an increased risk of serious cardiovascular events, especially when it is used for long periods of time or in very high-risk settings (e.g. immediately after heart surgery).

The FDA made the following interim recommendations:

- Practitioners prescribing Celecoxib (Celebrex®) should consider this emerging information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal (GI) bleeding, have a history of intolerance to non-selective NSAIDs or are not doing well on non-selective NSAIDs may be appropriate candidates for COX-2 selective agents.

- Individual patient risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account for each prescribing situation.
As a result of this public health advisory and to help ensure the safety and well-being of Medicaid beneficiaries, the prescribing practitioner must include:

- The condition being treated with the COX-2 selective agent by indicating the diagnosis code of the treated condition on all new prescriptions written for a COX-2 selective agent; and

- The reason a COX-2 selective agent is used rather than a non-selective NSAID (e.g. treatment failure or history of a GI bleed).

The diagnosis code and the rationale for the choice of a COX-2 selective agent must be noted in the prescriber’s handwriting. A rubber stamp notation is not acceptable. The diagnosis code and the rationale may be submitted as an attachment to the original prescription via facsimile. The attachment must be dated and written in the prescriber’s handwriting.

A prescription written for a COX-2 selective agent for a Medicaid beneficiary will only process without an override when the following conditions are met:

- A diagnosis code indicating the reason for treatment is documented and submitted; and

- When one of the following conditions exists:
  - Beneficiary has current prescription for H2 receptor antagonist;
  - Beneficiary has current prescription for proton pump inhibitor;
  - Beneficiary has current prescription for warfarin;
  - Beneficiary has current prescriptions indicating chronic use of oral steroids; or
  - Beneficiary is 60 years of age or older.

If, in the professional judgment of the prescriber, a determination is made which necessitates therapy with a COX-2 selective agent, the pharmacist may override this edit. The pharmacy provider must supply the reason for service code, professional service code and result of service code with the POS submission of the claim and have the information recorded on the hardcopy.
Maximum Dosage

Atypical Antipsychotic Agents

Pharmacy claims for doses of antipsychotic agents which exceed the maximum recommended doses will deny.

NOTE: Refer to Antipsychotic Agents of this section for the age limits and dosage schedules for antipsychotic agents.

The prescriber may choose to override an age or dosage limit for an antipsychotic medication. Overrides for antipsychotic medications can be addressed by the provider contacting the RxPA Unit. When the pharmacist cannot reach the prescriber or the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the antipsychotic prescription to be an “emergency.” In these emergency cases, the pharmacist must indicate “Emergency Prescription” on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system and override the age or dosage limit.

Agents Containing Acetaminophen or Aspirin

Due to the potential of hepatotoxicity, claims billed with a dosage of acetaminophen that exceeds four grams per day will deny. Claims for products containing aspirin will deny payment when the maximum daily dosage billed exceeds six grams per day. Please note that patients may also be consuming over the counter products that contain either acetaminophen or aspirin.

The maximum regimens apply to both brand name and generic products. As new products are added to the drug file, maximum daily dosages will apply.

Overrides for the (high dose) denial are only acceptable when the prescriber is consulted and approval is given. A notation stating the reason and the codes used to override the claim should be noted on the hardcopy prescription.
It is imperative that pharmacists use their professional judgment to determine an appropriate days’ supply based upon the directions noted by the prescriber.

**Suspending Agents**

Pharmacy claims for the following select suspending agents are reimbursable.

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compounding Vehicle Suspension No. 19</td>
<td>Mx-Sol Blend; Ora Blend</td>
</tr>
<tr>
<td>Compound Vehicle Suspension SF No. 20</td>
<td>Ora Plus</td>
</tr>
<tr>
<td>Compounding Vehicle No. 8</td>
<td>Ora Sweet</td>
</tr>
<tr>
<td>Compound Vehicle Sugar Free No. 9</td>
<td>Ora Sweet SF</td>
</tr>
</tbody>
</table>

**Sedative Hypnotic Agents**

Pharmacy claims which exceed the maximum daily dosage limit for selected sedative hypnotic agents will deny at POS.

The maximum daily doses for the selected sedative hypnotic agents are as follows:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Maximum Dose Per Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxepin (sedative-hypnotic only)</td>
<td>Silenor®</td>
<td>6 mg/day</td>
</tr>
<tr>
<td>Estazolam</td>
<td>Prosom®</td>
<td>2 mg/day</td>
</tr>
<tr>
<td>Eszopiclone</td>
<td>Lunesta®</td>
<td>3 mg/day</td>
</tr>
<tr>
<td>Flurazepam</td>
<td>Dalmame®</td>
<td>30 mg/day</td>
</tr>
<tr>
<td>Quazepam</td>
<td>Doral®</td>
<td>15 mg/day</td>
</tr>
<tr>
<td>Ramelteon</td>
<td>Rozerem®</td>
<td>8 mg/day</td>
</tr>
<tr>
<td>Generic Name</td>
<td>Brand Name</td>
<td>Maximum Dose Per Day</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Temazepam</td>
<td>Restoril®</td>
<td>30 mg/day</td>
</tr>
<tr>
<td>Triazolam</td>
<td>Halcion®</td>
<td>0.5 mg/day</td>
</tr>
<tr>
<td>Zaleplon</td>
<td>Sonata®</td>
<td>20 mg/day</td>
</tr>
<tr>
<td>Zolpidem IR tablet</td>
<td>Ambien®</td>
<td>10 mg/day</td>
</tr>
<tr>
<td>Zolpidem SL tablet</td>
<td>Edluar®</td>
<td>10 mg/day</td>
</tr>
<tr>
<td>Zolpidem oral spray</td>
<td>Zolpimist®</td>
<td>10 mg (2sprays)/day</td>
</tr>
<tr>
<td>Zolpidem ER tablet</td>
<td>Ambien CR®</td>
<td>12.5 mg/day</td>
</tr>
<tr>
<td>Zolpidem SL tablet</td>
<td>Intermezzo®</td>
<td>1.75mg/day (female)</td>
</tr>
<tr>
<td>Zolpidem SL tablet</td>
<td>Intermezzo®</td>
<td>3.5 mg/day (male)</td>
</tr>
</tbody>
</table>

**NOTE:** The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

**Tapentadol (Nucynta®)**

When the cumulative daily dosage for Tapentadol (Nucynta®) exceeds the maximum daily dosage of 700mg per day, the claim will deny.

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber’s reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system the reason for service code, professional service code and result of service code with the POS submission.

**Agents containing Tramadol**
Pharmacy claims for doses of agents containing Tramadol which exceed the maximum recommended doses will deny.

The maximum daily doses for agents containing Tramadol are as follows:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Maximum Dose per Day</th>
<th>Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol Immediate Release</td>
<td>400mg/day</td>
<td>&lt;76 years</td>
</tr>
<tr>
<td>Tramadol Immediate Release</td>
<td>300mg/day</td>
<td>&gt;75 years</td>
</tr>
<tr>
<td>Tramadol Sustained Release</td>
<td>300mg/day</td>
<td></td>
</tr>
<tr>
<td>Tramadol/Acetaminophen</td>
<td>8 tablets/day</td>
<td></td>
</tr>
</tbody>
</table>

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber’s reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription and supply the reason for service code, professional service code and result of service code with the POS submission.

NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Botulinum Toxins OnabotulinumtoxinA (Botox®), IncobotulinumtoxinA (Xeomin®), RimabotulinumtoxinB (Myobloc®)

Quantity Limit
Pharmacy claims for onabotulinumtoxinA (Botox®) will have quantity limits of 6 units every rolling 84 days for the 100 unit vial and 3 units every rolling 84 days for the 200 unit vial. Pharmacy claims for incobotulinumtoxinA (Xeomin®) will have quantity limits of 400 units every rolling 84 days.

Diagnosis Code Requirement

Prescriptions for onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) require an appropriate diagnosis code documented on the hard copy prescription by either the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy’s electronic recordkeeping system. The diagnosis code is required for the claim submission.

Acceptable Diagnosis Codes for OnabotulinumtoxinA (Botox®)

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>L74.510</td>
<td>Axillary Hyperhidrosis</td>
</tr>
<tr>
<td>G24.5</td>
<td>Blepharospasm</td>
</tr>
<tr>
<td>G24.3</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td>G43.7*</td>
<td>Chronic Migraine (Prophylaxis)</td>
</tr>
<tr>
<td>N32.81</td>
<td>Overactive Bladder</td>
</tr>
<tr>
<td>H49*, H50*, H51*</td>
<td>Strabismus</td>
</tr>
<tr>
<td>G35</td>
<td>Upper or Lower Limb Spasticity Associated with Multiple Sclerosis (Relapsing)</td>
</tr>
<tr>
<td>G80.0, G80.1, G80.2, G80.4, G80.8, G80.9</td>
<td>Upper or Lower Limb Spasticity Associated with Cerebral Palsy</td>
</tr>
<tr>
<td>G81.1*</td>
<td>Upper or Lower Limb Spasticity Associated with Spastic Hemiplegia</td>
</tr>
<tr>
<td>G82.53</td>
<td>Upper or Lower Limb Spasticity Associated with Complete Quadriplegia</td>
</tr>
<tr>
<td>G82.54</td>
<td>Upper or Lower Limb Spasticity Associated with Incomplete Quadriplegia</td>
</tr>
<tr>
<td>ICD-10-CM Diagnosis Code(s)</td>
<td>Description</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>L74.510</td>
<td>Axillary Hyperhidrosis</td>
</tr>
<tr>
<td>G24.5</td>
<td>Blepharospasm</td>
</tr>
<tr>
<td>G24.3</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td>G43.7*</td>
<td>Chronic Migraine (Prophylaxis)</td>
</tr>
<tr>
<td>N32.81</td>
<td>Overactive Bladder</td>
</tr>
<tr>
<td>H49*, H50*, H51*</td>
<td>Strabismus</td>
</tr>
<tr>
<td>G83.0</td>
<td>Upper Limb Spasticity Associated with Diplegia of Upper Limb</td>
</tr>
<tr>
<td>G83.1*, G83.2*, G83.3*</td>
<td>Spasticity Associated with Monoplegia of Upper or Lower Limb</td>
</tr>
<tr>
<td>I69.●31, I69.●32, I69.●33, I69.●34, I69.●39, I69.●41, I69.●42, I69.●43, I69.●44, I69.●49</td>
<td>Spasticity Associated with Monoplegia of Upper or Lower Limb due to Late Effects Cerebrovascular Disease</td>
</tr>
<tr>
<td>S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*</td>
<td>Upper or Lower Limb Spasticity Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)</td>
</tr>
<tr>
<td>N36.44, N31.9</td>
<td>Urinary Incontinence (Detrusor Overactivity Associated with Neurological Disease)</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code
● - any ONE number or letter of a valid ICD-10-CM diagnosis code
Acceptable Diagnosis Codes for IncobotulinumtoxinA (Xeomin®)

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G24.5</td>
<td>Blepharospasm</td>
</tr>
<tr>
<td>G24.3</td>
<td>Cervical Dystonia</td>
</tr>
<tr>
<td>K11.7</td>
<td>Chronic Sialorrhea</td>
</tr>
<tr>
<td>G35</td>
<td>Upper Limb Spasticity (ULS) Associated with Multiple Sclerosis (Relapsing)</td>
</tr>
<tr>
<td>G80.0, G80.1, G80.2, G80.4, G80.8, G80.9</td>
<td>Upper Limb Spasticity (ULS) Associated with Cerebral Palsy</td>
</tr>
<tr>
<td>G81.1*</td>
<td>Upper Limb Spasticity (ULS) Associated with Spastic Hemiplegia</td>
</tr>
<tr>
<td>G82.53</td>
<td>Upper Limb Spasticity (ULS) Associated with C5-C7 Complete Quadriplegia</td>
</tr>
<tr>
<td>G82.54</td>
<td>Upper Limb Spasticity (ULS) Associated with C5-C7 Incomplete Quadriplegia</td>
</tr>
<tr>
<td>G83.0</td>
<td>Upper Limb Spasticity (ULS) Associated with Diplegia of Upper Limb</td>
</tr>
<tr>
<td>S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*</td>
<td>Upper Limb Spasticity (ULS) Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)</td>
</tr>
<tr>
<td>G83.2*</td>
<td>Upper Limb Spasticity (ULS) Associated with Monoplegia of Upper Limb</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code
• - any ONE number or letter of a valid ICD-10-CM diagnosis code

Acceptable Diagnosis Codes for RimabotulinumtoxinB (Myobloc®)
Hydrocodone Containing Agents

Prescriptions for hydrocodone containing drugs will be limited to:

- 45 units per 15 days for hydrocodone/acetaminophen;
- 30 units per 15 days for hydrocodone bitartrate capsule ER 12 hour;
- 15 units per 15 days for hydrocodone bitartrate tablet ER 24 hour; and
- 30 units per 15 days for hydrocodone/ibuprofen within a 30-day period.

If a prescriber chooses to exceed the 15-day quantity limit for hydrocodone, he/she must submit a Rx PA16 to the RxPA Unit.

**NOTE:** All Schedule II prescriptions require a valid diagnosis code to process. Hydrocodone claims will not be subject to the 15-day quantity limit when one of the diagnosis codes below is submitted.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code(s)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>K11.7</td>
<td>Chronic sialorrhea</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code(s)</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>C00.<em>-C96.</em></td>
<td>Cancer</td>
</tr>
<tr>
<td>Z51.5</td>
<td>Palliative Care</td>
</tr>
</tbody>
</table>

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**NOTE:** The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.


Lidocaine Patches (Lidoderm®)
Pharmacy claims for lidocaine patches (Lidoderm®) have a quantity limit of 30 patches every rolling thirty days.

**Naltrexone Injection (Vivitrol®)**

Pharmacy claims for naltrexone injection (Vivitrol®) are subject to the following for reimbursement:
- Diagnosis code requirement;
- Age Limit;
- Quantity Limit; and
- Drug-Drug Interaction.

**Diagnosis Code Requirement**

The acceptable diagnosis code(s) for naltrexone injection (Vivitrol®) are listed below.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Diagnosis Description</th>
<th>ICD-10-CM Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naltrexone Injection</td>
<td>Alcohol Dependence</td>
<td>F10.2*</td>
</tr>
<tr>
<td>(Vivitrol®)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Opioid Dependence</td>
<td>F11.2*</td>
</tr>
</tbody>
</table>

* any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Age Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a minimum age requirement of 18 years old and older.

**Quantity Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a quantity limit of 1 unit (380mg/vial dose kit) per 28 rolling days.

**Drug-Drug Interaction**
harmacy claims for naltrexone injection (Vivitrol®) prescriptions will deny if there is an active claim on the beneficiary’s file for an opioid. Pharmacy claims for opioid prescriptions will deny if there is an active claim on the beneficiary’s file for naltrexone injection (Vivitrol®).

Opioids

Opioid prescription drugs have the following clinical edits:

- Diagnosis code requirement for all Schedule II narcotics;
- 15-day quantity limit for select opioids;
- 7-day quantity limit for select opioids for opioid naïve beneficiaries;
- Maximum of 90 Morphine Milligram Equivalent (MME) per day; and
- Prior drug use required for long-acting opioids.

Opioid 15-day Quantity Limit

Pharmacy claims for opioids will be subject to a 15-day quantity limit. The opioid quantity limits per 15-days are listed in the chart below.

<table>
<thead>
<tr>
<th>Description</th>
<th>Dosage Form</th>
<th>Units / 15 days</th>
<th>Representative Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocodone Bitartrate,</td>
<td>Capsule ER 12 hr, Tablet</td>
<td>30 units</td>
<td>Zohydro ER®, Vicoprofen®</td>
</tr>
<tr>
<td>Hydrocodone/Ibuprofen</td>
<td>Tablet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hydrocodone Bitartrate</td>
<td>Tablet ER 24 hr</td>
<td>15 units</td>
<td>Hysingla ER®</td>
</tr>
<tr>
<td>Hydrocodone/Acetaminophen</td>
<td>Short Acting Tablet/Capsule</td>
<td>45 units</td>
<td>Lortab®, Vicodin®</td>
</tr>
<tr>
<td>Hydromorphone HCl</td>
<td>Short Acting Tablet</td>
<td>45 units</td>
<td>Dilaudid®</td>
</tr>
<tr>
<td>Hydromorphone HCl</td>
<td>Tablet ER 24 hr</td>
<td>15 units</td>
<td>Exalgo®</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Tablet</td>
<td>45 units</td>
<td>Demerol®</td>
</tr>
<tr>
<td>Methadone</td>
<td>Tablet</td>
<td>45 units</td>
<td></td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td>Tablet</td>
<td>45 units</td>
<td></td>
</tr>
</tbody>
</table>
### Opioid Quantity Limits, Units per 15 Days Supply within a 30 day period

<table>
<thead>
<tr>
<th>Description</th>
<th>Dosage Form</th>
<th>Units / 15 days</th>
<th>Representative Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine Sulfate</td>
<td>Capsule ER 24 hr</td>
<td>15 units</td>
<td>Avinza®</td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td>Capsule SR Pellet, Tablet SA</td>
<td>30 units</td>
<td>Kadian®, MS Contin®</td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td>Tablet ER</td>
<td>60 units</td>
<td>Arymo ER ®</td>
</tr>
<tr>
<td>Morphine Sulfate/Naltrexone</td>
<td>Capsule SR Pellet</td>
<td>30 units</td>
<td>Embeda®</td>
</tr>
<tr>
<td>Oxycodone HCl, Oxycodone, Oxycodone/Acetaminophen</td>
<td>Tablet SR 12 hr, Capsule ER 12 hr</td>
<td>30 units</td>
<td>Oxycontin®, Xtampza ER®, Xartemis XR®</td>
</tr>
<tr>
<td>Oxycodone HCl, Oxycodone/Acetaminophen, Oxycodone/Aspirin</td>
<td>Tablet/Capsule</td>
<td>45 units</td>
<td>Roxicodone®, Endocet®, Percocet®, Roxicet®</td>
</tr>
<tr>
<td>Oxycodone/Ibuprofen</td>
<td>Tablet</td>
<td>14 units</td>
<td></td>
</tr>
<tr>
<td>Oxymorphone HCl</td>
<td>Tablet</td>
<td>45 units</td>
<td>Opana®</td>
</tr>
<tr>
<td>Oxymorphone HCl</td>
<td>Tablet SR 12 hr</td>
<td>30 units</td>
<td>Opana ER®</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>Tablet</td>
<td>45 units</td>
<td>Nucynta®</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>Tablet ER 12 hr</td>
<td>30 units</td>
<td>Nucynta ER®</td>
</tr>
<tr>
<td>Tramadol HCl</td>
<td>Tablet</td>
<td>45 units</td>
<td>Ultram®</td>
</tr>
<tr>
<td>Tramadol HCl</td>
<td>Tablet ER 24 hr, Capsule ER 24 hr</td>
<td>15 units</td>
<td>Ultram ER®, ConZip®</td>
</tr>
<tr>
<td>Tramadol/Acetaminophen</td>
<td>Tablet</td>
<td>40 units</td>
<td>Ultracet®</td>
</tr>
</tbody>
</table>

### Fentanyl Transdermal Patch Quantity Limits- Units per 30 Rolling Day Period

<table>
<thead>
<tr>
<th>Description</th>
<th>Dosage Form</th>
<th>Route</th>
<th>Strength</th>
<th>Units/30 Rolling Days</th>
<th>Representative Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>Patch</td>
<td>Transdermal</td>
<td>12, 25, 37.5, and 50 mcg/hr</td>
<td>10 units</td>
<td>Duragesic®</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>Patch</td>
<td>Transdermal</td>
<td>62.5, 75, 87.5, and 100 mcg/hr</td>
<td>20 units</td>
<td>Duragesic®</td>
</tr>
</tbody>
</table>

**NOTE:** The *POS User Guide* can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

Short-Acting Opioid 7-Day Quantity Limit (Opioid Naïve Beneficiaries)

Short-acting opioids will be limited to a 7-day supply for opioid-naïve beneficiaries. For this edit, opioid-naïve beneficiaries are defined as those who have not had an opioid claim paid within the last 90 days. The following chart lists short-acting opioids and corresponding quantity limits for opioid-naïve beneficiaries.

<table>
<thead>
<tr>
<th>Description</th>
<th>Dosage Form</th>
<th>Units/7 days</th>
<th>Representative Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine/Acetaminophen</td>
<td>Tablet</td>
<td>28</td>
<td>Tylenol® with Codeine</td>
</tr>
<tr>
<td>Hydrocodone/Acetaminophen</td>
<td>Tablet</td>
<td>28</td>
<td>Lortab®, Vicodin®</td>
</tr>
<tr>
<td>Hydrocodone/Ibuprofen</td>
<td>Tablet</td>
<td>28</td>
<td>Vicoprofen®</td>
</tr>
<tr>
<td>Hydromorphone HCl</td>
<td>Tablet</td>
<td>28</td>
<td>Dilaudid®</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Tablet</td>
<td>28</td>
<td>Demerol®</td>
</tr>
<tr>
<td>Morphine Sulfate</td>
<td></td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Oxycodone</td>
<td>Tablet/Capsule</td>
<td>28</td>
<td>Roxicodone®</td>
</tr>
<tr>
<td>Oxycodone/Acetaminophen</td>
<td></td>
<td>28</td>
<td>Endocet®, Percocet®, Roxicet®</td>
</tr>
<tr>
<td>Oxycodone/Aspirin</td>
<td></td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Oxycodone/Ibuprofen</td>
<td>Tablet</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>Oxymorphone HCl</td>
<td>Tablet</td>
<td>28</td>
<td>Opana®</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>Tablet</td>
<td>28</td>
<td>Nucynta®</td>
</tr>
<tr>
<td>Tramadol</td>
<td>Tablet</td>
<td>28</td>
<td>Ultram®</td>
</tr>
<tr>
<td>Tramadol/Acetaminophen</td>
<td>Tablet</td>
<td>28</td>
<td>Ultrace®</td>
</tr>
</tbody>
</table>

**NOTE:** The *POS User Guide* can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

Morphine Milligram Equivalent (MME) Limit

The Morphine Milligram Equivalent (MME) per day for all active opioid prescriptions for a beneficiary will be calculated. For each beneficiary, the cumulative daily MME for all active opioid prescriptions will be limited to a maximum of 90 MME per day.

Buprenorphine products for the treatment of Substance Use Disorder (SUD) will not be included in the MME limit.

NOTE: The POS User Guide can be accessed by the below link or by visiting Section 37.5.1 for detailed billing instructions and override procedures.
www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf

Long-Acting Opioid Prior Use Requirement

Pharmacy claims for an incoming prescription for a long-acting opioid will deny if there is not a paid claim for either a short-acting or long-acting opioid medication within the previous 90 days.

Opioid Quantity and MME Limit Exemptions

All Schedule II opioid prescriptions require a valid diagnosis code to process. There are exemptions to the edits for quantity limits and maximum daily MME limits for opioids. Pharmacy claims for opioid products will not be subject to the opioid quantity limits or 90 MME per day limit when the beneficiary has a diagnosis of burn, sickle cell crisis, cancer and/or palliative care. The exemptions to the opioid quantity and MME limit are listed in the chart.

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T20.2*</td>
<td>Burn of second degree of head, face, and neck</td>
</tr>
<tr>
<td>T20.3*</td>
<td>Burn of third degree of head, face, and neck</td>
</tr>
<tr>
<td>T20.6*</td>
<td>Corrosion of second degree of head, face, and neck</td>
</tr>
<tr>
<td>T20.7*</td>
<td>Corrosion of third degree of head, face, and neck</td>
</tr>
<tr>
<td>T21.2*</td>
<td>Burn of second degree trunk</td>
</tr>
<tr>
<td>T21.3*</td>
<td>Burn of third degree trunk</td>
</tr>
<tr>
<td>T21.6*</td>
<td>Corrosion of second degree of trunk</td>
</tr>
<tr>
<td>T21.7*</td>
<td>Corrosion of third degree trunk</td>
</tr>
<tr>
<td>ICD-10-CM Diagnosis Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>T22.2*</td>
<td>Burn of second degree of shoulder and upper limb, except wrist and hand</td>
</tr>
<tr>
<td>T22.3*</td>
<td>Burn of third degree of shoulder and upper limb, except wrist and hand</td>
</tr>
<tr>
<td>T22.6*</td>
<td>Corrosion of second degree of shoulder and upper limb, except wrist and hand</td>
</tr>
<tr>
<td>T22.7*</td>
<td>Corrosion of third degree of shoulder and upper limb, except wrist and hand</td>
</tr>
<tr>
<td>T23.2*</td>
<td>Burn of second degree of wrist and hand</td>
</tr>
<tr>
<td>T23.3*</td>
<td>Burn of third degree of wrist and hand</td>
</tr>
<tr>
<td>T23.6*</td>
<td>Corrosion of second degree of wrist and hand</td>
</tr>
<tr>
<td>T23.7*</td>
<td>Corrosion of third degree of wrist and hand</td>
</tr>
<tr>
<td>T24.2*</td>
<td>Burn of second degree of lower limb, except ankle and foot</td>
</tr>
<tr>
<td>T24.3*</td>
<td>Burn of third degree of lower limb, except ankle and foot</td>
</tr>
<tr>
<td>T24.6*</td>
<td>Corrosion of second degree of lower limb, except ankle and foot</td>
</tr>
<tr>
<td>T24.7*</td>
<td>Corrosion of third degree of lower limb, except ankle and foot</td>
</tr>
<tr>
<td>T25.2*</td>
<td>Burn of second degree of ankle and foot</td>
</tr>
<tr>
<td>T25.3*</td>
<td>Burn of third degree of ankle and foot</td>
</tr>
<tr>
<td>T25.6*</td>
<td>Corrosion of second degree of ankle and foot</td>
</tr>
<tr>
<td>T25.7*</td>
<td>Corrosion of third degree of ankle and foot</td>
</tr>
<tr>
<td>D57.0</td>
<td>Hb-SS disease with crisis</td>
</tr>
<tr>
<td>D57.00</td>
<td>Hb-SS disease with crisis, unspecified</td>
</tr>
<tr>
<td>D57.01</td>
<td>Hb-SS disease with acute chest syndrome</td>
</tr>
<tr>
<td>D57.02</td>
<td>Hb-SS disease with splenic sequestration</td>
</tr>
<tr>
<td>D57.21</td>
<td>Sickle-cell/Hb-C disease with crisis</td>
</tr>
<tr>
<td>D57.211</td>
<td>Sickle-cell/Hb-C disease with acute chest syndrome</td>
</tr>
<tr>
<td>D57.212</td>
<td>Sickle-cell/Hb-C disease with splenic sequestration</td>
</tr>
<tr>
<td>D57.219</td>
<td>Sickle-cell/Hb-C disease with splenic sequestration</td>
</tr>
<tr>
<td>D57.41</td>
<td>Sickle-cell thalassemia with crisis</td>
</tr>
</tbody>
</table>
### ICD-10-CM Diagnosis Code | Description
---|---
D57.411 | Sickle-cell thalassemia with acute chest syndrome
D57.412 | Sickle-cell thalassemia with splenic sequestration
D57.419 | Sickle-cell thalassemia with crisis, unspecified
D57.81 | Other sickle-cell disorders with crisis
D57.811 | Other sickle-cell disorders with acute chest syndrome
D57.812 | Other sickle-cell disorders with splenic sequestration
D57.819 | Other sickle-cell disorders with crisis, unspecified
C00.*-C96.* | Cancer
Z51.5 | Palliative Care

* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

### Opioid (Oral) Liquids

Prescriptions for opioid oral liquids will have a quantity limit of 180 mls or a 7-day supply, whichever is less.

### Serotonin Agents (Triptans)

Pharmacy claims for quantities of Serotonin agents (Triptans) which are in excess of the quantity limit will deny. Quantity limits are cumulative and are based on a rolling 30 days. Unless otherwise specified, quantity limits apply to all strengths of an agent.

Quantity limits for Serotonin agents (Triptans) are as follows:

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Dosage Form</th>
<th>Quantity Limit per 30 Rolling Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Almotriptan Maleate</td>
<td>Tablet</td>
<td>12 units</td>
</tr>
<tr>
<td>Eletriptan HBr</td>
<td>Tablet</td>
<td>6 units</td>
</tr>
<tr>
<td>Frovatriptan Succinate</td>
<td>Tablet</td>
<td>9 units</td>
</tr>
<tr>
<td>Naratriptan HCl</td>
<td>Tablet</td>
<td>9 units</td>
</tr>
</tbody>
</table>
If the prescribing practitioner chooses to exceed the quantity limit, the prescribing practitioner must provide the reason why the quantity limit needs to be exceeded. The pharmacist may override the quantity limit after consulting with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber’s reason why the quantity limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy’s electronic record keeping system the reason for service code, professional service code and result of service code with the POS submission.

### Quantity Limitations

Prescriptions payable under the Medicaid Program are limited as follows:

#### Maximum Allowable Quantities

The maximum quantity payable is either a one month’s supply or 100 unit doses, whichever is greater.

#### Maintenance Medication Quantities

Prescribed maintenance drugs for chronic illnesses should be prescribed and dispensed in economic quantities sufficient to meet the medical needs of the beneficiary. Listed below are drugs to be considered as maintenance drugs; these drugs should be dispensed in a one month’s supply:

- Anti-coagulants;
- Anti-convulsants;
- Oral anti-diabetics;
- Calcium gluconate and calcium lactate;
- Cardiovascular drugs, including diuretics, anti-hypertensives, and anti-hyperlipidemics;
- Estrogens;
- Iron supplements;
- Potassium supplements;
- Thyroids and anti-thyroid drugs; and
- Vitamins – D, K, B12 injections, folic acid, and nicotinic acid.

Coverage and Limitations for Long-Term Care Beneficiaries

Quantities for Long-Term Care Beneficiaries

Providers shall dispense a one month’s supply, unless the prescribing provider specifies a smaller quantity for medical reasons, to beneficiaries in long-term care facilities. Dispensing a smaller quantity should only be done in exceptional cases.

Specific quantity limitations for maintenance medications and prn prescriptions are as follows:

- “Maintenance” medications are those used to treat chronic conditions or illnesses. Initial therapy of a “maintenance” medication may be dispensed in a small quantity (e.g. a 10-day supply) to ensure patient tolerance before dispensing a one month’s supply of medication. The prospective DUR compliance module will only allow a refill on the eighth day of a ten-day therapy period. If on the eighth day of therapy the patient has progressed with no adverse effects, a one-month’s supply shall be dispensed unless otherwise specified by the prescriber.
• “PRN” prescriptions are those prescriptions that patients utilize on an “as needed” basis. For “prn” prescriptions, thirty units or a 10-day supply shall be supplied, unless otherwise specified by the prescriber.

The nursing home pharmacy consultant should periodically review if the “prn” order has become a “maintenance” one. In that event, refer to the “maintenance” drug policy. Otherwise, if every six months, a quantity of the “prn” medication remains unused by the resident, the health care team (nursing home administration, medical, nursing or pharmacy consultant) should reevaluate the necessity of the order as well as the quantity of the prescribed medication. Should the prescriber authorize an additional “prn” medication, then the subsequent dispensed quantity shall be reduced to an amount equal to the utilization of the prior six-month period.

Pharmacies are providing twenty-four hours coverage to the long-term care facilities. Prescription reorders should not be made until a three-day supply remains.

Co-Payment Exemption

Long-term care beneficiaries are exempt from co-payments and monthly prescriptions limits.

NOTE: Refer to Chapters 26: Intermediate Care Facilities for Individuals with Intellectual Disabilities and 34 – Nursing Facilities of the Medicaid Services Manual for detailed information regarding beneficiaries in LTC facilities.

Over the Counter Drugs

LTC facilities are responsible for providing all over the counter (OTC) drugs to Medicaid beneficiaries. OTC drugs are part of the per diem for LTC beneficiaries.

Over the Counter Drugs for Preventive Care

Select OTC agents for preventive care will be reimbursed when:

• The prescribing practitioner issues the beneficiary a prescription for the preventive care OTC agent; and

• The beneficiary meets the criteria to obtain the preventive care OTC agent.
<table>
<thead>
<tr>
<th>OTC Drug</th>
<th>Medicaid Beneficiary</th>
<th>Preventive Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin 81 mg</td>
<td>Women greater than 12 years of age</td>
<td>Cardiovascular disease, colorectal cancer, and preeclampsia prevention</td>
</tr>
<tr>
<td></td>
<td>Men greater than 44 years of age</td>
<td></td>
</tr>
<tr>
<td>Folic Acid 0.4mg and 0.8mg</td>
<td>Women ages 12-54</td>
<td>Pregnancy planning</td>
</tr>
<tr>
<td>Vitamin D 400 IU</td>
<td>Women and men greater than 64 years of age</td>
<td>Fall prevention</td>
</tr>
</tbody>
</table>

**Age Restriction**

Pharmacy claims submitted for beneficiaries outside of the age limits listed above will deny at POS.

**Days’ Supply**

Quantities of 100 units with 100 days’ supply will be allowed to process for payment.

**Copayment**

Pharmacy claims for the select preventive care OTC agents listed above will be exempt from copayment.

Coverage for aspirin 81 mg will be continued for beneficiaries greater than 79 years old; however, these pharmacy claims will be subject to copayment.

**Diabetic Supplies**

Medicaid will not reimburse pharmacies for claims for diabetic supplies when an individual resides in a long-term care facility.

**NOTE:** Refer to “Drugs with Special Payment Criteria/Limitations; Diabetic Testing Supplies” in this section for detailed information.

**Nebulizer Medications**

Medicaid will reimburse pharmacies for the nebulizer medications for those individuals who
reside in a long-term care facility who do not have Medicare.

**Medicare Skilled Nursing Facilities**

When a resident of a skilled nursing facility is in Medicare payment status, payment for prescription medications is the responsibility of the facility, as prescription services are included in the per diem paid by Medicare.

**Emergency Kits**

All drugs dispensed from an emergency kit shall be billed to the Medicaid Program indicating the date of service that coincides with the date of administration.

**Outpatient Drugs Covered by Medicare Part B**

Medicare Part B covers oral anticancer drugs, antiemetics, diabetic supplies, glucometers, antihemophilia factor products, oral immunosuppressive drugs, nebulizer medication and some other medications. Providers must be enrolled as Medicare suppliers and must bill Medicare first if the beneficiary receives Medicare benefits. Medicaid will pay any applicable deductibles and coinsurances.

**NOTE:** Refer to Section 37.5.7 Medicare Prescription Drug Coverage for detailed information on drugs covered by Medicare Part B.

**Drug Services for Hospice Beneficiaries**

“Hospice” is a concept that extends a process of care to terminally ill patients.

Hospice is a program of palliative (control of pain and symptoms) and supportive services that provides physical, psychological, social and spiritual care for dying persons and their families. Hospice care concentrates on assuring the quality of the terminal patient’s remaining life rather than on trying to prolong the length of that life.

For Medicare/Medicaid patients who have elected hospice, services covered in the beneficiary’s plan of care should not be billed to Medicaid. These services are covered in the hospice reimbursement.
To ensure the correct billing of drug services, it is imperative that the hospice provider communicate with the pharmacist to verify which drugs are related to the terminal illness (billed to the hospice) and which drugs are not related to the terminal illness (billed to Medicaid). The hospice shall assume that the distinction in billing drugs is understood by enrolled pharmacists who render services to the Medicaid beneficiaries who have elected hospice.

The pharmacy provider shall bill Louisiana Medicaid for out-patient pharmacy claims only for those drugs unrelated to the terminal illness.

Recoupment of drug claims erroneously paid to a pharmacy provider through Medicaid for those Medicaid beneficiaries who have elected hospice will be performed as they are identified. Any provider of services to a hospice beneficiary needs to clear with the hospice provider that the billed service is not included in the beneficiary’s plan of care. Erroneous payment will be recouped as identified.

NOTE: Refer to Chapter 24 - Hospice of the Medicaid Services Manual for detailed information.

GENERAL PROGRAM INFORMATION

The Pharmacy Program within the Louisiana Department of Health (LDH), Bureau of Health Services Financing (BHSF) covers all Food and Drug Administration (FDA) approved legend drugs that meet the Omnibus Budget Reconciliation Act (OBRA) ‘90 and OBRA ‘93 criteria with a few exceptions. The Pharmacy Program determines the reimbursement methodology for both the drug ingredient cost and the maximum allowable overhead cost (dispensing fee) for covered drugs.

The Pharmacy Program is responsible for the following components:

- Policy;
- Program development and implementation;
- Network development;
- Program coverage;
- Preferred drug list development and implementation and prior authorization for certain therapeutic classes;
Federal upper limit (FUL) for multiple source drugs;

Claims management;

Annual provider recertification;

Clinical interventions;

Prospective and retrospective drug utilization review (DUR);

Federal and state supplemental pharmaceutical manufacturer rebates;

Pharmacy provider desk audits;

Recipient Lock-In program;

Provider help desk;

Recipient help desk;

Provider relations; and

Provider education for prescribers and pharmacists.

The Pharmacy Program:

Initiates policy development;

Implements new policies and clarifies existing pharmacy policies, which include the services associated with outpatient drugs and Medicare/Medicaid pharmacy claims crossovers;

Approves all new drugs added to program coverage; and

Establishes any limitations on reimbursement or coverage in accordance with the federally approved reimbursement methodology.
The Pharmacy Program directs an extensive network of pharmacy providers and is also responsible for the integrity of several subsystems, including the drug file component of reference subsystem, the DUR subsystem and the drug portion of the Surveillance Utilization Review Subsystem (SURS).

**Medicaid Management Information System**

The Medicaid Management Information System (MMIS) is a computerized claims processing and information system designed to manage the Medicaid Program’s expenditures through effective claims processing and utilization control.

LDH contracts with a fiscal intermediary who operates the federally approved MMIS which is consistent with the Centers for Medicare and Medicaid Services (CMS) and LDH requirements. The fiscal intermediary (FI) is contracted to provide the following pharmacy-related services:

- Pharmacy claim processing through an on-line, real-time point of sale (POS) system;
- Coordination of the federally mandated Omnibus Budget Reconciliation Act of 1990 Drug Utilization Review (DUR) Board activities;
- Retrospective Drug Utilization Review (LaDUR);
- Prospective Drug Utilization Review (UniDUR);
- Educational articles - *Provider Update* newsletter article;
- Lock-In Program;
- DUR Board coordination;
- Preferred Drug List and prior authorization system;
- Monthly prescription limit system; and
- Electronic Data Inquiry/Clinical Drug Inquiry System (e-CDI).
PROVIDER REQUIREMENTS AND PARTICIPATION GUIDELINES

This section describes pharmacy provider qualifications, enrollment and provider records, how the provider can make changes to the provider record, Internal Revenue Services (IRS) reporting, provider rights and responsibilities, record keeping requirements, billing agents, and point of sale (POS) enrollment.

Providers should refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information on provider enrollment and requirements, including general standards for participation. (See Appendix 37.5.4 for information on accessing Chapter 1.)

Provider Qualifications

The Medicaid Program reimburses pharmacies, not individual pharmacists, for the provision of prescribed drugs.

A pharmacy is a facility licensed in accordance with R.S. 37:1164 (36): “Pharmacy means any place located within this state where drugs are dispensed and pharmacy primary care is provided, and any place outside of this state where drugs are dispensed and pharmacy primary care is provided to residents of this state.”

To enroll in the Medicaid Program, the pharmacy must have a community pharmacy or institutional pharmacy permit issued by the Louisiana Board of Pharmacy as defined by the Board’s regulations at LAC 46:LIII.1301 and §1701.

Administering Pharmacists

Pharmacists who have the “Authority to Administer” authorized by the Louisiana Board of Pharmacy may administer the influenza vaccine. Pharmacists who have this authority are required to obtain a Medicaid provider number in order for the enrolled pharmacies to be reimbursed for the administration of this vaccine. (Refer to Appendix 37.5.11 Medication Administration of this manual chapter for detailed information on medication administration, including vaccinations.)

Dispensing Physicians
Payment will be made for medications dispensed by a physician on a continuous basis only if the physician meets all of the following conditions:

- Is permitted as a dispensing physician with the Louisiana Board of Medical Examiners;
- When his/her main office is more than five miles from a facility which dispenses drugs; and
- Enrolls in the Medicaid Program as a pharmacy provider and complies with all other requirements of the prescribed drug services program.

Under the above circumstances, vendor payment (when the treating physician dispenses his own medications and bills under his own name or the name of his own clinic or hospital) will be made on the same basis as to pharmacy providers. (Refer to Section 37.3 Reimbursement for Services of this manual chapter for detailed information on reimbursement.)

**Provider Rights and Responsibilities**

**Right to Refuse Services**

A provider is not required to provide services to every recipient who requests services. A provider can limit the number of Medicaid recipients that the provider serves, and accept or reject recipients according to the pharmacy’s policies, except for the reasons described below:

- A provider cannot deny services to a recipient solely due to race, creed, color, national origin, disabling condition, or disability in accordance with the federal anti-discrimination laws; and
- A provider cannot deny services to a recipient solely due to the presence of third party insurance coverage or the recipient’s inability to pay a Medicaid co-payment.
Medical Assistance Program Integrity

The Louisiana Medical Assistance Program Integrity Law (MAPIL), R.S. 46:437.1-46 and 440.3, imposes terms and conditions on Medicaid providers. See Chapter 1 of the Medicaid Services Manual, Section 1 for information concerning the terms and conditions.

Prescription Provider Fee

A prescription fee shall be paid by each pharmacy and dispensing physician for each outpatient prescription (Medicaid and non-Medicaid) dispensed. The fee shall be $.10 per prescription dispensed by a pharmacist or dispensing physician. When a prescription is filled outside of Louisiana, but not shipped or delivered in any form or manner to a patient in the state, no provider fee shall be imposed. However, out-of-state pharmacies or dispensing physicians dispensing prescriptions which are shipped, mailed or delivered in any manner inside the state of Louisiana, shall be subject to the $.10 fee per prescription. Medicaid enrolled pharmacy providers must comply with this requirement as a condition of participation in the Medicaid Program.

Activity reports, either manually or electronically produced, must be available upon request and on-site at the pharmacy. These reports must detail the number of prescriptions dispensed and which provider fees were paid by month for any given month. Providers are assessed on a quarterly basis by the Louisiana Department of Health (LDH). This information must be readily available during an audit when requested by a representative of the Medicaid Program.

Professional Dispensing Fee Survey

All pharmacy providers must complete the professional dispensing fee surveys. These surveys are conducted periodically to determine the accuracy of the maximum allowable overhead cost (professional dispensing fee).

Federal Anti-Discrimination Laws

Providers must adhere to the following federal laws in order to maintain eligibility:

- Civil Rights Act of 1964, which prohibits discrimination on the basis of race, creed, color or national origin;
• Section 504 of the Rehabilitation Act of 1975, which prohibits discrimination on the basis of a disabling condition; and

• Americans with Disabilities Act of 1990, which assures equal access to services for persons with disabilities.

Solicitation

In accordance with R.S. 46:438.2, 46:438.4 and 42 U.S.C.1320a-7b, it is unlawful to knowingly solicit, offer, pay or receive any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring an individual to a person for the furnishing, or arranging for the furnishing, of any item or service for which payment may be made, in whole or in part, under the Medicaid Program, or in return for obtaining, purchasing, leasing, ordering, or arranging for or recommending, obtaining, purchasing, leasing, or ordering any goods, facility, item or service for which payment may be made, in whole or in part, under the Medicaid Program.

Confidentiality

All information about Medicaid recipients is confidential under federal law. Information cannot be released without the patient’s written consent unless the provider is billing a third party or releasing the information to a billing agent. Billing agents must adhere to all federal and state confidentiality requirements.

All medical and billing records must be made available to official representatives of the Medicaid Program upon request. The representative making the request must possess proper identification.

Health Insurance Portability and Accountability Act

State Medicaid programs are required to conduct reviews and audits of claims in order to comply with federal regulations 42 CFR 447.202.

LDH is a covered entity under the Health Insurance Portability and Accountability Act (HIPAA) and is exempt from the HIPAA privacy regulations regarding records for any claims for which Medicaid reimbursement is sought. This exemption extends to LDH contractors when acting on behalf of LDH. The HIPAA privacy regulations, 45 CFR 164.506 (a), provide that covered entities are permitted to use or disclose protected health information (PHI) for treatment, payment, or
health care operations. In addition, a “HIPAA Authorization” or “Opportunity to Agree or Object” by the individual is not required for uses and disclosures required by law.

Record Keeping Requirements

The provider must retain all medical, fiscal, professional, and business records on all services provided to all Medicaid recipients for a period of six years from the date of service. The records must be accessible, legible and comprehensible. If the provider is being audited, records must be retained until the audit is complete, even if six years is exceeded.

These records may be paper, film, or electronic, except as otherwise required by law or Medicaid policy.

Types of Records That Must Be Retained

The following types of records, as appropriate for the type of service provided, must be retained (the list is not all inclusive):

- Medicaid claim forms and any documents that are attached;
- Professional records, such as patient treatment plans and patient records;
- Prior authorization and service authorization information;
- Prescription records for Medicaid and other third party payors (including Medicare, private pay and cash);
- Business records, such as accounting ledgers, financial statements, purchase/acquisition records, invoices, inventory records, check registers, canceled checks, sales records, etc.;
- Tax records, including purchase documentation; and
- Provider enrollment documentation.
Requirements for Prescription Record

A patient record must be maintained for each recipient for whom new or refill prescriptions are dispensed. The record may be electronic or hard copy. The pharmacy’s patient record system must provide for the immediate retrieval of the information necessary for the pharmacist to identify previously dispensed drugs when dispensing a new or refill prescription.

All records must be maintained in accordance with the Louisiana Board of Pharmacy regulations.

Right to Review Records

Authorized state and federal agencies and their authorized representatives may audit or examine a provider’s or facility’s records without prior notice. This includes, but is not limited to, the following governmental authorities: LDH, the State Attorney General’s Medicaid Fraud Control Unit and the Department of Health and Human Services (DHHS). Providers must allow access to all Medicaid recipient records and other information that cannot be separated from the records. If requested, providers must furnish, at the provider’s expense, legible copies of all Medicaid related information to LDH, federal agencies or their representatives.

Incomplete Records

Providers who are not in compliance with the Medicaid documentation and record retention policies described in this section may be subject to administrative sanctions and recoupment of Medicaid payments. Medicaid payments for services lacking required documentation or appropriate signatures will be recouped.

Prohibition of Reassignment of Provider Claims

Medicaid payments cannot be reassigned to a factor. A factor is defined as an individual or organization, such as a collection agency or service bureau, that advances money to a provider for accounts receivable that the provider has assigned, sold or transferred to the individual organization for an added fee or a deduction of a portion of the accounts receivable. A factor does not include a billing agent.
Out-Of-State Providers

Enrollment Criteria

In accordance with LAC 50:1.701 (B), out-of-state pharmacies may enroll as providers in the Louisiana Medicaid Program to secure reimbursement for a specific claim or claims only under the following circumstances:

- When an emergency arises from an accident or illness;
- When the health of the individual would be endangered if he/she undertook travel or if care and services are postponed until his/her return to Louisiana;
- When it is general practice for residents of a particular locality to use medical resources in the medical trade areas outside of the state; or
- When the medical care and services, or needed supplementary resources, are not available within the state. Prior approval for these services is required.

If services are provided to a Medicaid recipient in accordance with the criteria detailed above, enrollment will be allowed to obtain a Medicaid provider number to secure payment of the claim. However, this Medicaid provider number will only be active to finalize the claim at issue, not to allow the out-of-state pharmacy to maintain continuous and active enrolled provider status. In no event can an out-of-state Medicaid provider number be active for 12 months from the date of service to secure payment of a single claim.

Medicare Crossover Claims

Out-of-state pharmacy providers will be allowed continuous Medicaid enrollment for crossover claims only. The out-of-state pharmacy must be enrolled in Medicare prior to enrolling in Louisiana’s Medicaid Program. When enrolling in the Medicaid Program, the out-of-state pharmacy must indicate that crossover billing is requested and submit a copy of their Medicare certification letter.
Enrollment Forms

Enrollment for the payment of a claim or claims meeting the above-referenced criteria, or for the payment of Medicare crossover claims, providers need to complete the “Basic Provider Enrollment Packet for Entities/Businesses” and the provider type-specific packet “26 Pharmacy”. (See Appendix 37.5.4 for information regarding provider enrollment).

Recipients Out of the Country

Medicaid does not reimburse for services provided to recipients when they are out of the United States.

Provider Enrollment

Every pharmacy must submit a provider enrollment application and sign an agreement in order to provide Medicaid services.

Medicaid Durable Medical Equipment/Supplies

A pharmacy provider is enrolled to bill for pharmacy services and durable medical equipment/supplies with one provider number.

NOTE: Refer to the Medicaid Services Manual, Chapter 18 Durable Medical Equipment for detailed information.

Medicare Enrollment

Pharmacies must contact the Medicare regional carrier to enroll as a Medicare provider. (See Appendix 37.5.4 for contact information.)

Refer to Appendix 37.5.7 Medicare Prescription Drug Coverage of this manual chapter for detailed information on Medicare prescription drug coverage.
Enrollment Process

The provider must submit a completed Medicaid enrollment package to the Medicaid fiscal intermediary (FI). The provider will be notified in writing by the FI when enrollment is complete. Refer to Appendix 37.5.4 for information on how to obtain provider enrollment forms.

The enrollment packet must include the following documents:

- Completed Form PE-50;
- Copy of pre-printed IRS document showing employer identification number (EIN) – CPO-545 or pre-printed payment coupon is acceptable – (W-9 forms are not acceptable);
- Completed Disclosure of Ownership and Control Interest Statement (CMS-1513) Form;
- Completed Dispensing Cost Survey forms;
- Completed Point of Sale forms (located in provider type-specific packet 26-Pharmacy);
- Copy of a voided check from the account where funds are to be electronically deposited (deposit slips are not accepted); and
- Copy of pharmacy license from the Louisiana Board of Pharmacy.

NOTE: If the request is for retroactive coverage, the license must be submitted that covers the retroactive period of coverage.

Out-of-State Pharmacy

When a pharmacy is located out-of-state and mails or delivers drugs to the state of Louisiana, the Louisiana Board of Pharmacy permit must be submitted along with the provider’s Board of Pharmacy permit from their home state.
Accuracy of Information

All statements or documents submitted by the provider must be true and accurate. Filing of false information is sufficient cause for termination from participation or denial of an application for enrollment.

Effective Date of Enrollment

Providers can request the desired date their new Medicaid provider number will become effective. The effective date entered will be considered in the enrollment process. All eligibility requirements must be met on the date requested for the date to be considered.

Providers shall not bill Medicaid prior to receipt of confirmation that they are successfully enrolled. Reimbursement will not be provided prior to the provider’s effective date of enrollment.

Licensure and Permits

Prescribed drug services providers must submit complete and legible copies of the required licenses and permits with the enrollment applications.

National Provider Identifier (NPI)

As a provision of the Health Insurance Portability and Accountability Act (HIPAA), providers must obtain and use their NPI number on all claims submissions. Providers who do not provide medical services are exempt from this requirement (i.e., non-emergency transportation, case management, and some home and community-based waiver services). Although HIPAA regulations address only electronic transactions, the Medicaid Program requires both the NPI number and the legacy seven-digit Medicaid provider number on hard copy claims.

Termination

A provider agreement can be terminated for any reason, at any time, by the provider or the state with 30 days written notice. All the conditions of the agreement remain in effect during the 30-day notice period and until termination is completed.
Exceptions to the 30-day notice, including but not limited to, are:

- If the provider is required to be licensed or certified, the effective date of termination will be the date that the license or certification became invalid;
- If the provider is suspended, excluded or terminated from Medicare or any state’s Medicaid program; or
- If the provider’s business is closed, abandoned, or non-operational, the effective date of termination will be the date that the business was closed, abandoned, or became non-operational.

Reinstatement

A provider must submit a new application, provider agreement, and other required forms to the fiscal agent to request reinstatement after a termination or suspension period. If the provider is enrolling under a different name or different tax ID number, the provider must furnish the prior name and tax ID number with the application.

Point of Sale Enrollment

POS claims processing provides on-line adjudication of Medicaid claims. With POS, a claim is electronically processed through the claims processing cycle in real-time with a response to the pharmacy within seconds of submission that indicates the recipient’s eligibility, and whether the claim is payable or rejected.

Application Forms

Providers must obtain authorization to submit claims via POS by completing the required forms included in the provider enrollment packet:

- Medicaid Pharmacy POS Provider Certification;
- Medicaid POS Agreement; and
- Pharmacy Provider Enrollment Amendment POS Enrollment.
Annual Re-certification

POS Certifications must be renewed annually. All applicable sections of this form must be completed in order for the recertification to be accepted by LDH. Recertification forms are mailed in October by LDH and are effective the following January.

Provider Record

A provider record is created by the Medicaid FI for each provider based on the information from the initial enrollment application.

Provider Identification (ID) Number

A seven-digit provider number is assigned by the FI when the provider has been approved for enrollment in the Medicaid Program. The provider ID number is used to identify the provider for billing and correspondence purposes. The provider ID number must be included on all correspondence to the FI or the Medicaid office.

Reporting Changes

All changes must be reported promptly to the FI. Information in a provider’s record can only be changed by submitting a written, signed and dated request on the provider’s letterhead stationery to the FI. (See Appendix 37.5.4 for contact information for Provider Enrollment).

NOTE: All correspondence must include the Medicaid provider number.

Change of Address

The provider must notify the FI of any change of address. The notification must include:

- The new business and mailing address(es);
- The physical location, if different;
- The provider’s previous address(es); and
- The effective date of the change.
Medicaid correspondence is sent to the billing address listed on the provider record.

**Change in Telephone Number**

The provider must notify the FI of any changes in telephone numbers. Notice of a change in telephone number(s) must include:

- The new telephone number(s);
- The provider’s previous telephone number(s); and
- The effective date of the change.

**Change in Electronic Funds Transfer**

The provider must notify the FI in writing **at least 60 days in advance of any change in financial institutions or accounts**. Failure to do so may result in lack of payment.

**Change in Federal Tax ID/ Social Security Number**

A new provider enrollment application must be completed if a provider’s federal tax identification/social security number changes.

**Provider No Longer Accepts Medicaid**

The provider must notify the FI should the pharmacy no longer accept Medicaid for any reason, including closing the business.

**Change of Ownership**

The provider must notify the FI **immediately of a change in ownership**. Failure to do so may result in departmental review. (See the Medicaid Services Manual, Chapter 1, Section 1.1, for a full description of Change in Ownership.)
The Pharmacy Program defines change of ownership based on the Louisiana Board of Pharmacy’s definition. Therefore, if a new Board of Pharmacy permit is issued due to a 50 percent or more shift in ownership, the provider is required to obtain a new Medicaid provider number.

**Reporting to the IRS**

Federal law requires Medicaid to report to IRS all payments made during the calendar year to any provider under a tax ID number.

**Louisiana Medicaid Website**

The “Pharmacy and Prescribing Providers” link on the Louisiana Medicaid website contains information to assist pharmacy providers in obtaining the following commonly requested information (See Appendix 37.5.4 for web address):

- **Single Preferred List** - The Single Preferred Drug List is a reference for the most current listing of preferred drugs as well as those drugs requiring prior authorization. This list is updated every 6 months. For additional information, refer to the Prior Authorization and Single Preferred Drug List in Section 37.1 Covered Services, Limitations, and Exclusions of this manual chapter.

- **Clinical Drug Inquiries** - The Clinical Drug Inquiry is a component of the Clinical Data Inquiry (e-CDI) that is available to pharmacists. It promotes the deliberate evaluation by providers to help prevent duplicate or inappropriate drug therapy. The e-CDI is available 24 hours a day and is updated on a daily basis. The e-CDI will provide clinical historical data on each Medicaid recipient for the current month, prior month, or prior 12 months. A copy of the displayed information can be printed in a print friendly version for the recipient’s clinical chart.

- **Prescriber Numbers** - A list of prescribing practitioner numbers and National Provider Identifier (NPI) numbers are available on the website. This listing is updated on a daily basis. For additional information refer to the “Accessing Prescriber Numbers” in Appendix 37.5.6 Prescribers of this manual chapter for more detailed information.
• **Prior Approval Program** - Details about the Prior Approval (PA) Program and process are available on the website along with contact numbers.

• **Recipient Eligibility**
  
  • **Medicaid Eligibility Verification System (MEVS)** - MEVS is an electronic system used to verify Medicaid recipient eligibility and third party liability information. This electronic verification process expedites reimbursement, reduces claim denials, and helps to eliminate fraud. Eligibility information for a recipient, including third party liability, health plan linkages, service limits and any restrictions, including Lock-In, may be obtained by accessing information through MEVS. Only one eligibility inquiry at a time may be made when using the web application. This system is available seven days a week, 24 hours per day except for occasional short maintenance periods. For additional information, refer to “Medicaid Verification” in Chapter 1 of the *Medicaid Services Manual*, Section 1.2 Recipient Eligibility.

  • **Recipient Eligibility Verification System (REVS)** - A telephonic system is also available to providers to verify eligibility information. REVS may be accessed through touch-tone telephone equipment using the fiscal intermediary’s toll-free telephone number. (See Appendix D for contact information). For additional information, refer to “Medicaid Verification” in Chapter 1 of the *Medicaid Services Manual*, Section 1.2 Recipient Eligibility.

• **Point of Sale User Guide** - The Point of Sale (POS) User Guide details the required information for claim submittal. This helpful manual lists National Council for Prescription Drug Program (NCPDP) fields and instructions for proper usage.

• **Vendor Specifications Document for the POS System** - Pharmacy providers using the Medicaid POS system are required to transmit their POS claims through
an authorized telecommunications switch vendor. This document outlines the requirements necessary for switch vendors to transmit pharmacy claims.

- **Third Party Liability Carrier Code List** - Private insurance companies are assigned a unique Louisiana carrier code. Pharmacy providers are asked to submit the third party liability (TPL) carrier code when coordinating claims for payment with a primary payor. For additional information, refer to “Third Party Liability” in Chapter 1 of the *Medicaid Services Manual*, and Section 37.3 of this manual chapter.

**Medicaid Fraud and Abuse**

To maintain the programmatic and fiscal integrity of the Medicaid Program, the federal and state governments have enacted laws, promulgated regulations and policies concerning fraud and abuse. It is the responsibility of the provider to become familiar with these laws and regulations.

In order for the Louisiana Department of Health (LDH) to receive federal funding for Medicaid services, federal regulations mandate that LDH perform certain program integrity functions. The primary functions of the Program Integrity Section are:

- Provider Enrollment;
- Fraud and Abuse Detection;
- Investigations;
- Enforcement;
- Administrative Sanctions; and
- Payment Error Rate Measurement (PERM).

Refer to Chapter 1 of the *Medicaid Services Manual*, Section 1.3 Program Integrity, to become familiar with the laws and regulations concerning fraud, abuse and other incorrect practices. This section is not all-inclusive nor does it constitute legal authority.
To report Medicaid fraud and/or abuse, contact Program Integrity. (Refer to the Appendix 37.5.4 for contact information)

Recipient Prescription Verification Letters

Prescription verification letters are sent to recipients in an effort to ensure that pharmacy services billed to Medicaid were received by the correct recipient and correctly billed. Each dispense date includes a picture of the actual drug(s) billed to Medicaid on the patient’s behalf. The recipient is asked to verify:

- They received a drug on that date of service;
- That the drug they received looks like the drug in the picture; and
- Confirm the amount of co-payment that they were asked to pay, if any.

All exceptions are investigated.

Surveillance Utilization Review Subsystem (SURS)

The fiscal intermediary, through its Surveillance Utilization Review Subsystem, can identify potential fraud and abuse situations by means of profile (SURS) reports. For detailed information concerning SURs and SURs profile reports refer to Title 50, Part I, Subpart 5, Chapter 41 – the Surveillance Utilization Review System (SURs) Rule.

Appeals

LDH provides a hearing to any provider who feels that he has been unfairly sanctioned. Specifically, the Division of Administrative Law (DAL), Health and Hospitals Section is responsible for conducting hearings for providers who have complaints. Requests for hearings should explain the reason for the request and should be made in writing. The request should be sent directly to the DAL.

Detailed information regarding the appeals procedure may be obtained from the DAL. (See Appendix 37.5.4 for contact information.)

PROVIDER AUDITS
Federal and State laws and regulations require the State Medicaid agency to ensure the integrity of the program through various monitoring, review and audit mechanisms. The Pharmacy Program is responsible for auditing Medicaid pharmacy providers. This section explains the audit program and provider responsibilities relative to audits.

Audit Purpose

The purpose of the pharmacy review/audit function is to assure that Medicaid pharmacy providers are billing and being reimbursed in compliance with federal and state laws and regulations and Pharmacy Program policy.

Audit Authority

State Medicaid programs are required to conduct reviews and audits of claims in order to comply with federal regulations at 42 CFR 447.202.

The Louisiana Department of Health (LDH) is a covered entity under the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Therefore, LDH is exempt from the HIPAA privacy regulations regarding records for any claims which Medicaid reimbursement is sought. This exemption extends to LDH contractors when acting on behalf of LDH. The federal HIPAA privacy regulations, 45 CFR 164.506 (a), provide that covered entities are permitted to use or disclose Protected Health Information (PHI) for treatment, payment or health care operations. In addition, a “HIPAA Authorization” or “Opportunity to Agree or Object” by the individual is not required for uses and disclosures required by law.

Audit Overview and Process

Since the inception of Medicaid, the Pharmacy Program has complied with the federal audit mandate.

Medicaid monitors the use of overrides for bypassing denial edits. Improper use of overrides and codes associated with these overrides by pharmacy providers may result in the disallowance of these overrides and administrative sanctions by Medicaid and the Board of Pharmacy.

Program reviews are also conducted of billings to assure required documentation is noted on hardcopy prescriptions for all pharmacy claims when an override indicator was used.
Pharmacists may receive written or telephonic requests from the auditors requesting additional information or copies of the hardcopy prescriptions or invoices in an effort to complete audit functions. When applicable, they may only ask for affirmation of correct billing.

Provider Responsibilities

Each provider upon enrolling in the Medicaid Program agrees to dispense prescriptions and operate within the Program’s laws and regulations as set forth in the approved Medicaid State Plans, administrative rules, Medicaid Program Provider Manual and other directives.

In an effort to facilitate the pharmacy audit process, information must be available upon request. This information is necessary in order to comply with the requirements for a pharmacy services provider enrolled in the Medicaid Program as stated in the provider enrollment form (PE 50) and to meet the requirements of the Louisiana State Board of Pharmacy.

At the time of audit, all Medicaid pharmacy providers must be able to produce a daily log or prescription register. This daily log whether routinely produced in hard copy or producible in hard copy at the time of audit, must contain at a minimum, for audit purposes, the following prescription data:

- Prescription number;
- Indicator as to new or refill prescription (0-11);
- Date of dispensing;
- Recipient’s name;
- Prescriber’s name;
- Drug name;
- NDC number;
- Quantity dispensed;
• Plan identifier indicating case or plan making payment; and

• Amount paid (including both copayment and plan payment, which may or may not be separated, i.e., \( \text{AMOUNT PAID} = \text{AMOUNT PLAN PAID} + \text{AMOUNT PATIENT PAID} \)).

Providers are required to refund overpayments identified by the audits and take appropriate corrective action.
REIMBURSEMENT FOR PHARMACY SERVICES

This section describes the methodologies that Medicaid uses to reimburse for prescribed drugs.

Reimbursement Methodology

The amount of reimbursement to pharmacies is determined by federal regulations and state policy. The fiscal intermediary has weekly checkwrites to reimburse the provider for those valid claims which are processed.

Medicaid reimburses the lowest of the:

- National Drug Acquisition Cost (NADAC) plus the professional dispensing fee;
- If NADAC is not available, use the Wholesale Acquisition Cost (WAC) plus the professional dispensing fee;
- Federal Upper Limit (FUL) plus the professional dispensing fee; or
- Providers’ usual and customary charge to the general public.

340B Purchased Drugs

Payment for self-administered drugs that are purchased by a covered entity through the 340B program shall be made at the 340B actual acquisition cost, which can be no more than the 340B ceiling price, plus the professional dispensing fee.

National Drug Code (NDC) System

Drugs are identified by the National Drug Code (NDC). The NDC is an 11-digit number. The first five digits identify the manufacturer or supplier, the next four digits identify the product and the last two digits identify the package size.
The provider must enter the entire 11-digit NDC for the actual product and package size dispensed on the claim as the NDC is critical for accurate reimbursement. Billing an NDC number other than the one for the product dispensed is a false claim, a violation of Medicaid policy and may be recouped.

Medicaid can only reimburse drugs whose NDC codes are on the Medicaid drug file.

Medicaid uses ingredient costs that are supplied and updated each week by a nationally recognized compendia.

**Professional Dispensing Fee**

The pharmacy provider will be reimbursed at the appropriate ingredient cost plus the professional dispensing fee or the usual and customary charge, whichever is less.

The professional dispensing fee for drugs dispensed to Louisiana Medicaid enrollees will not exceed $10.99 per prescription. The provider fee will be reimbursed separately, per legislative mandate.

The professional dispensing fee for drugs dispensed to Louisiana Medicaid enrollees and obtained through the Public Health Service 340B Program will be $10.99 per prescription. The provider fee will be reimbursed separately, per legislative mandate.

**Provider Fee**

All pharmacy providers and dispensing physicians are responsible for a ten cent (10¢) provider fee on all prescriptions they fill. The Medicaid professional dispensing fee does not include the provider fee mandated under state law.

**Usual and Customary Charges**

Federal regulations governing the Medicaid Program require that participating providers agree to charge no more for services to eligible beneficiaries than they charge for similar services to the general public.

In implementing this regulation, the Medicaid Program states that providers in the Pharmacy Program may not charge a higher professional dispensing fee, on the average, for Medicaid beneficiary’s’ prescriptions than is charged for non-beneficiary’s’ prescriptions. Consequently, pharmacists are required to indicate their usual and customary charge on their claims for prescription services even if this charge exceeds the Medicaid maximum payment.
Federal Upper Limits (FUL) Regulations

Federal Upper Limit prices are established by the Centers for Medicare and Medicaid Services (CMS). Federal regulations prohibit Medicaid from reimbursing providers more than the FUL, except as instructed.

When a prescriber indicates the brand name product is medically necessary for a particular beneficiary, and certifies that in his professional judgment the generic equivalent is not indicated, the FUL or LMAC limitations will not apply. The following procedure will apply in these cases:

• The certification must be in the prescriber’s handwriting and signed unless the prescription is submitted electronically;

• The certification may be written either directly on the prescription or on a separate sheet which is attached to the prescription or submitted electronically with prescriber approval;

• The standard phrases written by the prescriber on the prescription shall testify to the medical necessity of the brand name drug. The only acceptable phrases are “brand necessary” or “brand medically necessary”;

• If multiple prescriptions are written on the same prescription blank, the prescriber must certify which drugs require the brand name product, indicating “Brand Medically Necessary” for each prescription which requires the branded product;

• Phrases such as do not substitute, no generics or dispense as written are not acceptable for overriding MAC limitations;

• Providers should verify that the appropriate wording is properly documented at the time of dispensing; and

• Checking a printed box on the prescription to indicate that the brand is necessary is unacceptable.

Co-Payments for Prescription Services

The co-payment will be paid by the beneficiary and collected by the provider at the time the service is rendered. Medicaid reimbursement to the provider shall be adjusted to reflect the co-payment amount for which the beneficiary is liable. Providers shall continue billing their usual and customary charges for prescription services. The fiscal intermediary will calculate and deduct the co-payment amount from the amount allowed.
Co-payment Schedule

The following is the prescription co-payment schedule:

<table>
<thead>
<tr>
<th>Monthly Income</th>
<th>Copay</th>
</tr>
</thead>
<tbody>
<tr>
<td>When 5% of family’s monthly income is spent on copays</td>
<td>$0</td>
</tr>
<tr>
<td>Medication Cost</td>
<td>Copay</td>
</tr>
<tr>
<td>$10.00 or less</td>
<td>$0.50</td>
</tr>
<tr>
<td>$10.01 - $25.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>$25.01 - $50.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>$50.01 or more</td>
<td>$3.00</td>
</tr>
</tbody>
</table>

Co-payment Exemptions

The following pharmacy services are exempt from the co-payment requirement:

- Family planning services and supplies;
- Emergency services;
- Individuals younger than 21 years old;
- Pregnant women;
- Individuals who are inpatients in long-term care facilities or other institutions;
- Native Americans;
- Alaskan Eskimos;
Women who are receiving services on the basis of breast and cervical cancer;

Beneficiaries receiving preventive services such as the following:

- Aspirin 81 mg for women ages 12-19 years of age and men ages 45-79 years of age;
- Folic acid 0.4mg and 0.8mg for women ages 12-54 years of age; and
- Vitamin D 400 IU for women and men ages 65 and older;

Beneficiaries receiving hospice services; and

Beneficiaries with waiver type cases.

NOTE: Refer to Appendix D, POS User Guide for billing instructions.

Other Co-payment and Policies

In accordance with 42 CFR 447.15, the provider may not deny services to any eligible individual on account of the individual’s inability to pay the co-payment amount. The beneficiary’s assertion of his/her inability to pay the co-payment establishes the inability. Under 42 CFR 447.15, this service statement does not apply to any individual who is able to pay, nor does an individual’s inability to pay eliminate his or her liability for the co-payment. Providers shall not waive the beneficiary’s co-payment liability.

The pharmacy provider shall collect a co-payment for each drug dispensed and covered by Medicaid. **This co-payment is NOT taxable.** Providers should not collect tax on the co-payment.

Quantities dispensed by pharmacists shall not be adjusted to reflect the co-payment amounts paid by the beneficiary. By participation in the Pharmacy Program, providers have agreed to accept, as payment in full, the amounts paid by the agency plus any deductible, co-insurance or co-payment.

In accordance with CFR 447.56, co-payments of Medicaid household members are not to exceed five percent of the family income.

Department monitoring and auditing will be conducted to determine provider policies and compliance. Violators of this policy will be subject to penalty such as suspension from the program for one year.
Medicare Crossover Claims

Refer to Section 37.7 Medicare Prescription Drug Coverage regarding payment of services for which Medicaid reimburses providers for participants’ responsibilities of coinsurance and deductible payments.

Third Party Liability Claims

Refer to Section 37.8 Third Party Liability/Coordination of Benefits, regarding services which must be billed to Medicaid as the payor of last resort.
MANAGED CARE APPLICABILITY

Chapter 37: Pharmacy Benefits Management Services of the Medicaid Services Manual contains information about the fee-for-service benefits for Medicaid recipients. This manual chapter provides the minimum service requirements for the Pharmacy Services Program. Providers must comply with the service coverage requirements outlined in this policy.

For information concerning managed care benefits, providers should refer to the Managed Care Organization (MCO) manual.
APPENDIXES

Appendixes in this section:

37.5.1 – Forms and Links
37.5.2 – Claims Related Information
37.5.3 – Glossary
37.5.4 – Contact Information
37.5.5 – Preferred Drug List (PDL)
37.5.6 – Prescribers
37.5.7 – Medicare Prescription Drug Coverage
37.5.8 – Claims Submission and Processing Payments
37.5.9 – Public Health Service 340B Drug Pricing Program
37.5.10 – Total Parenteral Nutrition
37.5.11 – Medication Administration
37.5.12 – Patient Counseling and Drug Utilization Review (DUR)
37.5.13 – Lock-In Program
37.5.14 – Medicaid Drug Rebate
## FORMS AND LINKS

<table>
<thead>
<tr>
<th>FORM</th>
<th>USE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PA01</strong></td>
<td>Total Parenteral Nutrition providers are required to utilize this form to request prior authorization for TPN services.</td>
</tr>
<tr>
<td><strong>CMS-1500</strong></td>
<td>This form is submitted to receive reimbursement for Total Parenteral Nutrition services.</td>
</tr>
<tr>
<td>List of Drugs Payable on Drug File</td>
<td><a href="http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDA.pdf">www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDA.pdf</a></td>
</tr>
<tr>
<td>List of Drugs with Average Acquisition Rates</td>
<td><a href="http://www.mslc.com/Louisiana/">http://www.mslc.com/Louisiana/</a></td>
</tr>
<tr>
<td>List of DESI Drugs by National Drug Code (NDC)</td>
<td><a href="http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDB.pdf">www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDB.pdf</a></td>
</tr>
<tr>
<td>Single Preferred Drug List (PDL)</td>
<td>This link contains all forms in the clinical authorization and prior authorization process listed by drug. <a href="http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf">http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf</a></td>
</tr>
<tr>
<td>Form 211 – Drug Adjustment/Void</td>
<td><a href="http://www.lamedicaid.com/Provweb1/Forms/FINA_L_drugadjustforminstruct_71803.pdf">www.lamedicaid.com/Provweb1/Forms/FINA_L_drugadjustforminstruct_71803.pdf</a></td>
</tr>
<tr>
<td>PA01 Form – TPN Prior Authorization Form</td>
<td><a href="http://www.lamedicaid.com/Provweb1/Forms/Revise_dPA-010205052004WithInsts.pdf">www.lamedicaid.com/Provweb1/Forms/Revise_dPA-010205052004WithInsts.pdf</a></td>
</tr>
<tr>
<td>Diagnosis Code Chart</td>
<td><a href="http://www.lamedicaid.com/provweb1/Pharmacy/mFFS_ICD-10_Conversion_Table_Condensed.xlsx">http://www.lamedicaid.com/provweb1/Pharmacy/mFFS_ICD-10_Conversion_Table_Condensed.xlsx</a></td>
</tr>
</tbody>
</table>
CLAIMS RELATED INFORMATION

Hard copy billing of total parenteral nutrition (TPN) services is billed on the paper CMS-1500 (02/12) claim form or electronically on the 837P Professional transaction. Instructions in this appendix are for completing the CMS-1500; however, the same information is required when billing claims electronically. Items to be completed are listed as required, situational or optional.

**Required** information must be entered in order for the claim to process. Claims submitted with missing or invalid information in these fields will be returned unprocessed to the provider with a rejection letter listing the reason(s) the claims are being returned or will be denied through the system. These claims cannot be processed until corrected and resubmitted by the provider.

**Situational** information may be required (but only in certain circumstances as detailed in the instructions that follow).

Paper claims should be submitted to:

DXC Technology  
P.O. Box 91020  
Baton Rouge, LA  70821

**NOTE:** Electronic claims submission is the preferred method for billing. Claims are submitted on the 837P with the DME file extension. (See the EDI Specifications located on the Louisiana Medicaid web site at www.lamedicaid.com, directory link “HIPAA Information Center, sub-link “5010v of the Electronic Transactions” – 837P Professional Guide.

This appendix includes the following:

- Instructions for completing the CMS 1500 claim form and a sample of a completed CMS-1500 claim form; and
- Instructions for adjusting/voiding a claim and a sample of an adjusted CMS 1500 claim form.
CMS 1500 (02/12) INSTRUCTIONS FOR PHARMACY TPN SERVICES

You must write “DME” at the top center of the claim form!

<table>
<thead>
<tr>
<th>Locator #</th>
<th>Description</th>
<th>Instructions</th>
<th>Alerts</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Medicare / Medicaid / Tricare / Champva / Group Health Plan / Feca Blk Lung</td>
<td>Required – Enter an “X” in the box marked Medicaid (Medicaid #).</td>
<td>You must write “DME” at the top center of the Louisiana Medicaid claim form in LARGE letters.</td>
</tr>
<tr>
<td>1a</td>
<td>Insured's ID Number</td>
<td>Required – Enter the recipient’s 13 digit Medicaid ID number exactly as it appears when checking recipient eligibility through MEVS, eMEVS, or REVS.</td>
<td>NOTE: The recipients’ 13-digit Medicaid ID number must be used to bill claims. The CCN number from the plastic ID card is NOT acceptable. The ID number must match the recipient’s name in Block 2.</td>
</tr>
<tr>
<td>2</td>
<td>Patient's Name</td>
<td>Required – Enter the recipient’s last name, first name, middle initial.</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Patient's Birth Date</td>
<td>Situational – Enter the recipient’s date of birth using six (6) digits (MM DD YY). If there is only one digit in this field, precede that digit with a zero (for example, 01 02 07).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sex</td>
<td>Enter an “X” in the appropriate box to show the sex of the recipient.</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Insured's Name</td>
<td>Situational – Complete correctly if the recipient has other insurance; otherwise, leave blank.</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Patient's Address</td>
<td>Optional – Print the recipient's permanent address.</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Patient Relationship to Insured</td>
<td>Situational – Complete if appropriate or leave blank.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Insured's Address</td>
<td>Situational – Complete if appropriate or leave blank.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Reserved For NUCC Use</td>
<td>Leave Blank.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Other Insured's Name</td>
<td>Situational – Complete if appropriate or leave blank.</td>
<td></td>
</tr>
<tr>
<td>Column</td>
<td>Description</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9a</td>
<td>Other Insured's Policy or Group Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9b</td>
<td>Reserved For NUCC Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9c</td>
<td>Reserved For NUCC Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9d</td>
<td>Insurance Plan Name or Program Name</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Is Patient's Condition Related To:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Insured's Policy Group or FECA Number</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11a</td>
<td>Insured's Date of Birth Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11b</td>
<td>Other Claim ID (Designated by NUCC)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11c</td>
<td>Insurance Plan Name or Program Name</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11d</td>
<td>Is There Another Health Benefit Plan?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Patient's or Authorized Person's Signature (Release of Records)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Patient's or Authorized Person's Signature (Payment)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Situational** – If recipient has no other coverage, leave blank.

- If there is other commercial insurance coverage, the state assigned 6-digit TPL carrier code is required in this block. The carrier code is indicated on the Medicaid Eligibility Verification (MEVS) response as the Network Provider Identification Number.
- Make sure the EOB or EOBs from other insurance(s) are attached to the claim.

**ONLY the 6-digit code should be entered for commercial and Medicare HMO's in this field.**

**DO NOT enter dashes, hyphens, or the word TPL in the field.**

**NOTE: DO NOT ENTER A 6 DIGIT CODE FOR TRADITIONAL MEDICARE**
<table>
<thead>
<tr>
<th></th>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Date of Current Illness / Injury / Pregnancy</td>
<td>Optional.</td>
</tr>
<tr>
<td>15</td>
<td>Other Date</td>
<td>Leave Blank.</td>
</tr>
<tr>
<td>16</td>
<td>Dates Patient Unable to Work in Current Occupation</td>
<td>Optional.</td>
</tr>
<tr>
<td>17</td>
<td>Name of Referring Provider or Other Source</td>
<td>Required - Enter the applicable qualifier to the left of the vertical, dotted line to identify which provider is being reported.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DN  Referring Provider</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK  Ordering Provider</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enter the name (First Name, Middle Initial, Last Name) followed by the credentials of the professional who referred or ordered the service(s) or supply(ies) on the claim.</td>
</tr>
<tr>
<td>17a</td>
<td>Other ID#</td>
<td>Required – Enter the 7 digit Medicaid ID number of the referring or ordering provider.</td>
</tr>
<tr>
<td>17b</td>
<td>NPI #</td>
<td>Required - Enter the NPI number of the referring or ordering provider</td>
</tr>
<tr>
<td>18</td>
<td>Hospitalization Dates Related to Current Services</td>
<td>Optional.</td>
</tr>
<tr>
<td>19</td>
<td>Additional Claim Information (Designated by NUCC)</td>
<td>Leave Blank.</td>
</tr>
<tr>
<td>20</td>
<td>Outside Lab?</td>
<td>Optional.</td>
</tr>
<tr>
<td>21</td>
<td>ICD Ind.</td>
<td>Required – Enter the applicable ICD indicator to identify which version of ICD coding is being reported between the vertical, dotted lines in the upper right-hand portion of the field.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0  ICD-10-CM</td>
</tr>
<tr>
<td></td>
<td>Diagnosis or Nature of Illness or Injury</td>
<td>Required – Enter the most current ICD diagnosis code.</td>
</tr>
</tbody>
</table>

If multiple providers are involved, enter one provider using the following priority order:
1. Referring Provider
2. Ordering Provider

The 10-digit NPI Number is required.

The most specific diagnosis codes must be used. General codes are not acceptable.
| 22 | Resubmission and/or Original Reference Number | **Situational.** If filing an adjustment or void, enter an “A” for an adjustment or a “V” for a void as appropriate AND one of the appropriate reason codes for the adjustment or void in the “Code” portion of this field. Enter the internal control number from the paid claim line as it appears on the remittance advice in the “Original Ref. No.” portion of this field. Appropriate reason codes follow:  
**Adjustments**  
01 = Third Party Liability Recovery  
02 = Provider Correction  
03 = Fiscal Agent Error  
90 = State Office Use Only – Recovery  
99 = Other  
**Voids**  
10 = Claim Paid for Wrong Recipient  
11 = Claim Paid for Wrong Provider  
00 = Other | ICD-10 diagnosis codes must be used on claims for dates of service 10/1/15 forward. Refer to the provider notice concerning the federally required implementation of ICD-10 coding which is posted on the ICD-10 Tab at the top of the Home page ([www.lamedicaid.com](http://www.lamedicaid.com)). To adjust or void more than one claim line on a claim, a separate form is required for each claim line since each line has a different internal control number. |
| 23 | Prior Authorization Number | Required – Enter the correct 9-Digit PA number in this field. |  
| 24 | Supplemental Information | Situational – DME Providers are required to enter 11-digit NDC codes on claim detail lines for enteral feeding products only. DME providers must enter NDC information in the SHADED section of 24A – 24G of |
In addition to the procedure code, the National Drug Code (NDC) is required by the Deficit Reduction Act of 2005 and shall be entered in the shaded section of 24A through 24G.

Claims for enteral feeding products must include the NDC from the label of the product administered.

A list of the procedure codes and NDCs for products that currently require NDC information can be found on www.lamedicaid.com under the Fee Schedules directory link.

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>24A</td>
<td>Date(s) of Service</td>
<td>Required -- Enter the date of service for each procedure. Either 6-digit (MM DD YY) or eight digit (MM DD YYYY) format is acceptable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24B</td>
<td>Place of Service</td>
<td>Required -- Enter the appropriate place of service code for the services rendered.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24C</td>
<td>EMG</td>
<td>Situational – Complete is appropriate or leave blank.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24D</td>
<td>Procedures, Services, or Supplies</td>
<td>Required -- Enter the procedure code(s) for services rendered in the un-shaded area(s). When a modifier(s) is required, enter the applicable modifier in the appropriate field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24E</td>
<td>Diagnosis Pointer</td>
<td>Required – Indicate the most appropriate diagnosis for each procedure by entering the appropriate reference letter (&quot;A&quot;, &quot;B&quot;, etc.) in this block. More than one diagnosis/reference number may be related to a single procedure code.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24F</td>
<td>$Charges</td>
<td>Required -- Enter usual and customary charges for the service rendered.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The NDC indicated on the claim must match the NDC on the Prior Authorization.

Where modifiers are required, the modifier(s) on the claim must match the modifier(s) on the Prior Authorization.
<table>
<thead>
<tr>
<th>Column</th>
<th>Description</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>24G</td>
<td>Days or Units</td>
<td><strong>Required</strong> -- Enter the number of units billed for the procedure code entered on the same line in 24D</td>
</tr>
<tr>
<td>24H</td>
<td>EPSDT / Family Plan</td>
<td><strong>Situational</strong> -- Leave blank or enter a “Y” if services were performed as a result of an EPSDT referral.</td>
</tr>
<tr>
<td>24I</td>
<td>ID Qualifier</td>
<td><strong>Optional.</strong> If possible, leave blank for Louisiana Medicaid billing.</td>
</tr>
<tr>
<td>24J</td>
<td>Rendering Provider ID#</td>
<td>Leave Blank.</td>
</tr>
<tr>
<td>25</td>
<td>Federal Tax ID Number</td>
<td><strong>Optional.</strong></td>
</tr>
<tr>
<td>26</td>
<td>Patient’s Account No.</td>
<td><strong>Situational</strong> -- Enter the provider specific identifier assigned to the recipient. This number will appear on the Remittance Advice (RA). It may consist of letters and/or numbers and may be a maximum of 20 characters.</td>
</tr>
<tr>
<td>27</td>
<td>Accept Assignment?</td>
<td><strong>Optional.</strong> Claim filing acknowledges acceptance of Medicaid assignment.</td>
</tr>
<tr>
<td>28</td>
<td>Total Charge</td>
<td><strong>Required</strong> -- Enter the total of all charges listed on the claim.</td>
</tr>
</tbody>
</table>
| 29     | Amount Paid | **Situational** -- If TPL applies and block 9A is completed, enter the amount paid by the primary payor. Enter ‘0’ if the third party did not pay.  
If TPL does not apply to the claim, leave blank.  
**Do not report Medicare payments in this field.** |
| 30     | Reserved For NUCC Use | Leave Blank. |
| 31     | Signature of Physician or Supplier Including Degrees or Credentials Date | **Optional.** The practitioner or the practitioner’s authorized representative’s original signature is no longer required.  
Enter the date of the signature. |
| 32     | Service Facility Location Information | **Situational** -- Complete as appropriate or leave blank. |
| 32a    | NPI # | **Optional.** |
| 32b    | Other ID# | **Situational** -- Complete if appropriate or leave blank. |
## Billing Provider Info & Ph #

<table>
<thead>
<tr>
<th>33</th>
<th>Required -- Enter the provider name, address including zip code and telephone number.</th>
</tr>
</thead>
</table>
| 33a  | NPI#  
**Required** – Enter the billing provider's 10-digit NPI number.  
The 10-digit NPI Number must appear on paper claims. |
| 33b  | Other ID#  
**Required** – Enter the billing provider’s 7-digit Medicaid ID number.  
**ID Qualifier – Optional** – If possible, leave blank for Louisiana Medicaid claims.  
The 7-digit Medicaid Provider Number must appear on paper claims. |

A sample form is on the following page.
## SAMPLE CLAIM FORM

![Sample Claim Form Image]

---

**Page 9 of 12**

**Appendix 37.5.2**
ADJUSTING/VOIDING CLAIMS

An adjustment or void may be submitted electronically or by using the CMS-1500 (02/12) form.

Only a paid claim can be adjusted or voided. Denied claims must be corrected and resubmitted – not adjusted or voided.

Only one claim line can be adjusted or voided on each adjustment/void form.

For those claims where multiple services are billed and paid by service line, a separate adjustment/void form is required for each claim line if more than one claim line on a multiple line claim form must be adjusted or voided.

The provider should complete the information on the adjustment exactly as it appeared on the original claim, changing only the item(s) that was in error and noting the reason for the change in the space provided on the claim.

If a paid claim is being voided, the provider must enter all the information on the void from the original claim exactly as it appeared on the original claim. After a voided claim has appeared on the Remittance Advice, a corrected claim may be resubmitted (if applicable).

Only the paid claim's most recently approved control number (ICN) can be adjusted or voided; thus:

- If the claim has been successfully adjusted previously, the most current ICN (the ICN of the adjustment) must be used to further adjust the claim or to void the claim.
- If the claim has been successfully voided previously, the claim must be resubmitted as an original claim. The ICN of the voided claim is no longer active in claims history.

If a paid claim must be adjusted, almost all data can be corrected through an adjustment with the exception of the Provider Identification Number and the Recipient/Patient Identification Number.
Claims paid to an incorrect provider number or for the wrong Medicaid recipient cannot be adjusted. They must be voided and corrected claims submitted.

Adjustments/Voids Appearing on the Remittance Advice

When an Adjustment/Void Form has been processed, it will appear on the Remittance Advice under *Adjustment or Voided Claim*. The adjustment or void will appear first. The original claim line will appear in the section directly beneath the Adjustment/Void section. The approved adjustment will replace the approved original and will be listed under the "Adjustment" section on the RA. The original payment will be taken back on the same RA and appear in the "Previously Paid" column.

When the void claim is approved, it will be listed under the "Void" column of the RA.

An Adjustment/Void will generate Credit and Debit Entries which appear in the Remittance Summary on the last page of the Remittance Advice.

**NOTE:** DME must be written in large letters in the blank area at the top of the claim form.

*A sample form is on the following page*
### HEALTH INSURANCE CLAIM FORM

**APPROVED BY NATIONAL UNION FOR CLAIMS COMMISSION (NUCC) 88-88**

<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>MEDICARE/MEDICAID/THIRD PARTY</td>
</tr>
<tr>
<td>2.</td>
<td>PATIENT'S NAME (Last Name, First Name, Middle Initial)</td>
</tr>
<tr>
<td>3.</td>
<td>ADDRESS (City, State, Zip Code)</td>
</tr>
<tr>
<td>4.</td>
<td>PATIENT'S RELATIONSHIP TO INSURED</td>
</tr>
<tr>
<td>5.</td>
<td>INSURED'S ID NUMBER (For Provider in Item 1)</td>
</tr>
<tr>
<td>6.</td>
<td>CITY</td>
</tr>
<tr>
<td>7.</td>
<td>ZIP CODE</td>
</tr>
<tr>
<td>8.</td>
<td>OTHER INSURER'S NAME (Last Name, First Name, Middle Initial)</td>
</tr>
<tr>
<td>9.</td>
<td>CITY</td>
</tr>
<tr>
<td>10.</td>
<td>ZIP CODE</td>
</tr>
<tr>
<td>11.</td>
<td>INSURED'S GROUP OR FACA NUMBER</td>
</tr>
<tr>
<td>12.</td>
<td>CITY</td>
</tr>
<tr>
<td>13.</td>
<td>ZIP CODE</td>
</tr>
<tr>
<td>14.</td>
<td>PATIENT'S CONDITION RELATED TO CLAIM</td>
</tr>
<tr>
<td>15.</td>
<td>AUTO ACCIDENT</td>
</tr>
<tr>
<td>16.</td>
<td>OTHER CLAIMS TO BE COVERED BY NIOC</td>
</tr>
<tr>
<td>17.</td>
<td>INSURED'S HEALTH PLAN NAME</td>
</tr>
<tr>
<td>18.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>19.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>20.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>21.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>22.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>23.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>24.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>25.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>26.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>27.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>28.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>29.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>30.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>31.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>32.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>33.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>34.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>35.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>36.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>37.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>38.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>39.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>40.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>41.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>42.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>43.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>44.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>45.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>46.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>47.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>48.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>49.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>50.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>51.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>52.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>53.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>54.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>55.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>56.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>57.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>58.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>59.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>60.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>61.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>62.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>63.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>64.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>65.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>66.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>67.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>68.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>69.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>70.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>71.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>72.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>73.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>74.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>75.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>76.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>77.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>78.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>79.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>80.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>81.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>82.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>83.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>84.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>85.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>86.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>87.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>88.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>89.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>90.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>91.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>92.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>93.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>94.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>95.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>96.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>97.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>98.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>99.</td>
<td>OTHER INSURER'S STATEMENT OF INSURANCE</td>
</tr>
<tr>
<td>100.</td>
<td>PATIENT'S STATEMENT OF INSURANCE</td>
</tr>
</tbody>
</table>

GLOSSARY AND ACRONYMS

This is a list of abbreviations, acronyms, and definitions used in the Pharmacy Program manual chapter.

**Average Wholesale Price (AWP)** – The published suggested wholesale price of a drug. It is often used by pharmacies as a cost basis for pricing prescriptions.

**Bureau of Health Services Financing (BHSF)** – The Bureau within the Louisiana Department of Health responsible for the administration of the Medicaid Program.

**Centers for Medicare and Medicaid Services (CMS)** – The government agency within the U.S. Department of Health and Human Services (DHHS) responsible for federal administration of the Medicare and Medicaid programs (Titles XVIII, XIX and XXI of the Social Security Act).

**Louisiana Department of Health (LDH)** – The state agency responsible for administering the state’s Medicaid Program and other health and related services, including aging and adult services, public health, behavioral health, intellectual disabilities and addictive disorder services.

**Department of Health and Human Services (DHHS)** – The federal agency responsible for administering the Medicare and Medicaid Programs and other public health programs.

**Drug Efficacy Study Implementation (DESI) Drugs** – Drugs the Food and Drug Administration (FDA) has proposed to withdraw from the market because they lack substantial evidence of effectiveness.

**Dispense as Written (DAW)** – A prescribing directive issued by physicians to indicate that the pharmacy should not in any way alter a prescription. Such alterations are usually done in order to substitute a generic drug for the brand-name drug ordered.

**Drug Utilization Review (DUR)** – The quantitative evaluation of prescription drug use, physician prescribing patterns or patient drug utilization to determine the appropriateness of drug therapy.

**Dual Eligible** – Recipients who have Medicare and Medicaid coverage.

**Eligible (For purposes of the Pharmacy Program)** – An individual who has been determined to meet the Medicaid program’s eligibility criteria and is enrolled in the program.

**Estimated Acquisition Cost (EAC)** – An estimate of the price generally, and currently, paid by providers for a drug marketed or sold by a particular manufacturer or labeler in the package size.
most frequently purchased by providers.

**Federal Upper Limits (FUL)** – The upper limit amount that Medicaid can reimburse for a drug product if there are three or more generic versions of the product rated therapeutically equivalent, and there are at least three suppliers listed in the current editions of published national compendia. These limits are intended to assure that the federal government acts as a prudent buyer of drugs. The upper limits program seeks to achieve savings by taking advantage of current market prices.

**Fiscal Intermediary (FI)** – The private fiscal agent with which DHH contracts to operate the Medicaid Management Information System. The FI processes claims for Medicaid services provided under the Medical Assistance Program, issues appropriate payment and provides assistance to providers on claims.

**Full Benefit Dual Eligibles** – A population of low-income elderly individuals and individuals with disabilities who qualify for both Medicare and Medicaid coverage. While Medicare covers basic health services, including physician and hospital care, full benefit dual eligibles rely on Medicaid to pay Medicare premiums and cost-sharing and to cover critical benefits Medicare does not cover, such as long-term care and some prescription drugs.

**Intermediate Care Facility for Persons with Intellectual Disabilities (ICF/ID)** – A public or private facility that provides health and rehabilitation services to people with intellectual disabilities. An ICF/ID has four or more beds and provides “active treatment” to the residents.

**International Classification of Diseases, 10th Edition Clinical Modification (ICD-10-CM) (or its successor)** – A standard listing of diagnoses and identifying codes used by physicians for reporting diagnoses of health plan enrollees. The coding and terminology provide a uniform language that can accurately designate primary and secondary diagnoses and provide for reliable, consistent communications on claim forms.

**Lock-In** – An educational program administered by the Medicaid pharmacy program staff which restricts certain Medicaid enrollees to a specific physician and/or pharmacy.

**Intradialytic Parenteral Nutrition Therapy** – A parenteral therapy provided to an end stage renal disease (ESRD) recipient while the recipient is being dialyzed.

**Intravenous Nutrition** – Also referred to as Total Parenteral Nutrition (TPN) or hyperalimentation therapy.

**Long-Term Care** – A set of health care, personal care and social services required by persons who have lost, or never acquired, some degree of functional capacity (e.g., individuals who are
chronically ill, aged, have a physical, mental or intellectual disability) in an institution or at home, on a long-term basis. The term is often used more narrowly to refer only to long-term institutional care such as that provided in nursing facilities, homes for individuals with intellectual disabilities and mental hospitals. Ambulatory services such as home health care, which can also be provided on a long-term basis, are seen as alternatives to long-term institutional care.

**Medicaid** – A joint federal and state program that helps with medical costs for some individuals with limited income and resources according to approved Medicaid State Plans pursuant to Title XIX and XXI of the Social Security Act.

**Medicaid Eligibility Verification System (MEVS)** – Louisiana Medicaid’s electronic eligibility verification system accessed through a switch vendor.

**Medicaid Fraud** – An act of any person with the intent to defraud the state through any medical assistance program created under the federal Social Security Act and administered by the Department. (R.S. 14:70.1)

**Medicaid Management Information System (MMIS)** – The computerized claims processing and information retrieval system for the Medicaid Program. This system is an organized method of payment for claims for all Medicaid covered services. It includes all Medicaid providers and eligible recipients.

**Medicare** – The federal health insurance program which provides coverage to the aged and persons with disabilities under Title XVIII of the Social Security Act.

**Medicare (Part A/Part B)** – A U. S. health insurance program which provides hospital insurance (Part A) and supplemental medical insurance (Part B) for people aged 65 and over, for persons eligible for social security disability payments for two years or longer, and for certain workers and their dependents who need a kidney transplant or dialysis. Monies from payroll taxes and premiums from beneficiaries are deposited in special trust funds for use in meeting the expenses incurred by the insured.

**Medicare Part D** – Prescription drug coverage established by the Medicare Prescription Drug, Improvement and Modernization Act (MMA) of, which is available to all Medicare beneficiaries. Prescription drug coverage is available through private prescription drug plans (PDPs), which offer only prescription drug coverage, and Medicare Advantage Plans (MA PDs), which offer drug coverage integrated with the health coverage provided by the managed care plan. **Full benefit dual eligible Medicaid recipients no longer receive their pharmacy benefits through the Louisiana Medicaid Pharmacy Program, with the exception of some drugs excluded from the Part D benefit.**
National Drug Code (NDC) – A national classification system for identification of drugs that is similar to the Universal Product Code (UPC).

National Provider Identifier (NPI) – A 10-digit number mandated by the Health Insurance Portability and Accountability Act (HIPAA) for health care providers, which is a single provider identifier that replaces the multiple provider identifiers currently used to bill health plans.

Parenteral Nutrition Therapy – The introduction of nutrients by some means other than through the gastrointestinal tract, in particular intravenous, subcutaneous, intramuscular or intramedullary injection.

Over the Counter (OTC) – A drug product that does not require a prescription under federal or state law.

Point of Sale System (POS) – An electronic claims processing system which provides on-line adjudication of Medicaid claims. With POS, a claim is electronically processed entirely through the claims processing cycle in real-time, and within seconds of submission, a response is returned to the pharmacy that the recipient is eligible or ineligible and the claim is payable, duplicated or rejected.

Prior Authorization – The process of obtaining prior approval for a service or medication before payment can be made by the program. Prior authorization does not guarantee coverage as all program criteria must be met, such as recipient eligibility.

Provider/Provider Agency – An individual or agency enrolled with Medicaid under a provider agreement to furnish services to Medicaid recipients. Pharmacies or physicians may enroll with the state to prescribe/dispense prescriptions to Medicaid recipients.

Rebate – A monetary amount that is returned to a payor from a prescription drug manufacturer based upon utilization by a covered person or purchases by a provider.

Recipient – An individual who has been certified for medical benefits by the Medicaid Program. A recipient certified for Medicaid home and community-based waiver services may also be referred to as a participant.

Retrospective Review – Determination of medical necessity and/or appropriate billing practice for services already rendered.

Single Preferred Drug List (PDL) – Drugs that do NOT require prior authorization. These drugs may require clinical authorization.
Telecommunication Switch Vendor – A telecommunications services vendor who transfers via telephone lines, the prescription transaction from the pharmacy to the Medicaid fiscal intermediary.

Third Party Liability – Under Medicaid, third-party liability exists if there is any entity (i.e., other government programs or insurance) which is, or may be, liable to pay all or part of the medical cost or injury, disease, or disability of an applicant or recipient of Medicaid.

UniDUR – As part of the Point of Sale system, claims are subjected to editing for prospective drug utilization review.
### ACRONYMS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAP</td>
<td>American Academy of Pediatrics</td>
</tr>
<tr>
<td>ASP</td>
<td>Average Sales Price</td>
</tr>
<tr>
<td>AWP</td>
<td>Any Willing Provider OR Average Wholesale Price</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>CDI</td>
<td>Clinical Drug Inquiry</td>
</tr>
<tr>
<td>CFR</td>
<td>Code of Federal Regulations</td>
</tr>
<tr>
<td>CMSO</td>
<td>Center for Medicaid and State Operations</td>
</tr>
<tr>
<td>COB</td>
<td>Coordination of Benefits</td>
</tr>
<tr>
<td>DME</td>
<td>Durable Medical Equipment</td>
</tr>
<tr>
<td>DSM</td>
<td>Disease State Management</td>
</tr>
<tr>
<td>EFT</td>
<td>Electronic Funds Transfer</td>
</tr>
<tr>
<td>EOMB</td>
<td>Explanation of Medicare Benefits</td>
</tr>
<tr>
<td>ERA</td>
<td>Electronic Remittance Advice</td>
</tr>
<tr>
<td>ESRD</td>
<td>End Stage Renal Disease</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>HCPCS</td>
<td>HCFA Common Procedural Coding System</td>
</tr>
<tr>
<td>HRSA</td>
<td>Health Resources and Services Administration</td>
</tr>
<tr>
<td>ICN</td>
<td>Internal Control Number</td>
</tr>
<tr>
<td>IDPN</td>
<td>Intradialytic Parenteral Nutrition Therapy</td>
</tr>
<tr>
<td>LAC</td>
<td>Louisiana Administrative Code</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>LADUR</td>
<td>Louisiana Retrospective Drug Utilization Review</td>
</tr>
<tr>
<td>LAPRIMS</td>
<td>Louisiana Pharmacy Rebate Information Management System</td>
</tr>
<tr>
<td>R.S.</td>
<td>Louisiana Revised Statute</td>
</tr>
<tr>
<td>LMAC</td>
<td>Louisiana Maximum Allowable Cost</td>
</tr>
<tr>
<td>MAC</td>
<td>Maximum Allowable Cost</td>
</tr>
<tr>
<td>MAPIL</td>
<td>Medical Assistance Program Integrity Law</td>
</tr>
<tr>
<td>MMA</td>
<td>Medicare Prescription Drug, Improvement and Modernization Act of 2003</td>
</tr>
<tr>
<td>NCPDP</td>
<td>National Council for Prescription Drug Program</td>
</tr>
<tr>
<td>OBRA</td>
<td>Omnibus Budget Reconciliation Act</td>
</tr>
<tr>
<td>OTC</td>
<td>Over-the-Counter (drugs)</td>
</tr>
<tr>
<td>PA</td>
<td>Physician’s Assistant OR Prior Authorization</td>
</tr>
<tr>
<td>PAU</td>
<td>Prior Authorization Unit</td>
</tr>
<tr>
<td>PBM</td>
<td>Pharmacy Benefits Management</td>
</tr>
<tr>
<td>PCP</td>
<td>Primary Care Provider</td>
</tr>
<tr>
<td>PDL</td>
<td>Preferred Drug List</td>
</tr>
<tr>
<td>PHI</td>
<td>Protected Health Information</td>
</tr>
<tr>
<td>PHS</td>
<td>Public Health Service</td>
</tr>
<tr>
<td>PPBP</td>
<td>Provider Peer Based Profiling</td>
</tr>
<tr>
<td>PRN</td>
<td>As needed</td>
</tr>
<tr>
<td>QMB</td>
<td>Qualified Medicare Beneficiary</td>
</tr>
<tr>
<td>RA</td>
<td>Remittance Advice</td>
</tr>
</tbody>
</table>
### Appendix 37.5.3

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>REOMB</td>
<td>Recipient’s Explanation of Medical Benefits</td>
</tr>
<tr>
<td>REVS</td>
<td>Recipient Eligibility Verification System</td>
</tr>
<tr>
<td>SURS</td>
<td>Surveillance and Utilization Review Subsystem</td>
</tr>
<tr>
<td>TPN</td>
<td>Total Parenteral Nutrition</td>
</tr>
<tr>
<td>UCF</td>
<td>Universal Claim Form</td>
</tr>
<tr>
<td>ULM</td>
<td>University of Louisiana at Monroe</td>
</tr>
</tbody>
</table>
CONTACT INFORMATION

DXC Technology

Contact the Medicaid Program’s fiscal intermediary, DXC Technology for assistance with the following:

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>e-CDI technical support</td>
<td>DXC Technology</td>
</tr>
<tr>
<td></td>
<td>(877) 598-8753</td>
</tr>
<tr>
<td>Electronic Media Claims (EMC)</td>
<td>P.O. Box 91025</td>
</tr>
<tr>
<td>Electronic Claims sign up and testing</td>
<td>Baton Rouge, LA 70898</td>
</tr>
<tr>
<td></td>
<td>Phone: (225) 216-6000</td>
</tr>
<tr>
<td></td>
<td>Fax: (225) 216-6335</td>
</tr>
<tr>
<td>Pharmacy Point of Sale (POS)</td>
<td>P.O. Box 91019</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70821</td>
</tr>
<tr>
<td></td>
<td>Phone: (800) 648-0790 (Toll Free)</td>
</tr>
<tr>
<td></td>
<td>Phone: (225) 216-6381 (Local)</td>
</tr>
<tr>
<td></td>
<td>*After hours, please call REVS</td>
</tr>
<tr>
<td>Prior Authorization Unit (PAU)</td>
<td>DXC Technology – Prior Authorization</td>
</tr>
<tr>
<td></td>
<td>Phone: (800) 807-1320</td>
</tr>
<tr>
<td></td>
<td>E-PA Fax: 225-216-6481</td>
</tr>
<tr>
<td>Provider Enrollment Unit (PEU)</td>
<td>DXC Technology-Provider Enrollment</td>
</tr>
<tr>
<td></td>
<td>P. O. Box 80159</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70898-0159</td>
</tr>
<tr>
<td></td>
<td>(225) 216-6370</td>
</tr>
<tr>
<td></td>
<td>(225) 216-6392 Fax</td>
</tr>
<tr>
<td>Provider Relations Unit (PR)</td>
<td>DXC Technology – Provider Relations Unit</td>
</tr>
<tr>
<td></td>
<td>P. O. Box 91024</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70821</td>
</tr>
<tr>
<td></td>
<td>Phone: (225) 924-5040 or (800) 473-2783</td>
</tr>
<tr>
<td></td>
<td>Fax: (225) 216-6334</td>
</tr>
<tr>
<td>Recipient Eligibility Verification (REVS)</td>
<td>Phone: (800) 766-6323 (Toll Free)</td>
</tr>
<tr>
<td></td>
<td>Phone: (225) 216-7387 (Local)</td>
</tr>
</tbody>
</table>
### Contact Information

| Bureau of Health Services Financing (BHSF) – Medicaid State Office | P.O. Box 91030  
Baton Rouge, LA  70821  
Hot Line: (888) 342-6207 (Toll Free)  
[http://www.dhh.la.gov/index.cfm/subhome/1/n/331](http://www.dhh.la.gov/index.cfm/subhome/1/n/331) |
|---|---|
| Health Standards Section (HHS) | P.O. Box 3767  
Baton Rouge, LA  70821  
Phone: (225) 342-0128  
Fax: (225) 5292  
| Louisiana Children’s Health Insurance Program (LaCHIP) | (225) 342-0555 (Local)  
(877) 252-2447 (Toll Free)  
| Office of Aging and Adult Services (OAAS) | P.O. Box 2031  
Baton Rouge, LA  70821  
Phone: (866) 758-5038  
Fax: (225) 219-0202  
E-mail: MedWeb@dhh.la.gov  
[http://www.ldh.la.gov/index.cfm/subhome/12/n/7](http://www.ldh.la.gov/index.cfm/subhome/12/n/7) |
| Office of Behavioral Health (OBH) | P.O. Box 629  
Baton Rouge, LA  70821-0629  
Phone: 225-342-9500  
Fax: 225-342-5568  
Medicaid Customer Service (888) 342-6207  
[http://ldh.la.gov/index.cfm/subhome/10](http://ldh.la.gov/index.cfm/subhome/10) |
| Office for Citizens with Developmental Disabilities (OCDD) | 628 N. Fourth Street  
Baton Rouge, LA  70802  
Phone: (225) 342-0095 (Local)  
Phone: (866) 783-5553 (Toll-free)  
E-mail: ocddinfo@la.gov  
| Pharmacy Program | (800) 437-9101 |
| Take Charge Plus | Phone: (888) 342-6207 |
### Third Party Liability (TPL)

**Recovery and Premium Assistance Section**

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P. O. Box 3558</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70821</td>
</tr>
<tr>
<td></td>
<td>Phone: (225) 342-8662</td>
</tr>
<tr>
<td></td>
<td>Fax: (225) 342-1376</td>
</tr>
</tbody>
</table>

### Fraud Hotline

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>To report fraud</td>
<td>Program Integrity (PI) Section</td>
</tr>
<tr>
<td></td>
<td>P.O. Box 91030</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70821-9030</td>
</tr>
<tr>
<td></td>
<td>Fraud and Abuse Hotline: (800) 488-2917</td>
</tr>
<tr>
<td></td>
<td>Fax: (225) 219-4155</td>
</tr>
</tbody>
</table>

### Appeals

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>To file an appeal</td>
<td>Division of Administrative Law (DAL) -</td>
</tr>
<tr>
<td></td>
<td>Health and Hospitals Section</td>
</tr>
<tr>
<td></td>
<td>Post Office Box 4189</td>
</tr>
<tr>
<td></td>
<td>Baton Rouge, LA 70821-4189</td>
</tr>
<tr>
<td></td>
<td>225-342-0443</td>
</tr>
<tr>
<td></td>
<td>225-219-9823 (Fax)</td>
</tr>
</tbody>
</table>

### Other Helpful Contact Information:

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centers for Medicare and Medicaid Services</td>
<td><a href="https://www.cms.gov/">https://www.cms.gov/</a></td>
</tr>
<tr>
<td>Communi Form, LLS NCPDP Universal Claims Forms</td>
<td>Communi Form, LLC</td>
</tr>
<tr>
<td></td>
<td>Phone: (877) 817-3676</td>
</tr>
<tr>
<td></td>
<td><a href="https://www.ncpdp.org/Products/Universal-Claim-Forms">https://www.ncpdp.org/Products/Universal-Claim-Forms</a></td>
</tr>
<tr>
<td>TYPE OF ASSISTANCE</td>
<td>CONTACT INFORMATION</td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Office of Pharmacy Affairs                              | 5600 Fishers Lane  
Rockville, MD 20857  
301-594-4353  
800-628-6297  
OpaStaff@hrsa.hhs.gov  
https://www.hrsa.gov/opa |
| 340B Exclusion File                                     | https://340bopais.hrsa.gov/medicaidexclusionfiles                                    |
| Health Management Systems, Inc. (HMS)                  |  
Aetna Better Health  
Mailbox-MBU-LA_Enrollment@AETNA.com  
LHCC Healthcare Connections  
OICRequest@centene.com  
UHC Community Care Plan  
PI_COB_research@uhc.com  
AmeriHealthCarnitas  
888-922-0007  
Fee-for-Service  
Phone: (877) 204-1324  
Fax: (877) 204-1325  
E-mail: latpr@hms.com |  
Amerigroup  
ceuohi@amerigroup.com |
| Novitas Solutions, Inc.                                 | P.O. Box 3097  
Mechanicsburg, LA 17055-1815  
(855) 252-8782 |
| Office of Population Affairs (OPA) Clearinghouse        | P.O. Box 30686  
Bethesda, MD 20824-0686  
Phone: (866) 640-7827  
Fax: (866) 592-3299  
E-mail: Info@OPAclearinghouse.org |
<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louisiana Medicaid RxPA Operation</td>
<td>1800 Bienville Drive</td>
</tr>
<tr>
<td>ULM, School of Pharmacy</td>
<td>Monroe, LA 71201-3765</td>
</tr>
<tr>
<td>To obtain clinical pre-authorization</td>
<td>Phone: (866) 730-4357</td>
</tr>
<tr>
<td></td>
<td>Fax: (866) 797-2329</td>
</tr>
<tr>
<td></td>
<td><a href="http://www.lamedicaid.com/provweb1/Pharmacy/rxpa/rxpaindex.htm">http://www.lamedicaid.com/provweb1/Pharmacy/rxpa/rxpaindex.htm</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TYPE OF ASSISTANCE</th>
<th>CONTACT INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacy Help Desk</td>
<td>CVS Health</td>
</tr>
<tr>
<td>Questions concerning pharmacy claims billing</td>
<td>(855) 364-2977</td>
</tr>
<tr>
<td>Aetna</td>
<td>PerformRx</td>
</tr>
<tr>
<td></td>
<td>(800) 684-5502</td>
</tr>
<tr>
<td>AmeriHealth Caritas</td>
<td>DXC Technology</td>
</tr>
<tr>
<td></td>
<td>(800) 648-0790</td>
</tr>
<tr>
<td>Fee-for-Service</td>
<td>Express Scripts</td>
</tr>
<tr>
<td></td>
<td>(844) 367-6111</td>
</tr>
<tr>
<td>Healthy Blue</td>
<td>CVS Caremark</td>
</tr>
<tr>
<td></td>
<td>(800) 311-0543</td>
</tr>
<tr>
<td>Louisiana Healthcare Connections</td>
<td>Optum Rx</td>
</tr>
<tr>
<td></td>
<td>(866) 328-3108</td>
</tr>
</tbody>
</table>
LOUISIANA MEDICAID SINGLE PREFERRED DRUG LIST (PDL) AND NON-PREFERRED DRUG LIST (NPDL)

To access the most current and complete listing of criteria, forms, and drugs in the Medicaid PDL, prior authorization (PA), and clinical pre-authorization process, visit:

http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf
PRESCRIBERS

This section defines medical practitioners who are authorized to prescribe drugs covered by the Louisiana Medicaid Pharmacy Program. In addition, this section explains the requirement that all prescribers must have an individual Medicaid prescriber number and a National Provider Identifier (NPI) as a condition for prescription reimbursement by the program.

Qualified Prescribers

The Medicaid Program provides reimbursement for prescriptions provided to eligible recipients under regulations governing the Pharmacy Program. The prescriptions may be written by appropriate professionals who are authorized to prescribe under state law and have prescriptive authority from his/her licensing board. A qualified prescriber must be an enrolled Medicaid provider.

Prescriber Numbers

The integrity of the Pharmacy Program is dependent upon utilizing accurate data.

Each Medicaid prescriber is required to have an individual NPI and a Medicaid provider/prescriber number when submitting pharmacy claims for payment. In rare cases where a prescriber does not have a NPI, or the pharmacy cannot obtain the NPI, the pharmacy may substitute the prescriber’s Medicaid identification number in the claim submission. The system will only allow claims to be submitted with a seven-digit individual prescribing practitioner Medicaid identification number.

Prescribing practitioners who deliver health care services in state-operated mental health clinics, developmental centers and public health clinics must also have an assigned individual prescriber identification number and a NPI in order for the prescription to be reimbursed by the Medicaid Program.

Individual prescriber identification numbers are issued to all interns, residents and fellows currently in training.
Prescribers Who Are Not Medicaid Program Providers

Pharmacy providers may be reimbursed for prescriptions which are issued by prescribers who do not participate in the Medicaid Program but who have a valid Medicaid provider prescriber only number and a NPI.

If a prescribing practitioner does not have an individual Medicaid provider number, he/she should contact the fiscal intermediary (FI) Provider Enrollment Unit. (See Appendix D for contact information.)

Sanctioned Prescribers

The Medicaid Program will not reimburse pharmacy claims when the prescribing practitioner is sanctioned and/or is excluded from Medicaid program participation.

Edits have been placed on the prescriber identification numbers when prescriber licenses have been restricted, suspended or revoked. Pharmacy claims will be denied when the prescribing provider does not have prescriptive authority.

Accessing Prescriber Numbers

Pharmacy providers must make every effort to assure that the prescribing practitioner number billed is accurate. A listing of prescribing practitioner numbers is available on the Louisiana Medicaid website. This listing is updated monthly. (See Appendix D for information on accessing the website.)

Pharmacy providers may verify prescriber numbers by calling the Point of Sale (POS) Pharmacy Help Desk. (See Appendix 37.5.4 for contact information.)
MEDICARE PRESCRIPTION DRUG COVERAGE

This section describes the coordination of benefits between the Medicare Program and the Louisiana Medicaid Program for dual-eligibles.

Medicare

Medicare was enacted by Congress as part of the Social Security Amendments of 1965. It is a federal program managed by the Centers for Medicare and Medicaid Services (CMS). The state of Louisiana has no authority over the rules and laws that govern the Medicare Program.

For additional information concerning the Medicare Program, visit CMS’ website. (See Appendix 37.5.4 for contact information.)

Medicare Part B Crossover Claims

Medicare Part B covers a limited number of outpatient prescription drugs.

Medicare crossover claims are claims that have been approved for payment by Medicare and sent to Medicaid for payment towards the Medicare deductible and coinsurance.

Medicaid will only pay a crossover claim for recipients who are Qualified Medicare Beneficiaries (QMBs) when the service is covered by Medicaid. Other claims will deny as “non-covered”.

Coinsurance and deductibles are reimbursed through the Point of Sale (POS) system for covered Medicare Part B drugs and supplies when a dual-eligible individual is enrolled in the Medicare Advantage (Part C) Plan. The claims must be submitted to the Medicare Advantage Plan for payment prior to submitting to Medicaid as a coordinated claim.

Medicare Crossover Claims Submission

The provider must send claims for service provided to dual-eligible recipients to the Medicare carrier or intermediary for processing. Medicare will send the provider an explanation of Medicare benefits after the claim is processed. If Medicare has approved the claim, Medicaid will pay the deductible and/or coinsurance.
Medicare crossover claims are submitted to the Medicaid fiscal agent by one of the following methods:

- An electronic submission generated automatically by the Medicare intermediary or carrier; or
- A paper submission by the provider that includes the claim and the Explanation of Medicare Benefits (EOMB).

**Automated Crossover Carrier/Intermediary**

The automated Medicare intermediary/carrier for Part B prescription drugs is Cigna, also known as DMERC (Durable Medical Equipment Regional Carrier).

The provider may contact the National Supplier Clearinghouse. (See Appendix 37.5.4 for contact information.)

**General Medicare Part B Crossover Reimbursement Policies**

**Provider Participation**

A provider must be enrolled as a Medicaid provider in order to submit Medicare crossover claims.

**Time Limits**

The time limit for filing crossover claims with the Medicaid Program is six months from the date of the Medicare adjudication of the claim, providing the claim was filed timely with Medicare (12 months from the date of service).

**Reimbursement**

Payment allowance limits for Medicare Part B drugs and biologicals that are not paid on a cost or prospective payment basis are 106 percent of the Average Sales Price (ASP).

**Mandatory Assignment on all Drugs**

Under Section 114 of the Federal Benefits Improvement and Protection Act of 2000, payment for any drug or biological covered under Part B of Medicare may be made only on an assignment-related basis. Therefore, no charge or bill may be rendered to anyone for these drugs and
biologics for any amount except for any applicable unmet Medicare Part B deductible and coinsurance amounts.

Assignment is an agreement between the provider and the recipient. The provider agrees to accept the Medicare-approved amount as full payment for covered items or services.

If the provider accepts assignment, the beneficiary pays only 20 percent of the Medicare-approved charge, plus any portion of the unmet deductible. The beneficiary is not responsible for charges over the Medicare-approved amount.

Pharmacy providers who have agreed to accept assignment on all of their services are called “participating” providers. These providers always accept the Medicare-approved amount as payment in full for covered services.

Providers who choose to participate must do so for the calendar year. Providers who do not participate may still accept assignment on a claim-by-claim basis.

**Coordination of Benefits with Part B**

Pharmacy claim reimbursement must be coordinated with Medicare Part B and any private insurance plan in which a recipient is enrolled. Medicare may be primary or secondary to a private insurance plan. To determine whether Medicare is primary, contact Medicare. (See Appendix 37.5.4 for contact information.)

**Answers to Questions**

If providers have questions or concerns about Medicare claim processing or Medicare policy, they must follow Medicare’s procedures for resolving those issues.

If there are problems or concerns regarding Medicaid’s payment of crossover claims, the provider should contact the fiscal intermediary.

**Medicare Part B Outpatient Drug Coverage**

Medicare Part B covers a limited number of outpatient prescription drugs. Medicare Part B covers oral anticancer drugs, antiemetics, diabetic supplies, glucometers, antihemophilia factor products, oral immunosuppressive drugs, nebulizer medication and other medications. Providers must be enrolled as Medicare suppliers and must bill Medicare first if the recipient receives Medicare benefits. Medicaid will pay any applicable deductibles and coinsurances. Pharmacy providers must accept assignment on Medicare-covered prescription drugs.
Listed below are some of the outpatient drugs covered by Medicare and their payment criteria, if applicable.

Note: Refer to DMERC and the local Part B carrier for complete coverage information and updated the Healthcare Common Procedure Coding System (HCPCS) codes utilized in claim submissions.

**Immunosuppressive Drugs**

Immunosuppressive drugs are covered only for Medicare covered transplants. When a prescription is filled for these drugs and the individual is not an organ transplant recipient or Medicare Part B did not cover the transplant, refer to the Medicare Part D prescription drug plan.

**Oral Cancer Chemotherapy Drugs**

Medicare Part B provides coverage of oral, self-administered, anticancer chemotherapeutic agents. These drugs must be billed with NDC numbers.

**Antiemetic Drugs**

When oral antiemetic drugs are used in conjunction with intravenous cancer chemotherapeutic regimens, pharmacies shall bill Medicare first. The oral medication must be used as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, and must not exceed a 48-hour dosage regimen.

**Nebulizer Drugs**

Medicare will pay for medications used in a nebulizer for those recipients eligible for Medicare Part B. Refer to the Medicare Part D prescription drug plan when the recipient is in a long term care facility.

**Diabetic Supplies**

Medicare Part B covers diabetic supplies (lancets, lancet devices, glucose control solutions and blood glucose strips). Glucometers are covered in some instances.

Diabetic supplies and glucometers for long-term care recipients are covered in the nursing home per diem rate. It is allowable for Medicare Part B to be billed if the long-term care recipient is...
eligible for the benefit. Medicaid is not obligated to pay the coinsurance and deductible if the items are included in the Medicaid per diem. The Medicaid fiscal intermediary will automatically deny any crossover claims for diabetic supplies for long-term care recipients.

**Dispensing/Supply Fees**

Medicare reimburses for dispensing/supply fees when submitted with certain Part B payable drug claims. Dispensing fees are associated with nebulizer drugs. Supply fees are associated with oral antinecancer drugs, oral antiemetic drugs or immunosuppressive drugs.

**Antihemophilia Drugs**

Claims submitted by pharmacy providers for blood clotting factors shall be processed by the local Part B carrier. The local Medicare Part B carrier for the state of Louisiana is Novitas Solutions, Inc. (See Appendix 37.5.4 for contact information.)

**Medicare Part D Outpatient Drug Coverage**

Medicare Part D covered drugs include most prescription drugs, biological products, certain vaccines, insulin and medical supplies associated with the injection of insulin (syringes, needles, alcohol swabs and gauze). Some drugs will be excluded from Medicare Part D coverage as they are part of the Medicaid non-mandatory coverage provisions under sections 1927 (d)(2) and (d)(3) of the Social Security Act, or they are covered by Medicare Part A or B. The one exception is smoking cessation products, such as nicotine patches and gum, which will be covered by Medicare Part D. Reimbursement of prescription claims are determined by each individual prescription drug plan.

Medicare Part D will not cover those medications reimbursed by Medicare Part B. However, should Medicare Part B deny coverage because the drug does not meet the criteria for a Part B covered indication, the pharmacy provider should contact the Part D prescription plan.

**Medicaid Coverage for Other Excluded Part D Drugs**

To the extent that the Louisiana Medicaid Program covers the following Medicare excluded drugs for Medicaid recipients who are not full benefit dual Part D eligibles, Medicaid will be required to cover the excluded drugs for full benefit dual-eligibles.

All existing Pharmacy Program limits, co-payments and reimbursement policies apply to the Part D excluded prescriptions paid by the Medicaid Program.
Prescription Drug Program (PDP) or Medicare Advantage Plan (MA PD) non-preferred drugs are not covered, as there is a Medicare appeal process to obtain these medications.

The following excluded drugs are covered by the Medicaid Program unless they are covered by Medicare Part B or Part D.

- Agents when used for anorexia, weight loss or weight gain (Orlistat only);
- Agents when used to promote fertility when used for non-fertility treatment as described under specific state criteria;
- Agents when used for cosmetic purposes or hair growth (Isotretinoin only);
- Agents when used to promote smoking cessation as described under specific state criteria;
- Prescription vitamins and mineral products, except prenatal vitamins and fluoride:
  - Vitamin A preparations;
  - Vitamin B preparations;
  - Vitamin C preparations;
  - Vitamin D preparations;
  - Vitamin E preparations;
  - Geriatric vitamin preparations;
  - Pediatric vitamin preparations;
  - Vitamin K preparations;
  - Vitamin B12 preparations;
  - Folic Acid preparations;
  - Niacin preparations;
  - Vitamin B6 preparations;
  - Vitamin B1 preparations;
  - Multivitamin preparations;
  - Magnesium salt replacement;
  - Calcium replacement;
  - Urinary pH modifiers (Phosphorus); and
• Nonprescription drugs:
  • Sodium Chloride inhalation agents;
  • Contraceptives, topical;
  • Urinary pH modifiers;
  • Antihistamines (Diphenhydramine only);
  • 2nd Generation Antihistamines; and
  • 2nd Generation Antihistamine – Decongestant Combinations.

The Medicaid Program provides coverage for the following items which are not covered under 1927(d) (2) of the Social Security Act to all Medicaid recipients, including full benefit dual-eligibles unless Medicare Part B or Part D plans reimburse for these items.

• OTC Vitamin D preparations;
• OTC Vitamin E preparations;
• OTC Niacin preparations;
• OTC Calcium replacement agents;
• OTC Magnesium replacement agents;
• OTC Phosphate replacement agents;
• OTC Iron replacement agents;
• Normal saline and Heparin flushes;
• Diabetic supplies; and
• Family planning items.

Co-payments
The Medicaid co-payment schedule will apply for prescriptions for Part D excluded drugs that are covered by Medicaid.
CLAIMS SUBMISSION AND PROCESSING PAYMENTS

CLAIM SUBMISSION

This section describes:

- Claim submission requirements, including expression of drug quantities;
- Overrides;
- Time limits for claim submission; and
- Methods of claim submission.

National Drug Code

Drugs are identified on Medicaid claims and the Medicaid computer system drug file by the National Drug Code (NDC). The NDC is an 11-digit number. The first five digits identify the manufacturer or supplier, the next four digits identify the product and the last two digits identify the package size.

Use of NDCs

The provider must enter the entire 11-digit NDC for the actual product dispensed on the claim. Billing an NDC number, other than the one for the product dispensed, is a false claim and a violation of Medicaid policy.

NDC Code Not on the Drug File

Medicaid can only reimburse drugs whose NDC codes are on the Medicaid computer system drug file. If the NDC code is not on the Medicaid drug file, the provider may contact the Pharmacy Benefits Management (PBM) Help Desk and request that the drug be added. Drugs may be added in accordance with program policy and/or manufacturer participation in the federal drug rebate program. (See Appendix 37.5.4 for contact information.)
Drug Quantities and Unit of Measurement

Billing Unit Standard

Medicaid has adopted the National Council for Prescription Drug Programs (NCPDP) unit of measurement for the billing unit standard.

The NCPDP standard uses only three billing units to describe all drug products:

- Each;
- Milliliter (ml); or
- Gram (gm).

The use of “tablet,” “patch,” “kit,” etc. is not appropriate since these are dosage forms or package descriptions.

Dosage Forms Expressed as “Each”

The dosage forms that are expressed as “each” are:

- Solid oral medications such as tablets, capsules, etc., even when presented in dose packs or cycles;
- Suppositories;
- Transdermal patches;
- Powder packets;
- Disposable syringes; and
- Powder-filled vials, ampules and syringes for injection; irrigation; or inhalation (the quantity is the total number of vials dispensed, not the mls or gms of the final product).
Dosage Forms Expressed as “ml”

Dosage Forms that are expressed as “ml” are:

- Liquid oral medications;
- Ophthalmic and otic drops and suspensions;
- Reconstitutable oral products (the quantity is the number of milliliters in the bottle after reconstitution);
- Topical lotions or solutions;
- Liquid-filled vials, ampules or syringes for injection, irrigation or inhalation (the quantity is the total number of milliliters dispensed); and
- Inhalers and aerosols that are specified in milliliters by the manufacturer on the labeling.

Dosage Forms Expressed as “gm”

Dosage forms that are expressed as “gm” are:

- Topical or ophthalmic ointments and creams; and
- Inhalers and aerosols that are specified in grams by the manufacturer on the labeling.

Exceptions to the NCPDP Standard

The following are examples of exceptions to the NCPDP billing unit standard:

- Antihemophilic products must be expressed as the number of antihemophilic units dispensed, which will vary from vial to vial;
- Cordran® Tape and EpiPen® must be expressed as “each”;
• One Imitrex® or Diastat® kit with two syringes must be expressed as one “each”;

• One tube of Emla® cream with Tegaderm® patches must be expressed as one “each”;

• One heparin flush kit containing one syringe of heparin and two syringes of saline packaged in the same bag must be expressed as one “each”; and

• Helidac® combination therapy must be expressed as 56 dosing units.

Metric Decimal Quantities

Metric decimal quantity is used to express quantity dispensed. Providers must bill for drug quantities using decimal numbers. Whole drug numbers are no longer required. The provider must ensure that his/her software enters the correct quantity in the metric decimal field (i.e., 0.030 does not equal 30.000). Rounding is not allowed (i.e., 3.500 cannot be billed as 4.000).

Billing Questions

Billing questions regarding the correct unit type should be directed to the fiscal intermediary (FI) from 8:00am to 5:00pm, Monday through Friday. (See Appendix 37.5.4 for contact information.)

Prescriber Numbers

Prescription claims must indicate a valid individual Louisiana Medicaid prescriber number or National Provider Identifier (NPI) until only the NPI is required. Group practice numbers, hospital numbers and clinic numbers are not acceptable.

NOTE: See Appendix 37.5.6 Prescribers of this manual chapter for detailed prescriber policy.

Diagnosis Codes

Some pharmacy claims require diagnosis codes as a condition for program coverage and override of monthly prescription limits.

NOTE: See Section 37.1 Covered Services, Limitations and Exclusions of this manual chapter for specific program policy involving diagnosis codes.
Overrides

Listed below are the detailed policies regarding overrides. Refer to Appendix 37.5.1 for the link to access POS User Guide for details regarding claims submission requiring overrides.

Federal Upper Limits /Louisiana Maximum Allowable Cost Limitations

A prescriber may certify that a specified brand is medically necessary for a particular recipient. The Federal upper limit (FUL) or Louisiana Maximum Allowable Cost (LMAC) limitations for that medication will not apply.

The certification must be written either directly on, or must be a signed attachment (which may be faxed) to, the prescription. The certification must be continued in the prescriber’s handwriting. The only acceptable phrases are “brand necessary” or “brand medically necessary”.

NOTE: See “Multiple Source Drugs” in Section 37.3 Reimbursement for Services of this manual chapter for detailed information.

Prescriptions Limit

The Medicaid Program has a four prescription monthly limit. The prescription monthly limit can be overridden when the prescribing practitioner authorizes the medical necessity of the drug and communicates to the pharmacist the following information in his own handwriting or by telephone or other telecommunications device noted on, or attached to, the hard copy prescription:

- “Medically Necessary Override”; and
- A valid numeric diagnosis code that directly relates to each drug prescribed that is over the four prescription limit. (A literal description is not acceptable in lieu of a diagnosis code.)

Early Refills

If the recipient has requested the same medication at the same pharmacy five or more days early for a 30-day supply, or prior to 85 percent of medication being utilized, a claim is denied for early refill. Narcotic analgesics will deny for an early refill edit when less than 90 percent of the medication has been utilized. This translates into a two-day window based on a 30-day supply.
In some cases, the pharmacist may have knowledge of dosage changes which would warrant a recipient’s request for medication earlier than previously reported in the estimated days’ supply. With those requests, pharmacists may override this edit by documenting the circumstances on the prescription hard copy and reference the POS User Guide for detailed claims filing instructions.

**Ingredient Duplication**

A claim denial will occur as the recipient attempts to obtain the same drug from a different pharmacy sooner than is anticipated based on the estimated days’ supply.

After consultation with a physician, recipient and/or the POS Help Desk, the provider must determine whether there are extenuating circumstances which substantiate the dispensing of a duplicate claim. If extenuating circumstances exist, the provider must use procedures to initiate an override of the denial for the duplicate ingredient.

The provider must document on the prescription hard copy the circumstances for the override and reference the POS User Guide for detailed filing instructions.

**Duration of Therapy**

The Pharmacy Program has duration of therapy modules for the H2 antagonists, proton pump inhibitors (PPIs), sucralfate and Hepatitis C medications.

**NOTE:** See Section 37.1 Covered Services, Limitations and Exclusions and Appendix 37.5.1 for the link to access the Point of Sale User Guide of this manual chapter for detailed information.

**Therapeutic Duplication**

The Medicaid Program denies pharmacy claims for drugs in the following classes if the recipient has an active paid claim on file for another drug in the same therapeutic class. Antipsychotic agents require two active prescriptions on file to deny for therapeutic duplication.

- First and second generation antihistamines and first and second generation antihistamine combination agents;
- Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations, ACE Inhibitors/Calcium Channel Blocker Combinations;
- Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations;
- ARB/Calcium Channel Blocker Combinations;
- Beta Adrenergic Blocking Agents and Beta-adrenergic Blocking Agent/Diuretic Combinations;
- Calcium Channel Blockers;
- Calcium Channel Blocker/Antihyperlipidemia Agent Combination;
- Potassium Replacement Agents;
- Tricyclic Antidepressants;
- Selective Serotonin Reuptake Inhibitors;
- Antipsychotic Agents (typical and atypical);
- Antipsychotic/Selective Serotonin Reuptake Inhibitor Combinations;
- Anti-anxiety Agents;
- Sedative Hypnotic Agents;
- Attention Deficit Disorder Agents;
- Non-steroidal Anti-inflammatory Agents (inclusive of COX-2 selective agent);
- Short Acting Opiate Agents;
- Long Acting Opiate Agents; and
- Proton Pump Inhibitors.

Override provisions will be allowed after contacting the prescriber. If an override is determined to be appropriate, additional hard-copy documentation on the new prescription is necessary. The
reason for service code, professional service code and result of service code are required for audit purposes. Diagnosis codes may be required in some instances.

**NOTE:** See Section 37.1 Covered Services, Limitations and Exclusions and Appendix 37.5.1 for the link to access the POS User Guide of this manual chapter for detailed claims filing instructions.

### Unnecessary Drug Therapy

The Pharmacy Program has an unnecessary drug therapy module for the use of celecoxib (Celebrex®), armodafinil (Nuvigil®), and modafinil (Provigil®).

A valid diagnosis code is required, as well as a valid condition, warranting the COX-2 selective agent, celecoxib (Celebrex®), and armodafinil (Nuvigil®, and modafinil (Provigil®). Should the recipient not have a valid condition, and the prescriber determines that the drug therapy is necessary, the pharmacy provider must supply the reason for service code, professional service code and result of service code with the POS submission. This information must be documented on the hard copy prescription.

**NOTE:** See “Prospective Drug Utilization Policies/Limits/Edits” in Section 37.1 Covered Services, Limitations and Exclusions of this manual chapter for detailed information.

### Drug/Drug Interaction

A valid diagnosis code is required for all Sildenafil (Revatio®) and Tadalafil (Adcirca®) prescriptions.

Override provisions for the drug to drug interaction between Sildenafil or Tadalafil and nitrates will be allowed after contacting the prescriber. The pharmacist must document the reason the prescriber required both drugs. Additionally, documentation of the reason for service code, professional service code and result of service code is required on the hard copy prescription and for submission of the POS claim.

### Coordination of Benefits

Certain circumstances allow for the override of edits which allows Medicaid to be the primary payor.
NOTE: See “Override Capabilities and Codes” in Section 37.3 Reimbursement/Third Party Liability/Coordination of Benefits of this manual chapter for detailed information on these overrides.

**Pregnancy Co-Payment**

Services furnished to pregnant women, if such services are related to the pregnancy or any other medical conditions that complicate the pregnancy, are exempt from co-payments.

When a prescribing provider issues a prescription to a pregnant woman, he or she shall indicate on the prescription that the recipient is pregnant. In the case of a telephoned prescription, the information that the recipient is pregnant shall be communicated to the pharmacist and the pharmacist must document on the prescription that the recipient is pregnant.

When the prescribing provider authorizes a prescription for a pregnant recipient, the pharmacist shall maintain the proper documentation on the prescription, for audit purposes, indicating that the individual is pregnant.

NOTE: See Appendix 37.5.1 for the link to access POS User Guide of this manual chapter for detailed claims filing instructions.

**Age and Gender Overrides**

Some drugs have age and/or sex restrictions.

Pharmacy providers should contact the Pharmacy Program to address questions regarding age or sex restrictions. (See Appendix 37.5.4 for contact information.)

NOTE: See “Drugs with Special Payment Criteria/Limitations” in Section 37.1 Covered Services, Limitations and Exclusions for other criteria and Appendix 37.5.1 to access the link to the POS User Guide for detailed billing information.

**Maximum Dosage**

Selected medications have maximum dosage limits. Prescriptions for atypical antipsychotic agents, agents containing tramadol and tapentadol (Nucynta®) will deny when the maximum recommended doses are exceeded.
Due to the potential of hepatotoxicity, claims billed with a dosage of acetaminophen that exceeds four grams per day will deny. Claims for products containing aspirin will deny payment when the maximum daily dosage billed exceeds six grams a day.

The prescriber must be consulted and the reason and override codes must be documented on the hard copy prescription. The pharmacy must supply the reason for service code, professional service code and result of service code with the POS submission.

**Quantity Exceeds Program Maximum**

Pharmacy claims for selected medications used in the management of pain are subject to maximum quantities. Quantity limits are cumulative, based on a rolling days’ supply and apply to all strengths of an agent. Selected medications may be eligible for an override with prescriber authorization and documentation. If the prescriber chooses to exceed the limit, he/she must provide the reason why the quantity limit needs to be exceeded. After consulting with the prescriber, the pharmacist must document the prescriber’s reason and DUR override codes on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system. The pharmacist should reference the POS User Guide for detailed claims filing instructions.

Most prescriptions for recipients who have confirmed diagnosis of cancer are exempt from quantity limits for pain medications. All prescriptions for Schedule II narcotic agents require a diagnosis code documented on the hardcopy prescription. When a diagnosis code is not on the prescription and the prescriber cannot be reached, the pharmacist can then determine if the recipient cannot wait to receive the medication and override the edit.

**Prior Authorization (PA) Emergency**

This emergency procedure may be used when the PA Unit is closed (Sundays and Monday-Saturday before 8am and after 6pm) or when the PA system is unavailable. The pharmacist should also use professional judgment in situations that would necessitate an emergency supply.

Prescriptions indicating emergency situations shall be dispensed in a minimum quantity of a 72-hour or a three-day supply. **Refills for the dispensing of the non-preferred products in these emergency situations are not permitted.**

The prescribing practitioner must indicate that the prescription is an emergency prescription (Rx) on the face of the prescription if hard copy or if the prescription is called in to the pharmacy, the
emergency status of the prescription must be communicated to the pharmacist who must indicate “Emergency by Pharmacist” on the hard copy prescription.

**Hospital Discharge Prescriptions for Atypical Antipsychotic Agents**

When a recipient is discharged from a hospital with a prescription for an atypical antipsychotic prescription, the prescribing practitioner must indicate on the face of the prescription, if hard copy, that the prescription is a “Hospital Discharge” or if the prescription is called in to the pharmacy, the “Hospital Discharge” status of the prescription must be communicated to the pharmacist who must indicate “Hospital Discharge” on the hard copy of the prescription.

In situations where the prescribing practitioner is unavailable and the pharmacist determines the prescription is a “Hospital Discharge” prescription, the pharmacist must indicate “Hospital Discharge” on the hard copy prescription.

Claims for “Hospital Discharge” prescriptions needing prior authorization will be submitted using the same process used for an emergency override.

Prescriptions for “Hospital Discharge” products shall be dispensed in a minimum quantity of a three-day supply and refills for the dispensing of the non-preferred products are not permitted. The recipient’s practitioner must contact the PA Unit to request authorization to continue the medication past the “Hospital Discharge” supply, and a new prescription must be issued.

**Lock-In Emergency**

This override is provided because the Louisiana Department of Health (LDH) recognizes that there may be unusual circumstances when it is necessary for a pharmacy or physician provider to grant services for a Lock-In recipient when the provider is not the Lock-In provider. Payment will be made to any pharmacist enrolled in the Medicaid Program who grants services to a Lock-In recipient in emergency situations or when life sustaining medicines are required. Prescriptions written as a result of an emergency visit or as a discharge prescription following a hospital admission are applicable for payment if the correct emergency procedure is followed.

The notation “Emergency Prescription” or “Discharge Prescription” should be written on the hardcopy prescription by either the prescribing physician or the dispensing pharmacist. Please ensure that the notation is included on the hard copy claim for audit purposes.

NOTE: See Appendix 37.5.13 Lock-In Program of this manual chapter for detailed information.
Types of Pharmacy Claims

Types of Claim Submissions

Providers can submit prescribed drug claims through the POS system, an electronic batch system upon testing and approval, or on paper claim forms. The paper claim form for Medicaid prescribed drug services is the NCPDP Universal Claim Form.

Point of Sale Claim Submission

Medicaid pharmacy providers can submit Medicaid claims through a LDH authorized electronic switch vendor using on-line, real time, point of sale (POS) processing. The transaction is processed through the claims processing cycle, and the disposition of the claim is returned to the pharmacy within seconds of submission.

POS processing is available through authorized telecommunication vendors that are connected to virtually every pharmacy in the United States.

Features of POS

The POS system is designed to work under the general framework of standards and protocols established by the NCPDP. It uses methods of communication that are in place for other pharmacy POS processing. POS uses the Health Insurance Portability and Accountability Act (HIPAA) approved telecommunication standard, NCPDP D.0.

The POS system is available 24 hours per day, seven days per week, except for scheduled downtime for system maintenance.

Authorization to Use POS

To obtain authorization to submit Medicaid claims through POS, the provider must submit the POS authorization agreements to the Medicaid fiscal agent.

NOTE: See “Point of Sale (POS) Enrollment” in Section 37.2 Provider Requirements and Participation Guidelines in this manual chapter for information on provider enrollment.
Electronic Claim Submission (BATCH)

Providers interested in using the NCPDP 1.2 Batch version must contact the POS Help Desk. Testing and approval are required. (See Appendix 37.5.4 for contact information)

Hard Copy Submission

When it is necessary to paper bill the Medicaid Program for services, pharmacy providers must use the NCPDP Universal Claim Form (UCF) regardless of date of service. No photocopied versions are acceptable.

Ordering the Claim Forms

NCPDP Universal Claim Forms may be purchased from Communi Form, LLC. (See Appendix 37.5.4 for contact information.)

Claim Submission

All information, whether handwritten or computer generated, must be legible and completely contained in the designated area of the claim form. Claims submitted on the UCF claim form to the FI.

Retroactive Eligibility Claim Submission

When filing prescription claims for recipients with retroactive Medicaid, with a date of service greater than one year, providers must file these claims hard copy for special handling.

Claims less than one year may be submitted on-line, with some exceptions. Claims over one year for recipients with retroactive coverage, e.g., spend-down medically needy recipients, should be sent to Medicaid Management Information Systems within LDH with a note of explanation or a copy of the recipient’s Medicaid identification card as soon as possible. These claims must be sent to the Bureau of Health Services Financing. (See Appendix 37.5.4 for contact information.)

Billing Instructions

All fields of the Universal Claim Form are not numbered; however, all fields are denoted as “Required”, “Not Required”, or “Leave Blank” as appropriate.
“Required” information must be entered to ensure processing of the claim. “Not required” information is optional, based on entry of a previous field. “Leave Blank” is a field unrelated to pharmacy claims.

NOTE: See Appendix 37.5.1 of this manual chapter for an example of the Universal Claim Form and billing instructions.

Claim Adjustments

From time to time some claims submitted and paid require adjustments. This can be done through the POS claim reversal process, which involves reversing the incorrect claim and resubmitting a new, corrected claim via POS. Claims requiring adjustments may be reversed within the timely filing period by using the pharmacy provider NPI, date of service and prescription number. Upon reversal, the claim may be resubmitted with the corrected information.

In some instances, it is necessary to submit a hard copy adjustment claim form.

NOTE: See Appendix 37.5.1 to access the link to the POS User Guide of this manual chapter for instructions for both types of claim adjustments.

NOTE: See Appendix 37.5.1 of this manual chapter for Form 211 Drug Adjustment Form and instructions for completion.

Time Limit for Submission of Medicaid Claims

Timely Claim Submission

Medicaid providers should submit claims immediately after providing services so that any problems with a claim can be corrected and the claim resubmitted before the filing deadline.

Twelve Month Filing Limit

A claim for services rendered must be received by the Department or its fiscal intermediary no later than 12 months from the date of service.
Dates of Service Greater Than Two Years Old

Claims with dates of service over two years old are not to be submitted to the fiscal intermediary or to Medicaid for overriding of the timely filing edit unless one or more of the guidelines listed below is met:

- The recipient was certified for retroactive Medicaid benefits;
- The recipient won a Medicare or SSI appeal in which he was granted retroactive Medicaid benefits; and/or
- The failure of the claim to pay was not the fault of the provider each time the claim was adjudicated.

Medicare/Third Party Payor Insurance Claims

Claims for recipients who have Medicare or other insurance must be submitted to a third party payor prior to sending the claim to Medicaid.

A claim coordinated with a third party payor shall be submitted to the fiscal intermediary within 12 months of the date of service.

The time limit for filing Medicare crossover claims to the Medicaid Program is six months from the date of the Medicare adjudication of the claim, providing the claim was filed timely with Medicare (12 months from the date of service).

Proof of Timely Filing

Medicaid claims received after the maximum timely filing date cannot be processed unless the provider is able to furnish proof of timely filing. Such proof may include the following:

- A Remittance Advice indicating that the claim was processed earlier (within the specified timeframe); or
- Proof of retroactive eligibility.
When resubmitting the claim and documentation, providers must be certain that the claim is legible to ensure accurate processing. Documentation must reference the individual recipient and date of service.

Billing for Spend-Down Medically Needy Recipients

Any provider who has medical bills from the exact date of the recipient’s spend-down will receive a Spend-down Medically Needy Notice (Form 110-MNP) from the local Medicaid office. This form will notify the provider of the co-payment amount due by the recipient and the amount to be billed to Medicaid. The provider must attach this form to the claim and submit the claim manually to the fiscal intermediary for processing. The provider cannot bill the recipient for any amount over the amount specified on the Form 110-MNP under recipient liability. If service(s) were provided on the date of spend-down but does not appear on the 110-MNP form, the provider should contact the local Medicaid office that issued the form to get a corrected form.

CLAIMS PROCESSING and PAYMENTS

Claims for Medicaid reimbursement are processed by the Medicaid fiscal intermediary (FI). This section describes claims processing and gives the provider information about the remittance advice as well as how to obtain help with claims processing problems.

Claims Processing

Claim Entry

Point of Sale (POS) claims enter the claims processing system directly through a telecommunications network and adjudicate in real time. Paper claims are keyed directly into the system for adjudication. Paper claims should be submitted to the FI. (See Appendix 37.5.4 for contact information.)

Claim Adjudication

The system edits the claim information and determines the status or disposition of the claim. This process is known as claim adjudication.
Disposition of Claim

A claim disposition can be:

- **Paid** - payment is approved in accordance with program criteria; or
- **Denied** - payment cannot be made because the information supplied indicates the claim does not meet program criteria, or information necessary for payment was either erroneous or missing.

Processing Time Frames

POS claims submitted by the end of the day on Thursday typically appear as adjudicated/pended on the provider’s remittance advice (RA) the following Tuesday. Payments are made to the provider based upon the Louisiana Department of Health’ (LDH) payment guidelines. Paper claims are processed for adjudication within 10 to 30 days.

POS Claims

Pharmacy claims are processed through a LDH approved switch vendor through the POS system. The POS system is designed to work under the general framework of standards and protocols established by the National Council for Prescription Drug Programs (NCPDP). It uses methods of communication which are in place for other pharmacy POS processing.

NOTE: Refer to Appendix 37.5.1 for the link to access of the POS User Guide of this manual chapter for comprehensive information.

Paper Claims

Paper claims are screened for completion. If information is missing, the claim will not be entered into the system and will be returned to the provider. The provider needs to correct the error, attach any missing documentation and return the claim for processing.

Pharmacy providers should verify payment or denial of paper claims on their weekly RA. Paper claims should be resubmitted if the services meet the criteria for payment.
Remittance Advice

The RA plays an important communication role between the provider, the Medicaid Program, and the FI. Aside from providing a record of transactions, the RA assists providers in resolving and correcting possible errors and reconciling paid claims. The RA also serves as a bulletin board for messages from the Medicaid Program.

The RA is the control document which informs the provider of the current status of submitted claims. It is sent out each week when the provider has an adjudicated claim.

On the line immediately below each claim, a code will be printed representing denial reasons and payment reduction reasons. Messages explaining all codes found on the RA will be found on a separate page following the status listing of all claims. The only type of claim status which will not have a code is one which is paid as billed.

If the provider uses a medical record number (which may consist of up to 16 alpha and/or numeric characters), it will appear on the line immediately following the recipient's number.

Internal Control Number

At the end of each claim line is the 13-digit internal control number (ICN) assigned to that claim line. Each separate claim line is assigned a unique ICN for tracking and audit purposes. Following is a breakdown of the 13-digits of the ICN and what they represent:

Position 1: Last Digit of Current Year

Positions 2-4: Julian Date - ordinal day of 365-day year

Position 5: Media Code - 0 = paper claim with no attachments

1 = Electronic batched claim
3 = System adjustment
4 = System void
5 = Paper claim with attachments
6 = Resubmission
7 = Pharmacy POS electronic claim

Positions 6-8: Batch Number - for FI internal purposes

Positions 9-11: Sequence Number - for FI internal purposes
Positions 12-13: Number of Lines within Claim

00 = First line
01 = Second line
02 = Third line, etc.

Copies of the five most current weeks’ RAs are available on the Louisiana Medicaid website’s password-protected section, “Weekly Remittance Advices”.

Electronic Remittance Advice

The Electronic Media Claims (EMC) Department offers Electronic Remittance Advices (ERA) in the ANSI X12 835 format. The 835 would be in addition to the NCPDP response. This allows providers to have their RAs transmitted from the FI and posted to accounts electronically. Further information may be obtained by calling the FI. (See Appendix D for contact information.)

Remittance Advice Breakdown

Claims presented on the RA can appear under one of several headings: Approved Original Claims (paid claims); Denied Claims; Claims in Process; Adjustment Claims; Previously Paid Claims; and Voided Claims. When reviewing the RA, providers should look carefully at the heading under which the claims appear to assist with the reconciliation process.

Claims appearing under the heading, "Claims in Process", indicate claims that have been received by the FI, and should not be worked until they appear as either "Approved Original Claims" or "Denied Claims."

Remittance Summary

"Approved Original Claims" may appear with zero (0 dollar) payments. These claims are still considered paid claims. Claims pay a zero amount legitimately, based on other insurance payments, maximum allowable payments, etc.

When providers choose to return checks to adjust or void a claim rather than completing an adjustment/void form, the checks will initially appear as a financial transaction on the front of the RA to acknowledge receipt of that check. The provider's check number and amount will be indicated, as well as an internal control number (ICN) which is assigned to the check. If claims associated with the check are processed immediately, they will appear on the same RA as the check financial transaction, under the heading of "adjustment or void" as appropriate, as well as the corresponding "previously paid claim." The amount of the check posted to the RA should offset
the amount recouped from the RA as a result of the adjustment/void, and other payments should not be affected. However, if the adjustments/voids cannot be processed on the same RA, the check will be posted and appear on the financial page of the RA under "Suspense Balance Brought Forward" where it will be carried forward on forthcoming RA's until all adjustments/voids are processed. As the adjustments/voids are processed, they will appear on the RA and the amount of money being recouped will be deducted from the "Suspense Balance Brought Forward" until all claims payments returned are processed.

It is the provider's responsibility to track these refund checks and corresponding claims until they are all processed.

When providers choose to submit adjustment/void forms for refunds, the claims are adjusted/voided on the RA, the monies recouped will appear on the RA appropriately as "Adjustment Claims" or "Voided Claims." A corresponding "Previously Paid Claim" will also be indicated. The system calculates the difference between what has been paid ("Previously Paid Claim") and the additional amount being paid or the amount being recouped through the adjustment/void. If additional money is being paid, it will be added to the provider’s check and the payment should be posted to the appropriate recipient's account. If money is being recouped, it will be deducted from the provider’s check amount. This process means that when recoupments appear on the RA, the paid claims must be posted as payments to the appropriate recipient accounts through the bookkeeping process, and the recoupments must be deducted from the accounts of the recipients for which adjustment or voids appear. If the total voided exceeds the total original payment, a negative balance occurs, and money will be recouped out of future checks. This also includes state recoupments, Surveillance and Utilization Review Subsystem (SURS) recoupments and cost settlements.
Below are the summary headings which may appear on the financial summary page and an explanation of each.

- **Suspense Balance Brought Forward** - A refund check or portion of a refund check carried forward from a previous RA because all associated claims have not been processed;
- **Approved Original Claim** - Total of all approved (paid) claims appearing on this RA;
- **Adjustment Claims** - Total of all claims being adjusted on this RA; **Previously Paid Claim** - Total of all previously paid claims which correspond to an adjustment or void appearing on this RA;
- **Void Claims** - Total of all claims being voided on this RA;
- **Net Current Claims Transactions** - Total number of all claims related transactions appearing on this RA (approved, adjustments, previously paid, voided, denied, claims in process); **Suspense Balance Brought Forward** - A refund check or portion of a refund check carried forward from a previous RA because all associated claims have not been processed;
- **Approved Original Claim** - Total of all approved (paid) claims appearing on this RA;
- **Adjustment Claims** - Total of all claims being adjusted on this RA;
- **Previously Paid Claim** - Total of all previously paid claims which correspond to an adjustment or void appearing on this RA;
- **Void Claims** - Total of all claims being voided on this RA;
- **Net Current Claims Transactions** - Total number of all claims related transactions appearing on this RA (approved, adjustments, previously paid, voided, denied, claims in process);
• **Net Current Financial Transactions** - Total number of all financial transactions appearing on the RA;

• **Prior Negative Balance** - If a negative balance has been created through adjustments or voids processed, the negative balance is carried forward to the next RA. (This also includes state recoupments, SURS recoupments and cost settlements.);

• **Recoupment Bypassed by LDH**;

• **Withheld for Future Recoveries** - Difference between provider checks posted on the RA and the deduction from those checks when associated claims are processed on the same RA as the posting of the check. (This is added to Suspense Balance Brought Forward on the next RA.);

• **Total Payments This RA** - Total of current check;

• **Total Copayment Deducted This RA** - Total pharmacy co-payments deducted for this RA;

• **Suspense Balance Carried Forward** - Total of Suspense Balance Brought Forward and withheld for future recoveries;

• **Y-T-D Amount Paid** - Total amount paid for the calendar year;

• **Denied Claims** - Total of all denied claims appearing on this RA; and

• **Claims in Process** - Total of all pending claims appearing on this RA.

**Messages**

Important messages appear on the RA pertinent to the pharmacy program. Messages include, but are not limited to the following:

• Updates to program policy;

• Changes in participating manufacturers in the federal rebate program; and
• Changes in the Federal Upper Limits (FULs) and Louisiana Maximum Allowable Costs (LMACs).

Help Desk

POS information is available to Pharmacy providers between 8:00 a.m. and 5:00 p.m. Monday through Friday by contacting the FI’s POS Helpdesk. (See Appendix 37.5.4 for contact information.)

Section 340B of the Public Health Services Act requires drug manufacturers that receive reimbursement from state Medicaid programs to supply drugs to the 340B Drug Pricing Program at a discounted rate. The Office of Pharmacy Affairs (OPA) of the Bureau of Primary Health Care at the Health Resources and Services Administration (HRSA) administers the program. This Federal program is run by Apexus’ Prime Vendor Program, which negotiates discounted drug products for use by covered entities that are certified as 340B providers.

To participate in the 340B program eligible entities must register with HRSA. Recertification must be completed annually, and 340B drugs may only be dispensed by eligible organizations to eligible patients. Drug manufacturers and HRSA have the authority to audit covered entities for program compliance. Additional information may be found on the HRSA website. (See Appendix D for contact information.)

Reimbursement Methodology

Covered Entity

Self-administered drugs (ambulatory and retail medications) that are purchased by a covered entity through the 340B program, and dispensed to patients, who are covered by Medicaid, shall be billed to Medicaid at actual acquisition cost plus a professional dispensing fee. 340B drug stock cannot be used in an inpatient setting.

Contract pharmacies are not permitted to bill Medicaid for drugs purchased at 340B pricing.
Contract Pharmacies

Covered entities that are not equipped to provide pharmacy services may contract with pharmacy providers. A “ship to, bill to” procedure is used in which the covered entity purchases 340B stock that is shipped directly to the contract pharmacy.

Claims billed to Medicaid by contract pharmacies are only excluded from Medicaid’s drug rebate program if the contract pharmacy is listed in the HRSA Exclusion File. To be listed in the exclusion file, the pharmacy:

- Has attested to HRSA that all of its Medicaid claims are “carved-in” to the 340B program; and
- All of their Medicaid claims are dispensed from 340B stock, whether the claims were billed for the covered entity or as part of the pharmacy’s regular retail business.

It is the responsibility of the covered entity to ensure their 340B program and any contract pharmacies are in compliance with HRSA requirements. Information on HRSA’s guidelines for contract pharmacy agreements, responsibilities and requirements can be located on HRSA website. (See Appendix D for contact information.)

**NOTE:** Refer to Section 37.2 Pharmacy Provider Enrollment and Participation Guidelines of this manual chapter for additional enrollment and participation information.

HRSA maintains a national 340B exclusion file for use by all state Medicaid programs during drug rebate invoicing. The file is available to the public for download. (See Appendix D for information on accessing the file.)

All 340B covered entities are required to determine whether their Medicaid claims are “carved-in” or “carved-out” of their 340B program. “Carved-in” means that all drug claims billed to Medicaid are dispensed from regular stock purchased through the 340B program. Each covered entity attests to its status to HRSA and only those that carve all Medicaid patients into their 340B programs are excluded from each state’s drug rebate program.

Claims billed to Medicaid by contract pharmacies are only excluded from drug rebate invoicing if the contract pharmacy has attested to HRSA that all Medicaid claims are “carved-in” to the 340B program and all of their Medicaid claims are dispensed from 340B stock. The covered entity’s carved-in status does not apply to its network pharmacies. If the contract pharmacy bills Medicaid claims in its regular business, none of that pharmacy’s claims will be excluded from drug rebate invoicing.
The Medicaid Program reviews the HRSA exclusion file quarterly with each invoicing cycle and removes providers from drug rebate invoicing according to the term dates provided by HRSA.

The Medicaid Program invoices drug manufacturers for fee-for-service Medicaid and managed care Medicaid claims. Claims billed by covered entities that are listed on the HRSA exclusion file are removed from invoicing for both fee-for-service and managed care Medicaid patients.

Questions regarding the 340B program should be directed to HRSA, Office of Pharmacy Affairs. (See Appendix D for contact information.)

Providers may also contact the Pharmacy Program.
TOTAL PARENTERAL NUTRITION

This section explains the Total Parenteral Nutrition (TPN) therapy coverage, limitations, prior authorization, reimbursement methodology and claim submission.

Provider Enrollment

Refer to Section 37.2 Provider Requirements and Participation Guidelines for enrollment instructions.

Program Coverage

The program covers the following services, equipment and supplies when medical necessity and other program criteria are met:

- Parenteral Nutrition Therapy/TPN is covered for a patient with permanent, severe pathology of the alimentary tract which does not allow absorption of sufficient nutrients to maintain weight and strength commensurate with the recipient's general condition;
- Intradialytic Parenteral Nutrition Therapy (IDPN) provided to an end stage renal disease (ESRD) patient while the patient is being dialyzed; and/or
- Equipment and supplies, infusion pumps and accessories.

TPN Medical Necessity Criteria

A. Parenteral nutrition is covered for a recipient with permanent, severe pathology of the alimentary tract which does not allow absorption of sufficient nutrients to maintain weight and strength commensurate with the recipient's general condition.

B. Parenteral nutrition is considered to be medically necessary when any of the following conditions exist. The conditions must be deemed to be severe enough that the recipient would not be able to maintain his/her weight and strength on only oral intake or tube enteral nutrition. The recipient:

1. Has undergone recent (within the past three months) massive small bowel resection leaving less than or equal to 5 feet of small bowel beyond the ligament of Treitz;
2. Has a short bowel syndrome that is severe enough that the recipient has net gastrointestinal fluid and electrolyte malabsorption such that on an oral intake of 2.5-3 liters/day the enteral losses exceed 50 percent of the oral/enteral intake and the urine output is less than 1 liter/day;

3. Requires bowel rest for at least three months and is receiving intravenously 20-35 cal/kg/day for treatment of symptomatic pancreatitis with/without pancreatic pseudocyst, severe exacerbation of regional enteritis, or a proximal enterocutaneous fistula where tube feeding distal to the fistula is not possible;

4. Has complete mechanical small bowel obstruction where surgery is not an option;

5. Is significantly malnourished (10 percent weight loss over three months or less and serum albumin less than or equal to 3.4 gm/dl) and has very severe fat malabsorption (fecal fat exceeds 50 percent of oral/enteral intake on a diet of at least 50 gm of fat/day as measured by a standard 72 hour fecal fat test); or

6. Is significantly malnourished (10 percent weight loss over three months or less and serum albumin less than or equal to 3.4 gm/dl) and has a severe motility disturbance of the small intestine and/or stomach which is unresponsive to prokinetic medication. Prokinetic medication is defined as the presence of daily symptoms of nausea and vomiting while taking maximal doses and is demonstrated either:

   a. Scintigraphically (solid meal gastric emptying study demonstrates that the isotope fails to reach the right colon by six hours following ingestion); or

   b. Radiographically (barium or radiopaque pellets fail to reach the right colon by six hours following administration).
NOTE: These studies must be performed when the recipient is not acutely ill and is not on any medication which would decrease bowel motility.

C. Maintenance of weight and strength commensurate with the recipient's overall health status must require intravenous nutrition and must not be possible utilizing all of the following approaches:

1. Modifying the nutrient composition of the enteral diet (e.g., lactose free, gluten free, low in long chain triglycerides, substitution with medium chain triglycerides, provision of protein as peptides or amino acids, etc.); and

2. Utilizing pharmacologic means to treat the etiology of the malabsorption (e.g., pancreatic enzymes or bile salts, broad spectrum antibiotics for bacterial overgrowth, prokinetic medication for reduced motility, etc.).

D. Recipients who do not meet the criteria in B.1-6.b must meet criteria in C.1-2 (modification of diet and pharmacologic intervention) in addition to the following criteria:

1. The recipient is malnourished (10 percent weight loss over three months or less and serum albumin less than or equal to 3.4 gm/dl); and

2. A disease and clinical condition has been documented as being present and it has not responded to altering the manner of delivery of appropriate nutrients (e.g., slow infusion of nutrients through a tube with the tip located in the stomach or jejunum).

E. The following are some examples of moderate abnormalities which would require a failed trial of tube enteral nutrition before PN would be covered:

1. Moderate fat malabsorption - fecal fat exceeds 25 percent of oral/enteral intake on a diet of at least 50 gm fat/day as measured by a standard 72 hour fecal fat test;
2. Diagnosis of malabsorption with objective confirmation by methods other than 72 hour fecal fat test (e.g., Sudan stain of stool, dxylose test, etc.);

3. Gastroparesis which has been demonstrated:
   a. Radiographically or scintigraphically as described in Subsection B above with the isotope or pellets failing to reach the jejunum in three to six hours; or
   b. By manometric motility studies with results consistent with an abnormal gastric emptying, and which is unresponsive to prokinetic medication;

4. A small bowel motility disturbance which is unresponsive to prokinetic medication, demonstrated with a gastric to right colon transit time between three to six hours;

5. Small bowel resection leaving greater than 5 feet of small bowel beyond the ligament of Treitz;

6. Short bowel syndrome which is not severe (as defined in B.2);

7. Mild to moderate exacerbation of regional enteritis, or an enterocutaneous fistula; or

8. Partial mechanical small bowel obstruction where surgery is not an option.

F. Documentation must support that a concerted effort has been made to place a tube. For gastroparesis, tube placement must be post-pylorus, preferably in the jejunum. Use of a double lumen tube should be considered. Placement of the tube in the jejunum must be objectively verified.
by radiographic studies or fluoroscopy. Placement via endoscopy or open surgical procedure would also verify location of the tube.

G. A trial with enteral nutrition must be documented, with appropriate attention to dilution, rate, and alternative formulas to address side effects of diarrhea.

H. PN can be covered in a recipient with the ability to obtain partial nutrition from oral intake or a combination of oral/enteral or oral/enteral/parenteral intake as long as the following criteria are met:

1. A permanent condition of the alimentary tract is present which has been deemed to require parenteral therapy because of its severity;

2. A permanent condition of the alimentary tract is present which is unresponsive to standard medical management; and

3. The person is unable to maintain weight and strength.

I. If the medical necessity criteria for parenteral nutrition are met, medically necessary nutrients, administration supplies and equipment are covered. PN solutions containing little or no amino acids and/or carbohydrates would be covered only in situations stated in B.1, 2, or 4 above.

**Documentation Requirements**

Recipients covered under Paragraph B.4 must have documentation of the persistence of their condition. Recipients covered under B.5–D.2 must have documentation that sufficient improvement of their underlying condition has not occurred which would permit discontinuation of parenteral nutrition.
Coverage for these recipients would be continued if the treatment has been effective as evidenced by an improvement of weight and/or serum albumin. If there has been no improvement, subsequent claims will be denied unless the physician clearly documents the medical necessity for continued parenteral nutrition and any changes to the therapeutic regimen that are planned, e.g., an increase in the quantity of parenteral nutrients provided.

A total caloric daily intake (parenteral, enteral and oral) of 20-35 cal/kg/day is considered sufficient to achieve or maintain appropriate body weight. The ordering physician must document in the medical record the medical necessity for a caloric intake outside this range in an individual recipient.

Parenteral nutrition would usually be non-covered for recipients who do not meet criteria in H.1-3, but will be considered on an individual case basis if detailed documentation is submitted.

Recipients covered under criteria in B.1 or 2 must have documentation that adequate small bowel adaptation had not occurred which would permit tube enteral or oral feedings.

Recipients covered under B.3 must have documentation of worsening of their underlying condition during attempts to resume oral feedings.

The ordering physician must document the medical necessity for protein orders outside of the range of 0.8-1.5 gm/kg/day, dextrose concentration less than 10 percent, or lipid use greater than 15 units of a 20 percent solution or 30 units of a 10 percent solution per month.

If the medical necessity for special parenteral formulas is not substantiated, authorization of payment will be denied.

For the initial request and for revised requests or reconsiderations involving a change in the order, there must be additional documentation to support the medical necessity of the following orders, if applicable.
Appendix 37.5.10

• The need for special nutrients;

• The need for dextrose concentration less than 10 percent; and

• The need for lipids more than 15 units of a 20 percent solution or 30 units of a 10 percent solution per month.

After the first six months, the PA request must include a physician's statement describing the continued need for parenteral nutrition. For situations described in B.5-D.2 under Medical Necessity Criteria, the PA request must include the results of the most recent serum albumin (within two weeks of the request date) and the recipient's most recent weight with the date of each. If the results indicate malnutrition, there should be a physician's statement describing the continued need for parenteral nutrition and any changes to the therapeutic regimen that are planned.

Exclusionary Criteria

Parenteral nutrition will be denied as non-covered in situations involving temporary impairments. The recipient must have:

• A condition involving the small intestine and/or its exocrine glands which significantly impairs the absorption of nutrients; or

• A disease of the stomach and/or intestine which is a motility disorder and impairs the ability of nutrients to be transported through the gastrointestinal (GI) system. There must be objective evidence supporting the clinical diagnosis.

Parenteral nutrition is not covered for the recipient with a functioning gastrointestinal tract whose need for parenteral nutrition is only due to:
• A swallowing disorder;

• A temporary defect in gastric emptying such as a metabolic or electrolyte disorder;

• A psychological disorder impairing food intake such as depression;

• A metabolic disorder inducing anorexia such as cancer;

• A physical disorder impairing food intake such as the dyspnea of severe pulmonary or cardiac disease;

• A side effect of a medication; or

• Renal failure and/or dialysis.

Intradialytic Parenteral Nutrition Therapy

Intradialytic Parenteral Nutrition Therapy (IDPN) is parenteral nutrition therapy provided to a recipient with end stage renal disease (ESRD) while the recipient is being dialyzed.

In order to cover IDPN, documentation must be clear and precise to verify that the recipient suffers from a permanently impaired gastrointestinal tract and that there is insufficient absorption of nutrients to maintain adequate strength and weight. The supporting documentation must substantiate that the recipient cannot be maintained on oral or enteral feedings and that due to severe pathology of the alimentary tract, the recipient must be intravenously infused with nutrients.

Infusions must be vital to the nutritional stability of the recipient and not supplemental to a deficient diet or deficiencies caused by dialysis. Physical signs, symptoms and test results indicating severe pathology of the alimentary tract must be clearly evident in any documentation submitted. Recipients receiving IDPN
must also meet the criteria for parenteral nutrition.

If the medical necessity criteria for parenteral nutrition are met, one supply kit and one administration kit will be covered for each day that parenteral nutrition is necessary and used.

**Equipment and Supplies**

An infusion pump is used to deliver nutritional requirements intravenously. Infusion pumps are covered for the delivery of parenteral nutrition for those recipients who cannot absorb nutrients by the gastrointestinal tract. Only one pump (ambulatory or stationary) will be covered at any one time. Additional pumps will be denied as not medically necessary.

- An external ambulatory infusion pump is a small portable electrical device that is used to deliver parenteral nutrition. It is designed to be carried or worn by the recipient.

- A stationary infusion pump is an electrical device, which serves the same purpose as an ambulatory pump, but is larger and typically mounted on a pole.

An intravenous (IV) pole is a device to suspend fluid to be administered by gravity or pump. An IV pole will be covered when a recipient is receiving parenteral fluids and the recipient is not using an ambulatory infusion pump.

Infusion pumps, ambulatory and stationary, are indicated for the administration of parenteral medication in the home when parenteral administration of the medication in the home is reasonable and medically necessary, and an infusion pump is necessary to safely administer the medication.

An external ambulatory infusion pump is a small portable electrical device that is used to deliver parenteral medication. It is designed to be carried or worn by the recipient.
Prior Authorization

Prior Authorization Requirements

Parenteral nutrition therapy may be approved by the Prior Authorization Unit (PAU) at periodic intervals not to exceed six months. However, Medicaid will pay for no more than one month's supply of nutrients at any one time. All requests to the PAU shall include:

- The prognosis as well as the diagnosis;
- The date the recipient was first infused;
- Whether the recipient has been trained to use parenteral equipment;
- A statement that the recipient is capable of operating the parenteral equipment;
- Either the Medicaid certificate of medical necessity form for TPN, or the Medicare certificate of medical necessity form, Form DMERC 10.02A, completed and signed by the treating physician; and
- Documentation showing that the recipient has a permanent impairment. Permanence does not require a determination that there is no possibility that the recipient's condition may improve sometime in the future. Medical documentation must substantiate that the condition is expected to last a long and indefinite duration (at least three months).

Additional documentation must be included with the initial request for parenteral nutrition.

In the situations addressed in B.1-4 under Medical Necessity Criteria, the documentation must include
copies of the operative report and/or hospital discharge summary and/or x-ray reports and/or a physician letter which document the condition and the necessity for PN therapy.

For the situations addressed in B.5 and D.2 under Medical Necessity Criteria (when appropriate), include the results of the fecal fat test and dates of the test.

For the situations addressed in B.6 and D.2 under Medical Necessity Criteria, include a copy of the report of the small bowel motility study and a list of medications that the recipient was on at the time of the test.

For the situations addressed in B.5 – D.2 under Medical Necessity Criteria, include the results of serum albumin and the date of the test (within one week prior to initiation of PN) and a copy of a nutritional assessment by a physician, dietitian or other qualified professional within one week prior to initiation of PN, to include the following information:

- Current weight with date and weight one – three months prior to initiation of PN;
- Estimated daily calorie intake during the prior month and by what route (e.g., oral, tube);
- Statement of whether there were caloric losses from vomiting or diarrhea and whether these estimated losses are reflected in the calorie count; and
- Description of any dietary modifications made or supplements tried during the prior month (e.g., low fat, extra medium chain triglycerides, etc.).

For situations described in D.2 under Medical Necessity Criteria, include:

- A statement from the physician;
- Copies of objective studies; and
• Excerpts of the medical record giving the following information:
  
  • Specific etiology for the gastroparesis, small bowel dysmotility, malabsorption;
  • A detailed description of the trial of tube enteral nutrition including the beginning and ending dates of the trial, duration of time that the tube was in place, the type and size of tube, the location of tip of the tube, the name of the enteral nutrient, the quantity, concentration and rate of administration, and the results;
  • A copy of the x-ray report or procedure report documenting placement of the tube in the jejunum;
  • Prokinetic medications used, dosage, and dates of use;
  • Nondietary treatment given during prior month directed at etiology of malabsorption (e.g., antibiotic for bacterial overgrowth); and
  • Any medications used that might impair GI tolerance to enteral feedings (e.g., anticholinergics, opiates, tricyclics, phenothiazines, etc.) or that might interfere with test results (e.g., mineral oil, etc.) and a statement explaining the need for these medications.

Any other information which supports the medical necessity for parenteral nutrition may also be included.

Prior Authorization Requests

The Prior Authorization (PA) request shall be submitted to the fiscal intermediary Prior Authorization Unit (PAU) where it will be considered for payment. Provider may contact the PAU (See Appendix 37.5.4 for contact information.)

Providers may complete and submit electronic PA forms. These forms may be accessed at www.lamedicaid.com. For more information contact the PAU.

NOTE: Refer to Appendix 37.5.1 for Form PA01 and instructions or providers may access this form at www.lamedicaid.com.
Once a PA request is approved, the provider and recipient are notified of the approval, as well as what services have been approved. A prior authorization number is attached to the approved request. This number is to be used in the billing process.

**Emergency Requests**

A request is considered an emergency if a delay in obtaining the parenteral nutrition therapy would be life-threatening to the recipient. Providers should call the PAU’s toll-free number. Providers should then fax a completed PA 01 form, documentation of the parenteral therapy and life-threatening situation (i.e. pending discharge). Once an approval or denial is determined within 48 hours, the procedure codes, authorized reimbursement rate and prior authorization number is phoned to the provider. A determination letter is later mailed to the provider and recipient.

**Medicare Crossover Claims**

Claims for Total Parenteral Nutrition and equipment reimbursed by Medicare do not require prior authorization from Medicaid when these claims cross over from Medicare to Medicaid for payment.

Claims denied by Medicare due to lack of medical necessity will not be considered for coverage by Medicaid.

Medicare non-covered services may be considered for coverage by Medicaid Claims, when that service is a Medicaid covered service; however, prior authorization is necessary.

**Third Party Liability**

When a Medicaid recipient has private insurance and Medicaid, prior authorization is required from all
payors, including Medicaid.

**Reimbursement Methodology**

The following is the Medicaid reimbursement schedule:

- Reimbursement for Total Parenteral Nutrition Therapy (TPN) formula is 80 percent of the Medicare Fee Schedule amount or billed charges, whichever is the lesser amount;
- Reimbursement for TPN supplies is 70 percent of the Medicare Fee Schedule or billed charges, whichever is the lesser amount; and
- Reimbursement for TPN infusion pumps is 70 percent of the Medicare Fee Schedule or billed charges, whichever is the lesser amount.

**Claim Submission**

**Medicaid Claims**

Claims for TPN should be submitted on the CMS-1500. (See Appendix 37.5.1 for information on how to access this form.)

**Medicare Crossover Claims**

Medicare claims will automatically cross over to Medicaid when the provider is enrolled as a Medicare provider.

**NOTE:** See Medicare Part B Crossover Claims in Appendix G: Medicare Prescription Drug Coverage for additional detailed information.
Third Party Liability

When a recipient has both Medicaid and private insurance, the provider is required to submit the claim to the private insurance first. The provider’s remittance advice from the private insurance company should be submitted with the claim to Medicaid.

Adjustments/Voids

Providers should complete Form 213 Adjustment/Void form for TPN services submitted that require adjustments or voids.

NOTE: Refer to Appendix 37.5.1 of this manual chapter for a copy of this form.
MEDICATION ADMINISTRATION

The Louisiana Board of Pharmacy has set minimum requirements regarding the administration of medications by licensed Louisiana pharmacists. Currently the Medicaid Program will reimburse enrolled pharmacies when these credentialed pharmacists administer the influenza vaccine.

Louisiana Board of Pharmacy

Pharmacists in Louisiana must be registered by the Louisiana Board of Pharmacy to administer medications. Louisiana Board of Pharmacy Regulations regarding Prescription Orders to Administer Medications may be found at LAC 46:LIII.521.

Pharmacist Provider Number

Authorized Pharmacists

Pharmacists who are registered with the Louisiana Board of Pharmacy and have the “Authority to Administer” must obtain a Medicaid pharmacist provider number in order to bill the Medicaid Program. To confirm or request enrollment, authorized pharmacists should contact the Provider Enrollment Unit. (See Appendix 37.5.4 for contact information.)

National Provider Identifier (NPI)

Pharmacists who have a National Provider Identifier (NPI) must report it to the fiscal intermediary and may include it in the claim submission.

Influenza Vaccine Administration by Pharmacist

Claim Requirements

The Medicaid Program will reimburse enrolled pharmacies when an immunization is given by a pharmacist who has a Louisiana Board of Pharmacy “Authority to Administer”. The administering pharmacist’s Medicaid provider number or his/her NPI must be included on the claim.
When a prescription for the influenza vaccine is written by a prescribing practitioner, that practitioner’s NPI or Medicaid number should be included in the claim. When a prescription order does not exist, the vaccinating pharmacist shall enter his/her Medicaid provider number or NPI as the prescriber and submit the claim.

**Vaccination Reimbursement**

The Medicaid Program reimburses enrolled pharmacies for the administration and the cost of the influenza vaccine for Medicaid recipients who are 19 years of age and older when the administering pharmacist is an enrolled Medicaid provider. No reimbursement of the vaccine or supplies will be made for children under the age of 19. Only the administration fee will be reimbursed for these recipients.

**Bypassed Editing**

Claims for influenza vaccines will process without edits for the four prescription limit, requirements to bill other insurance and Lock-In.

**Copayments**

Recipients may not be charged co-payments for the influenza vaccines.

**NOTE:** See Appendix 37.5.1A for the link to access the Point of Sale User Guide for detailed information regarding the submission of these claims.

**Electronic Drug Clinical Inquiry (e-CDI)**

Paid claims for administration fees will be posted on the Electronic Clinical Drug Inquiry (e-CDI). When Medicaid reimburses a pharmacy for an administration fee claim, the name of the influenza vaccine and date of payment will be listed. This application is available on the Louisiana Medicaid website.

**Vaccination Documentation**

Pharmacists must document immunizations administered in the Louisiana Immunization Network for Kids Statewide (LINKS) registry. For additional information, see the Louisiana Department of Health’s website. (See Appendix 37.5.4 for contact information.)
PATIENT COUNSELING AND DRUG UTILIZATION REVIEW (DUR)

Federal and state laws and regulations require that pharmacists provide the pharmaceutical care services described below. The intent of the laws and regulations is to improve the quality of pharmaceutical care by ensuring that medications are appropriate, medically necessary and not likely to have adverse medical results.

The Pharmacy Program utilizes several different Drug Utilization Review (DUR) applications in its program that are either federally and/or state mandated.

In 1990 the federal Omnibus Budget Reconciliation Act (OBRA) amended the Social Security Act to include the specific requirement that states must administer a DUR Program with a DUR Board. OBRA 90 states that a drug use review program assures that prescriptions are appropriate, are medically necessary and are not likely to result in adverse medical results. In accordance with the Act and federal regulations, states are mandated to have a Medicaid DUR program with the goal, “…to ensure appropriate drug therapy, while permitting sufficient professional prerogatives to allow for individual drug therapy.” The federal DUR program’s required components are:

- Recipient counseling;
- Prospective drug review;
- Retrospective drug use review;
- An educational program; and
- A state DUR Board.

Patient Counseling

Patient counseling must be offered and provided in accordance with the Louisiana Board of Pharmacy Regulations at LAC, 46:LIII, §517.
Components of Patient Counseling

In accordance with those regulations, the pharmacist, at a minimum, should be convinced that the recipient or caregiver is informed of the following:

- Name and description of the medications;
- Dosage form, dosage, route of administration and duration of therapy;
- Special directions and precautions for preparation, administration and use by the recipient;
- Common severe side effects or adverse effects or interactions and therapeutic contraindications that may be encountered, including their avoidance and the action required in the event of their occurrence;
- Techniques for self-monitoring drug therapy;
- Proper storage of the medication;
- Prescription refill information, if any; and
- The action to be taken in the event of a missed dose.

Exceptions to Counseling Requirement

Counseling is not required for inpatients of a hospital or institution where a nurse or other licensed health care professional is authorized to administer medications.

Waiver

According to the regulations, no pharmacist or pharmacy may solicit or encourage blanket waivers for patient counseling. However, the regulations do not prohibit the recipient or caregiver from declining patient counseling.
Prospective Utilization Review (UniDUR)

Prior to filling or refilling a prescription, the pharmacist must review the prescription and the patient record for therapeutic appropriateness.

If there is an indication of possible drug contraindications or abuse, the pharmacist must take appropriate action to resolve the issue(s).

UniDUR Features

UniDUR has the following features.

- UniDUR provides real-time screening of all Point of Sale (POS) prescription drug claims against the Louisiana Medicaid clinical database.

- UniDUR reports “clinical events” as defined by the Pharmacy Program. The events are based on extensive development research done by the program staff, contractors, fiscal intermediary (FI), University of Louisiana at Monroe (ULM) School of Pharmacy, and the Drug Utilization Review (DUR) Board.

- UniDUR provides an on-line response to a pharmacy within seconds of significant UniDUR events with the disposition of the claim.

How UniDUR Works

The UniDUR system accepts POS transactions from the Medicaid claims adjudication system and screens each prescription against a patient’s prescription profile. The profile includes the recipient’s active drug products, medical diagnosis profile, gender and age.

Screening occurs using one or more of the clinical screening modules that are based upon the clinical criteria defined by Pharmacy Program staff. The results of the screening are returned to the claims adjudication system in the form of clinical events. The system then completes the adjudication of the claim according to the program’s established parameters and sends a response to the pharmacy.
Clinical Events

If a potential drug issue is identified, a clinical event is triggered, and the pharmacy will receive a UniDUR message. Prescriptions are screened for the following potential drug issues:

- Compliance Monitoring – refills too early or too late;
- Prescribing Limits – excessive or inadequate dosages, or duration of therapy;
- Therapeutic Duplication – two or more prescriptions with duplicative actions, whether prescribed by the same or different prescribers;
- Drug-Drug Interaction – drugs that should not be taken concurrently;
- Drug-Disease Precaution – specific drugs that may cause harm in recipients with certain known medical conditions;
- Disease-Drug Precaution – diseases where specified drugs are suggested for use to deter disease progression or complications; and
- Pregnancy Precaution – drugs with high risk of fetal harm dispensed to childbearing women.

NOTE: Refer to “Prospective Drug Utilization Policies/Limits/Edits” in Section 37.1 Covered Services, Limitations, and Exclusions of this manual chapter for detailed policy information.

Medicaid Responses to a Clinical Event

Depending on the severity of the clinical event, Medicaid may:

- Suppress the response to the pharmacy, but report it in aggregate to Medicaid staff;
- Return the response to the pharmacy for informational purposes, not require any action and pay the claim as submitted; or
- Return the response to the pharmacy, require the pharmacist to take appropriate action and report that action in the form of a claim override. Medicaid will deny payment if the pharmacist does not correctly override the claim.
Required Action

When a UniDUR response is received, the pharmacist must verify the information against the recipient’s drug profile and current prescription, evaluate the conflict and decide whether or not to dispense the drug. Actions can range from conferring with the recipient and checking the recipient’s profile to consulting with the prescriber.

If the message is “early refill” or “therapeutic duplication”, the pharmacist must determine whether the prescription should be filled, refused or changed.

If the pharmacist or recipient is unaware of any conflicting prescriptions, the pharmacist may call the Point of Sale (POS) Help Desk for additional information on the UniDUR message. (See Appendix 37.5.4 for POS Help Desk contact number.)

NOTE: Refer to Appendix 37.5.1 to access the Point of Sale User Guide and Section 37.1 Covered Services, Limitations, and Exclusions of this manual chapter for detailed information and instructions on the Prospective Drug Utilization Review (UniDUR) feature of the LMPBM System.

Retrospective Drug Utilization Review

The federal retrospective DUR requirements recognize the functions of Medicaid Management Information Systems (MMIS) and Surveillance and Utilization Review (SUR) subsystems which were in effect prior to OBRA 1990. The regulations, therefore, permit states to limit retrospective DUR review activities to those that focus on appropriate and medically necessary care to avoid duplication of activities relating to fraud and abuse under the SUR program.

LaDUR

The retrospective drug utilization review program in Louisiana is called LaDUR. The Pharmacy Program, through a contract with the FI, Molina, administers LaDUR as a component of its DUR system.

The LaDUR program includes four regional committees, each comprised of three pharmacist providers and one physician provider located throughout the state, who conduct monthly reviews of Medicaid recipients’ prescription profiles. (These reviews assess the possibility of underutilization, over-utilization or contra-indications of prescription therapy by querying a recipient’s disease history and drug utilization.) The committees correspond with recipients’
prescribers and pharmacists regarding their observations in an effort to identify prescription therapies and utilization patterns that correspond to specified therapeutic criteria.

**LaDUR’s Enhanced Focus**

LaDUR has been enhanced in recent years by shifting its focus from a fundamental review of therapeutic drug criteria based on a recipient’s prescription utilization to the examination of a recipient’s disease states.

Extensive technical programming enhancements have allowed identification of prescription use or absence within a disease state. This shifts the program’s focus from issues of over-utilization and drug duplication to a disease management focus. For example, clinical practice guidelines from the American Diabetes Association were reviewed by the DUR Board to develop standards for LaDUR.

**Drug Utilization Review Board**

The federal OBRA ’90 statute requires each state to establish a DUR Board. The Louisiana Department of Health (LDH), Bureau of Health Services Financing (BHSF) has established a Drug Utilization Review Board to assist the agency in assessing its DUR Program.

**DUR Board Functions**

The Board should:

- Make recommendations and approve predetermined criteria established in retrospective DUR and prospective DUR;

- Evaluate the use of predetermined criteria and standards in use and make recommendations to the BHSF concerning modification or elimination of existing predetermined criteria and standards or the adoption of new ones;

- Recommend guidelines governing written predetermined criteria and standards that pharmacies not using approved software must use in performing prospective DUR;

- Identify educational topics to improve prescribing and dispensing practices;

- Make recommendations regarding interventions to improve quality of drug therapy;
• Periodically re-evaluate educational interventions;

• Be a knowledgeable group, dedicated to assisting the agency in the administration of its DUR Program in an advisory capacity; and

• Prepare an annual report.

LaDUR Board Membership

Federal statute specifies the general board membership.

The membership of the DUR Board shall consist of at least one-third, but not more than 51 percent, licensed and actively practicing physicians, and at least one third licensed and actively practicing pharmacists.

The committee shall be composed of at least eight members (or approved designees) appointed by the secretary of LDH.

The committee shall consist of healthcare professionals who have recognized knowledge in:

• Clinically appropriate prescribing of covered outpatient drugs;

• Clinically appropriate dispensing and monitoring of covered outpatient drugs;

• Drug use review, evaluation and intervention; and

• Medical quality assurance.
LOCK-IN PROGRAM

The Lock-In Program is designed to educate recipients who may be misusing program benefits and to ensure that program funds are used to provide optimum healthcare services for recipients. Recipients who misuse or over-utilize pharmacy and physician benefits may be restricted to the use of:

- One pharmacy and/or specialty pharmacy;
- One physician; and
- Up to three specialists, if needed, for Physician-Pharmacy Lock-In.

In addition, recipients may be restricted to one pharmacy and/or specialty pharmacy provider (for Pharmacy Only Lock-In). Claims written by dental prescribers are exempt from Lock-In edits.

Choosing a Lock-In Provider

A Medicaid recipient loses his/her freedom of choice of providers when selected for enrollment in the Lock-In program. A Lock-In recipient must choose the following as his/her Lock-in providers:

- One primary care physician provider;
- Up to three specialist(s) when warranted; and
- One pharmacy provider and/or specialty pharmacy if needed.

Only physicians can prescribe medications for Lock-In recipients. Approval of selections is required from the Louisiana Medicaid Pharmacy Program.

Under most circumstances, recipients with providers listed under the Lock-In segment of Recipient Eligibility Verification System (REVS) or Medicaid Eligibility Verification System (MEVS) are restricted to receiving physician and pharmacy services from these providers.
The Lock-In system affects the recipients only in the areas of physician and pharmacy services. Services other than physician or prescription drug services may be rendered to eligible recipients without Lock-In restrictions.

If a recipient chooses to change Lock-In provider(s) or add a specialist, the recipient must contact the Lock-In Unit. If a provider chooses to no longer be a recipient’s Lock-In provider, the provider should contact the Lock-In Unit. (See Appendix 37.5.4 for contact information.)

Specialist

The recipient may add up to three specialist providers when his/her medical condition warrants treatment by a specialist.

Infusion Pharmacy

In special circumstances, a recipient may need the services of an infusion pharmacy and is allowed to add a second pharmacy to bill intravenous medication only.

Lock-In Emergencies

Providers not named on the Lock-In segment accessed through MEVS or REVS can provide services; however, no payment will be made to these providers. The Bureau of Health Services Financing (BHSF) recognizes that there will be unusual circumstances when it is necessary for a pharmacy or physician provider to grant services for a Lock-In recipient when the provider is not named on the eligibility file on REVS or MEVS. Payment will be made to any physician or pharmacist enrolled in Louisiana Medicaid who grants services to a Lock-In recipient in emergency situations, or when life-sustaining medicines are required. Prescriptions written as a result of an emergency visit or as a discharge prescription following a hospital admission are applicable for payment if the correct emergency procedure is followed. These claims should be submitted electronically with an emergency override. The notation “Emergency Prescription” or “Discharge Prescription” must be written on the hardcopy prescription by either the prescribing physician or the dispensing pharmacist.

NOTE: Refer to Appendix 37.5.1 for a link to access the (POS) User Guide for detailed information regarding submission of these claims.
Section 37.5.13: LOCK-IN PROGRAM

Referrals

There may be circumstances under which it is necessary for a Lock-In physician to refer the Lock-In recipient for consultation with another physician on a short term basis. (The consulting physician may be reimbursed for the consultation if that consulting physician enters the name and provider number of the referring Lock-In physician in the Referring Physician block on the claim).

Prescriptions written by the consulting physician will deny when submitted by the Lock-In pharmacy. These prescriptions may be rewritten or authorized by one of the recipient's Lock-In physicians. The pharmacist should submit these prescription claims with the authorizing Lock-In physician's Medicaid provider number.
MEDICAID DRUG REBATE PROGRAM

Rebate Programs

The Pharmacy Program administers the federally mandated drug rebate program and the State Supplemental Drug Rebate Program for Louisiana’s Medicaid Program. The Pharmacy Program contracts with the University of New Orleans (UNO) to operate both drug rebate programs.

Pharmacists must bill the actual national drug code (NDC) of the drug dispensed to ensure that the rebate paid by the drug manufacturer is correct.

Manufacturers are allowed to audit utilization data of both rebate programs. The Pharmacy Program also audits this data to ensure accurate provider billing as this data is used to calculate the rebate amounts. Providers may be contacted by rebate staff in an effort to resolve rebate disputes with the manufacturers. Providers must respond to the auditor’s request for information.

The state supplemental and federal unit rebate amounts are confidential and cannot be disclosed for purposes other than rebate invoicing and verification.

Federally Mandated Drug Rebate Program

The federally mandated drug rebate program is one of the provisions included by Congress in its budget bill, the Omnibus Budget Reconciliation Act of 1990 (OBRA ’90). It is the result of Congress’ attempt to reduce and control federal and state expenditures for prescription drug products provided to Medicaid patients and to eliminate discriminatory pricing.

The law requires a drug manufacturer to enter into, and have in effect, a national rebate agreement with the Secretary of the Department of Health and Human Services (DHHS) for states to receive federal funding for outpatient drugs dispensed to Medicaid patients.

The drug rebate program is administered at the national level by the DHHS Centers for Medicare and Medicaid Services (CMS)’ Center for Medicaid and State Operations (CMSO).

State Supplemental Drug Rebate Program

Louisiana Medicaid’s State Supplemental Drug Rebate Program provides state and manufacturer contracted rebates in addition to those received through the federally mandated rebate program.
Effective October 1, 2004, CMS authorized the state to expand its supplemental rebate program and enter into a Multi-State Pooling Supplemental Rebate Agreement (SRA) with the intent of increasing efficiency and economy in the Medicaid program.

The state separately reports the supplemental rebate agreements to the Secretary of DHHS.